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ABSTRACT 
 
Campylobacter jejuni is a zoonotic, foodborne pathogen causing gastroenteritis in 
humans. The multidrug efflux pump CmeABC plays a key role in antimicrobial 
resistance by extruding structurally diverse compounds and is essential for intestinal 
colonization by mediating bile resistance. Expression of cmeABC is under the control of 
CmeR, a TetR family transcriptional regulator, and CosR, an oxidative stress response 
regulator. However, the molecular basis and functional consequences of differential 
CmeABC expression as well as the interactive role of CosR and CmeR in modulating 
cmeABC expression are still unknown. To address these questions, we performed two sets 
of studies. In the first study, we evaluated differential expression of cmeABC in naturally 
occurring C. jejuni isolates and identified the mutations associated with overexpression of 
cmeABC. It was found that 67% of examined C. jejuni isolates exhibited a CmeABC-
overexpressed phenotype as determined by immunoblotting and real-time RT-PCR. This 
phenotype was further linked to mutations in the cmeABC promoter sequence that 
decreased the binding of CmeR to the promoter DNA or a reduced cmeR expression.  
Consequently, both types of mutation increased expression of cmeABC.  Additionally, the 
CmeABC-overexpressed phenotype was associated with increased emergence of 
ciprofloxacin-resistant mutants in cultures treated with a fluoroquinolone antibiotic. 
 In the second study, we demonstrated that CmeR and CosR simultaneously bound 
to two separate sites in the cmeABC promoter, providing dual repression of cmeABC 
expression.  The two regulators interact with the cmeABC promoter independently, but 
maximal repression by CmeR and CosR requires a 17 bp spacer between the binding sites 
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as shortening the spacer interferes with CmeR binding of the promoter in the presence of 
CosR. Additionally, we demonstrated that CosR utilizes the single cysteine residue 
(C218) to sense oxidative stress as oxidation of C218 inhibited CosR binding to the 
promoter, providing a mechanistic explanation for oxidative-stress-induced, CosR-
mediated overexpression of cmeABC.  
 Together, these results reveal sophisticated mechanisms that modulate expression 
of cmeABC and identify a new signal (oxidative stress) that interacts with this efflux 
system. Considering the important role of CmeABC in Campylobacter pathobiology, the 
diverse mechanisms influencing cmeABC expression may facilitate Campylobacter 
adaptation to diverse environmental conditions. 
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CHAPTER 1: GENERAL INTRODUCTION 
 
Introduction 
 
Campylobacter is a gram-negative, microaerobic organism causing foodborne 
gastroenteritis in an estimated 845,024 people per year in the United States (1).  
Campylobacter jejuni, followed by Campylobacter coli, is the most common 
Campylobacter species associated with foodborne disease (2).   Campylobacter is a 
commensal enteric organism of many animal species including birds (especially 
domestic poultry), swine, and ruminants (2).  Undercooked poultry meat and 
unpasteurized (raw) milk are common vehicles for transmission of Campylobacter to 
humans (2, 3). Symptoms of campylobacteriosis include watery or bloody diarrhea, 
abdominal cramps, and fever.  Illness may persist for 1 week and typically resolves 
with symptomatic treatment (4, 5).  In immunocompromised individuals or persons 
with prolonged or severe disease, antimicrobial treatment is indicated (2). 
Fluoroquinolones and macrolides are drugs of choice for treatment of 
campylobacteriosis in humans, however increasing resistance, particularly to 
fluoroquinolones, complicates the treatment (4-6).  
Antimicrobial extrusion mediated by multidrug efflux pumps is one mechanism 
bacteria utilize to provide intrinsic and acquired resistance to structurally diverse 
toxic compounds, including antimicrobials.  Multidrug efflux pumps are classified 
into 5 major families, but in gram-negative bacteria, the resistance nodulation cell 
division (RND) family provides the majority of clinically relevant antimicrobial 
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resistance (7).  CmeABC (Cme for Campylobacter multidrug efflux) is a member of 
the RND family and is the predominant efflux pump in C. jejuni (8). CmeABC is 
comprised of an inner membrane protein named CmeB, a periplasmic fusion protein 
named CmeA, and an outer membrane protein named CmeC, which are transcribed 
from a 3-gene operon (8).  CmeABC extrudes structurally diverse compounds such a 
bile salts, detergents, ciprofloxacin, and erythromycin, and its extrusion of bile is 
essential for Campylobacter to colonize the intestinal tract (8, 9).  A TetR family 
regulator named CmeR functions as a repressor for cmeABC, allowing a low, basal 
level of expression in wild-type organisms (10, 11). However, expression of cmeABC 
can be induced by certain compounds. For example, bile induces expression of 
cmeABC, which renders Campylobacter more tolerant to bile (10, 12, 13). This 
induction is through CmeR. In the presence of bile, CmeR undergoes a 
conformational change, disassociating from the cmeABC promoter and increasing 
cmeABC expression (10, 12, 13).   
By extruding antimicrobials, CmeABC functions synergistically with other 
acquired resistance mechanisms, such as target gene modifications, leading to high 
levels of resistance to macrolides, tetracyclines, and fluoroquinolones (14-17). 
Fluoroquinolone resistant Campylobacter can outcompete sensitive bacteria even in 
the absence of antimicrobial treatment (18), leading to long-term persistence of 
fluoroquinolone-resistant Campylobacter.  Due to concerns over increasing 
fluoroquinolone resistance in Campylobacter, this class of antimicrobials was 
withdrawn from U.S. poultry production in 2005.  Unfortunately, the continued 
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persistence of fluoroquinolone resistant mutants has been documented on farms and 
in meat after the fluoroquinolone ban (19, 20).  
Recently, a controversial mechanism of bactericidal antibiotic-mediated cell death 
was proposed involving reactive oxygen species (ROS) (21). ROS, such as hydrogen 
peroxide, superoxide, and hydroxyl radicals, induce oxidative damage to cells and can 
result in cell death (22, 23). Kohanski et. al. reported the fluoroquinolone, β-lactam, 
and aminoglycoside classes of antibiotics induced formation of hydroxyl radicals and 
proposed that ROS production was a direct mechanism for bactericidal antibiotic-
mediated killing of bacterial cells  (21).  It was further proposed that treatment with 
these antibiotics elevated intracellular iron levels and induced the Fenton reaction, 
increasing the level of hydroxyl radicals in treated bacterial cells (21). However, two 
recent studies by Keren et. al. and Liu and Imlay were unable to confirm increased 
iron levels (24) or correlate ROS levels with cell death (25). In addition, contradictory 
results were shown at several levels (24, 25) in the pathway proposed by Kohanski et. 
al., leading to the conclusion that antibiotic killing was not directly mediated by ROS. 
Regardless if ROS is the direct or indirect killing mechanism, oxidative stress is 
commonly encountered and bacterial organisms have developed multiple ways to deal 
with oxidative stress (22, 23, 26).   
In bacteria, there are key regulatory proteins that modulate the response and 
resistance to oxidative stress (22, 26, 27). Interestingly, recent findings revealed that 
some regulatory proteins that modulate efflux pump expression are also involved in 
the oxidative stress response (22, 28-30).  For example, MexR of Pseudomonas 
aeruginosa and MgrA of Staphylococcus aureus are two efflux pump regulators that 
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respond to oxidative stress (28, 30). Both regulators utilize cysteine residues to sense 
oxidative stress and modulate their DNA-binding function.  Cysteine oxidation is a 
known mechanism for protein regulators to modulate gene expression (26, 31). The 
oxidized cysteine residues cause a conformational change in the regulator, altering 
their regulatory activities (26, 31).  
CosR (Campylobacter oxidative stress regulator) is an orphan response regulator 
of C. jejuni that functions as an oxidative stress response regulator modulating the 
expression of several genes including of katA, sodB, and ahpC (27, 32).  These three 
genes encode enzymes to detoxify hydrogen peroxide, superoxide, and organic 
hydrogen peroxide, respectively (33-35).  Recently, CosR was shown to bind to the 
promoter of cmeABC and repress its expression (32). How CosR senses oxidative 
stress and how it interacts with CmeR in modulating the expression of cmeABC have 
not been determined. CosR contains a single cysteine residue, C218, but it is 
unknown if this residue is involved in modulating CosR function in response to 
oxidative stress.   
 The genetic locus of cmeABC is highly conserved in C. jejuni and C. coli (36, 37), 
but its expression levels in naturally occurring C. jejuni isolates have not been 
measured.  Considering the importance of CmeABC in Campylobacter pathobiology, 
the varied expression levels of CmeABC and its use of multiple regulatory pathways 
are expected to provide Campylobacter with flexibility to adapt to various 
environments and conditions. To address this hypothesis, we performed studies to 
examine differential expression of CmeABC in naturally occurring C. jejuni isolates, 
to analyze genetic mechanisms and functional consequences associated with 
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CmeABC differential expression, to evaluate how CosR senses oxidative stress, and 
how CosR interacts with CmeR in modulating the expression of cmeABC. Findings 
from these studies have significantly improved our understanding of the mechanisms 
governing the expression of cmeABC expression and provide new insights into the 
adaption of Campylobacter to various environmental conditions. 
 
Dissertation Organization 
 
This dissertation is organized in the alternative journal paper format.  Chapter 1 is 
a general introduction.  Chapter 2 is a review of the literature.  Chapters 3 and 4 are 
manuscripts to be submitted to the Journal of Bacteriology. Tables and Figures 
immediately follow each manuscript. Tara Grinnage-Pulley (Ph.D. candidate) and 
Qijing Zhang (major professor) were the primary researchers responsible for 
experimental design, statistical analysis, and manuscript preparation.  Tara Grinnage-
Pulley performed the experiments with technical assistance from Dr. Orhan Sahin and 
Samantha Terhorst. Dr. Yang Mu constructed the pQECj0355c plasmid used in 
Chapter 4.  Qijing Zhang will be the corresponding author upon manuscript 
submission.  Chapter 5 is the general conclusions from this work.  References are 
provided at the end of each chapter.  
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CHAPTER 2: LITERATURE REVIEW 
 
The Organism: Campylobacter 
 
Campylobacter, currently known as a causative agent of foodborne gastroenteritis in 
humans, was first recognized as a cause of ovine abortion (1).  The first published reports 
of the organism in 1913 resulted from an investigation into epizootic abortion of cattle 
and sheep initiated at the request of the British Board of Agriculture and Fisheries (1, 2).   
In carrying out those studies, John McFadyean and Stewart Stockholm documented 
isolation of a "comma shaped, actively motile" organism in 1906 from the uterine mucosa 
of a ewe (1). The same organism was also isolated from bovine abortions in the United 
States in 1919 and named Vibrio fetus (2).  Identification of additional Vibrio species 
from veterinary cases continued in the following years, including Vibrio jejuni in 1931 
from dysentery in calves and Vibrio bubulus from bovine semen and vaginal samples (2, 
3). The first reports of disease in humans were from a 1938 outbreak of enteritis due to 
unpasteurized milk (4).  Fecal cultures were negative, but fecal smears and blood cultures 
were observed to contain V. jejuni-like organisms (2, 4).  V. fetus was successfully 
isolated in 1947 from the blood of pregnant women hospitalized for fever of unknown 
origin that ultimately aborted (2).  V. fetus and a related Vibro were reported in 1957 from 
human cases of enteritis (2). In 1968, the related Vibrio was finally cultured from human 
feces (2). 
The genus Campylobacter was created with the organisms known as V. fetus and V. 
bubulus in 1963 (3).  Separation from Vibrio was based on the low G+C content, non-
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fermentative metabolism, and microaerophilic growth.  In 1973, the taxonomy was 
revised to 4 species: Campylobacter coli, Campylobacter jejuni, Campylobacter fetus, 
and Campylobacter sputorum.  C. sputorum was divided into two subspecies C. sputorum 
subspecies sputorum and C. sputorum subspecies bubulus, formerly C. bulbulus (3). 
Current taxonomic classification is Epsilonproteobacteria of the Campylobacteraceae 
family (5) with the genus Campylobacter including 27 species and 8 subspecies.  The 
organism of study in this work C. jejuni is comprised of 2 subspecies C. jejuni subspecies 
jejuni and C. jejuni subspecies doylei (5).  All references to C. jejuni in this work refer to 
C. jejuni subspecies jejuni. 
Campylobacter is a gram negative, microaerobic, naturally transformable organism 
with one or two polar flagella (6-10). A microaerobic atmosphere with 5-7% oxygen, 
10% carbon dioxide, and the balance in nitrogen or hydrogen can be created by 
commercially available gas generating packs or pumping the gas mixture from a gas tank 
into a sealed jar (11).  A few species, C. rectus, C. gracilis, C. showae, are unique in their 
optimal growth under anaerobic conditions (3). Incubation is at 30-37° C for non-
thermophillic species or 42° C thermophillic species and can range from 24 to 48 hours 
depending on species (11). Morphology of the rods varies with organisms being 
described as S-shaped, gull winged or comma, curved or spiral shaped (12).  As cultures 
age they become more coccoid (5, 12).  
Culture media for Campylobacter are continually undergoing development to 
optimize recovery from diverse habitats (13-17) and no single media has been reported as 
a 'gold standard' for isolation of all species (3).  Campylobacters have been recovered 
from fecal samples, aborted fetal tissue, meat products, water, oral cavity, and milk (5, 7). 
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Basal media such as Columbia, Mueller Hinton, and Brucella, among numerous others, 
have been described for routine growth (11).  Lysed horse blood or defibrinated blood 
from various species can be added at 5-15% to improve viability (12, 16).   A variety of 
selective and enrichment medias for detection from environmental, food or fecal samples 
have been described (13, 15-17).  Antimicrobials polymixin B, trimethoprim, rifampicin 
and various other combinations have been used to inhibit overgrowth of yeast and other 
bacteria (11, 16).  Selective agents, temperature, and presence of blood can influence 
species recovery (11, 18, 19).  
Differentiation between Campylobacter species by traditional biochemical methods 
and growth characteristics is possible, but is not always reliable, especially for the 
biochemical tests (3).  C. jejuni and C. coli, the main human pathogens, are differentiated 
by the hippurate test.  C. coli is always hippurate-negative, while most but not all C. 
jejuni strains are hippurate-positive. Based on their growth temperature, Campylobacter 
species have been characterized as non-thermophillic, such a C. fetus, and thermophillic 
such as C. coli and C. jejuni (16, 17). Molecular methods are commonly used to 
differentiate Campylobacter species and subspecies today.  Some examples include pulse 
field gel electrophoresis (PFGE), restriction length fragment polymorphism (RFLP), 
multi-locus sequence typing (MLST), and amplification of 16SrRNA or species specific 
genes by PCR (20-24).  
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Epidemiology of Campylobacter as a Cause of Foodborne Disease 
 
Campylobacter ranks fourth out of 31 known foodborne pathogens tracked by the 
Centers for Disease Control and Prevention (CDC) in pathogens causing disease in 
humans (25).   Classification of foodborne pathogens by those causing illness, 
hospitalization, or death, places Camplyobacter within the top 5 pathogens in each of 
these categories, a distinction shared only with Norovirus and non-typhoidal Salmonella 
(25).  The CDC estimates campylobacteriosis causes illness in 845,000 people per year 
and 8,463 hospitalizations (25).   C. jejuni infections account for 90% of foodborne cases 
associated with Campylobacter, while 5-10% of cases are caused by C. coli (6, 26).  
However, C. fetus subspecies fetus, C. fetus subspecies veneralis, C. hyointestinalis, C. 
lari, C. upsalinesis, C. helveticus, C. concisus, C. curvus C. shanae, C. graciti, C. 
sputorum, C. rectus, and C. mucosalis, have also been implicated in zoonotic disease. 
Domestic poultry is an important reservoir for foodborne disease as avian species 
carry Campylobacter as a commensal organism (6, 27-29).  Chickens are reported to 
harbor 109 CFU/gram of Campylobacter in their cecum (6, 27-31) that can contaminate 
the carcass at slaughter during evisceration.  Transmission to humans is primarily through 
undercooked poultry or poultry products, such as liver pâté (27, 32-34).   Poultry meat 
can also serve as a source if raw foods (salads) or cooked foods are cross-contaminated 
with raw poultry (27, 32, 33).  Unpasteurized milk and contaminated water are other 
sources of infection and usually involve larger outbreaks of disease (27, 32, 33). The 
infective dose for humans is 500-800 organisms with strain and host factors greatly 
influencing the dose (6, 8).  
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In animals, the majority of transmission is fecal-oral (28, 35) through ingestion of 
food or water contaminated by animals shedding Campylobacter in the feces.  Pregnant 
animals infected with Campylobacter will also spread the organism from aborted fetal 
tissue and other uterine secretions to serve as a source of infection in the environment 
(36). Campylobacter is ubiquitous in the environment and can infect many animal species 
such as birds, cattle, sheep, and pet cats and dogs (6). Flies and wildlife species may 
serve as vectors for domestic species (37, 38). One exception to the oral transmission is 
bovine genital campylobacteriosis, which is transmitted sexually (39).  
In poultry, Campylobacter is not usually found in chicks less than 2-3 weeks old 
(28, 40, 41).  There is no consensus on the initial source of infection in poultry (28), but it 
is likely that multiple sources contribute to flock infection.  Once a bird is colonized, the 
remainder of the flock quickly becomes positive (40, 41). Chickens require far fewer 
organisms compared to humans for colonization, only 35-40 organisms which may 
partially account for the rapid spread (42, 43).   
 
Clinical Campylobacter Infections 
 
Disease in humans  
Campylobacteriosis occurs in all ages, with peaks in children less than 4 years old 
and in adults 15 to 39 years old in developed countries (44).  In contrast, developing 
countries see a peak in clinical cases during childhood and then a sharp decline in cases 
with age (6).  Immunocompetent individuals tend to have disease limited to the intestine 
and may clear the organism or become asymptomatic carriers (6). In developing 
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countries, the prevalence of asymptomatic infections (by fecal culture) are estimated at 
15% (6).  This appears to be mimicked in industrialized countries where occupationally-
exposed individuals, such as poultry abattoir workers, experience clinical disease in the 
beginning of employment, but rarely develop clinical disease as employment continues 
(6, 44, 45).  
Campylobacteriosis has an incubation period of 24-48 hours (46).  Symptoms include 
watery or bloody diarrhea, abdominal pain, fever, and nausea with fever sometimes 
starting 1-2 days before the onset of diarrhea (46).  Duration of clinical illness is typically 
2-4 days, but symptoms can continue up to one week (6). Infections are usually self-
limiting in immunocompetent individuals with home rehydration and symptomatic 
treatment used until symptoms resolve (7, 47, 48). Immunocompromised individuals 
particularly those with AIDS or humoral immune deficiencies tend to have more severe 
disease, often with bacteremia (6). Antimicrobial treatment is recommended for 
immunocompromised individuals with enteritis and in immunocompetent individuals 
when disease is severe or prolonged (7, 47).  
Fluoroquinolones are the initial treatment choice for gastroenteritis of unknown 
bacterial origin as many enteric bacteria are sensitive to these drugs (47). However, with 
no pathognomonic symptoms, clinical campylobacteriosis is indistinguishable from many 
other causes of gastroenteritis.  Increased resistance of Campylobacter to 
fluoroquinolones makes this drug class a poor choice for treatment in individuals infected 
with Campylobacter. Macrolides are drugs of choice in suspected or known 
Campylobacter infections (7, 47). Fluoroquinolones were withdrawn from poultry 
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production in 2005 by the United States Food and Drug Administration, in an effort to 
decrease the level of fluoroquinolone resistant Campylobacter in foods of animal origin. 
 
Disease in animals 
In avian species, Campylobacter is regarded as a commensal organism, but clinical 
disease can be seen in other species (35).  Bovine genital campylobacteriosis in an 
infection with C. fetus subspecies veneralis or C. fetus subspecies fetus causing infertility 
in cattle (39). C. coli has been reported to cause diarrhea in weaning pigs (29). In sheep 
and cattle, C. jejuni and C. fetus subspecies fetus are causes of abortion (29, 36, 49). 
 Recent emergence of C. jejuni as the primary cause of ovine abortion in the United 
States is attributed to a highly virulent sheep abortion clone (22, 49).  The clone is also 
found causing abortion in cattle and goats. Additionally, this clone has been recovered 
from bovine feces and healthy sheep (22). This clone is zoonotic as it has been associated 
with a number of gastroenteritis cases in humans (22). The known zoonotic transmission 
route for this clone is raw milk (22).  
 Numerous Campylobacter species have been recovered from domestic dogs and 
cats including C. upsaliensis, C. helveticus, and C. jejuni (50-52).  The role of 
Campylobacter in disease of pets is unclear as Campylobacter can be found in healthy 
animals and those with diarrhea (51, 53).  Animals with enteritis can be treated, but 
clearance of the organism, as denoted by negative culture, is not recommended as an 
indicator of treatment efficacy (50, 51).  Clearance may not be seen if the animal is re-
infected or if other pathogens were the source of infection and Campylobacter is carried 
as a commensal (51).  
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Sequelae to Campylobacter Infection 
 
Guillian Barré syndrome (GBS) and reactive arthritis (ReA) have been linked to 
Campylobacter infections (6, 26, 54). GBS is an autoimmune disease defined as “a 
progressive motor weakness of more than one limb with low or absent reflexes” by 
Asbury and Cornblath (54, 55).  In severe cases the respiratory system can be affected 
with mortality rates of 2-3% (54). Campylobacter enteritis usually occurs 2-4 weeks prior 
to the onset of symptoms (6, 26, 54).   Poropatich et. al. reported that 31% of GBS cases 
were related to previous Campylobacter infections (54).   Individuals affected by GBS 
usually recover in 6 to 12 months (6). Reactive arthritis is a sterile inflammation of the 
joints occurring within 4 weeks of a bacterial intestinal or urinary infection (26).  It 
occurs in 1-5% of Campylobacter infections (26). Affected individuals recover within 6 
months (26).   
Both GBS and ReA are believed to result from autoimmune disease secondary to 
immune recognition of C. jejuni like molecules, also known as molecular mimicry (26, 
54).  During infection, lipo-oligosaccharides of Campylobacter promote development of 
antibodies that cross-react with host antigens resulting in an inflammatory response (6).   
The host antigens in GBS are the sugar moieties of neuron gangliosides (6), but the exact 
antigen is unknown for ReA (26).  Conflicting study results on the role for the human 
leukocyte antigen, HLA-B27 as the host target antigen in ReA have been reported and a 
definitive target for this disease is still under investigation (56, 57).  
Campylobacter is also implicated in chronic gastrointestinal disorders such as 
inflammatory bowel disease (Crohn’s disease and ulcerative colitis) and irritable bowel 
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syndrome (58).  Inflammatory bowel disease is characterized by activated T-lymphocytes 
in chronic, reoccurring intestinal inflammation (58).   Irritable bowel disease is a non- 
inflammatory motility disorder of the colon (59).  Campylobacter infections may serve to 
exacerbate disease or be a preceding event in both conditions (58).   
 
Pathogenesis of Infection 
 
After ingestion, Campylobacter must survive gastric acid, bile, and other host defense 
mechanisms to cause clinical disease in humans. Black et. al. observed an array of 
clinical symptoms during experimental infection of humans (60).  Similar symptoms are 
observed in natural infections.  It is unclear why diarrhea is watery or mucoid in some 
individuals while it is bloody in others, but host factors and strain virulence are suggested 
to play a role (44, 48).   Host factors influencing disease outcome are immune status, the 
commensal and pathogenic organisms present in the intestines, and concurrent systemic 
infections (61).  Pathogen factors include strain, dose, and challenge frequency (61).  C. 
jejuni is naturally transformable, which has partially accounted for strain variability (9, 
10, 46).   
Two mechanisms are proposed for causing diarrhea in humans (6, 62).  The first 
mechanism involves adhesion to intestinal epithelium and toxin production resulting in a 
secretory diarrhea (62). Alternatively, adhesion and intestinal epithelium invasion 
combined with the host inflammatory response result in bloody diarrhea (6).  
Several virulence factors have been described for Campylobacter colonization and 
clinical disease. Motility is a requirement for colonization allowing Campylobacter to 
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reach the mucosal layer and intestinal epithelial cells (63-66).  Motility requires the 
production of flagella (FlaA) and the flagellar apparatus is also involved in secretion of 
attachment and invasion proteins (63-68). CiaB, Campylobacter invasion antigen B, is 
one protein secreted by the flagellar apparatus that is also required for adhesion (68, 69). 
A fibronectin binding outer membrane protein, CadF, is also required for adhesion and 
invasion (70). Another essential factor for intestinal colonization is the CmeABC efflux 
pump as it is a key component of bile resistance (71, 72).  Conflicting results have been 
reported on the necessity of a capsule in colonization (73, 74). In chickens, the capsule is 
not required for C. jejuni colonization (74), but is required to cause diarrhea in ferrets 
(73).  In vitro, loss of the capsule increased Campylobacter sensitivity to serum and 
reduced adherence and invasion (73, 74).  This reduced adherence and invasion may be 
due to production of hydrogen peroxide by the intestinal mucosa as a capsule is required 
in defense against this oxidative damage (74, 75).  
Production of toxins is a common pathogenic mechanism for enteric bacterial 
pathogens, such as Salmonella, E. coli, and Shigella to induce diarrhea (76).  C. jejuni 
encodes a single toxin, cytolethal distending toxin (CDT) (48, 77).  CDT prevents 
eukaryotic cells from entering mitosis leading to cytoplasmic distention and cell death 
(48, 58, 62, 78). A decrease in the integrity of the intestinal barrier due to the death of 
intestinal epithelial cells may promote translocation of Campylobacter from the intestinal 
lumen into the mucosa (79). Additionally, CDT has pro-inflammatory effects in the 
intestines inducing production of CXCL-8 (IL-8) (80, 81).  CXCL-8 can subsequently 
attract neutrophils to the intestines further inducing inflammation and cellular damage 
(44, 82). CDT influences the severity of enteritis in suckling mice (83) and NF-kappaB 
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deficient mice while in immunocompetent mice, CDT is required for persistent infection 
(84). CDT may be one of the strain related factors in clinical disease as CDT is detected 
in many, but not all C. jejuni strains (44). 
 
Antimicrobial Resistance Mechanisms in Campylobacter 
 
Bile resistance 
 Bile is a digestive secretion produced in the liver and excreted into the intestines 
to aid in digestions of dietary lipids (85).  Bile consists of proteins, ions, cholesterol, 
pigments, and bile salts (85, 86). Bile salts are amphipathic molecules secreted into the 
intestines to emulsify lipids (85).  This amphipathic nature allows bile to act as a 
detergent infiltrating fat particles and incorporating them into micelles for absorption 
(85).  This infiltrative action is not restricted to dietary lipids, but also applies to the 
membranes of bacterial pathogens (85).  Disruption of the bacterial phospholipid 
membrane results in a loss of selective permeability and cell death (85, 86).  Bile is also 
thought to interact with bacterial DNA and proteins, disrupting signaling and growth 
processes, although the exact mechanisms are unknown (86). The killing action of bile is 
concentration dependent with the highest concentration in the duodenum where bile is 
secreted (85).  These mechanisms allow bile to inhibit or kill most bacterial pathogens, 
unless adapted to the intestinal environment, as an innate defense against intestinal 
infection (85).  
 C. jejuni is recovered from the lower intestines and/ or cecum of the hosts.  As an 
enteric pathogen, C. jejuni has adapted to tolerate bile, which has been employed as a 
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component in selective media for isolation of Campylobacter. Bile modulates the 
expression of a number of genes in C. jejuni. For example, bile upregulates expression of 
flagellin, membrane or secreted proteins, and other virulence genes in C. jejuni such as 
ciaB and cmeABC (69, 87). Other genes differentially regulated by bile are involved in 
iron storage, energy utilization, and signal transduction (69, 87). Multiple factors 
contributing to bile resistance in Campylobacter have been identified.  The multidrug 
efflux pump CmeABC is a key player for bile resistance by extruding bile from the 
interior of the cell (72). The cmeABC mutants lost the ability to grow in intestinal extracts 
and colonize chickens, indicating the essential function of cmeABC in bile resistance 
(71). Another contributing factor for bile resistance is CbrR, an orphan response regulator 
(88). Mutants of CbrR were unable to grow in bile-containing media and were severely 
attenuated in colonizing chickens (88).   How CbrR contributes to bile resistance is 
unknown as the regulon of CbrR has not been identified. CmeR, a Tet-family regulator 
and pleiotropic regulator of C. jejuni, is also able to respond to bile (89, 90).  CmeR 
interacts with bile and modulates the expression levels of cmeABC and other genes such 
as Cj0561c (89-91), a putative periplasmic protein.     
 
Multidrug efflux pumps 
Bacterial efflux pumps are cell membrane transporters extruding a variety of 
compounds and have physiologic roles in addition to providing antimicrobial resistance 
(92).  Bacterial efflux pumps are single or multi-unit transporter proteins that extrude 
compounds from the cytoplasm and/or periplasma (93, 94).  There are five families of 
efflux transporters: ATP binding cassettes (ABC), the resistance-nodulation cell division 
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(RND), major facilitator super family (MFS), multidrug and toxin extrusion family 
(MATE), and small multidrug resistance family  (SMR) (95).  Based on energy 
utilization the transporters are categorized as primary or secondary transporters (96).  
Primary transporters, the members of the ABC family, utilize ATP-hydrolysis for energy 
(94, 96).  The remaining transporter families are secondary transporters, utilizing ion 
gradients as an energy source (96).  
ABC transporters are found in plants, archaea, prokaryotes, and eukaryotes (94).  
Although the transporters have evolved across the kingdoms, the basic structure has 2 
transmembrane domains for transport and 2 nucleotide binding domains for ATP 
hydrolysis (94).  MFS family transporters are H+-drug anti-porters (97). MFS transporters 
can function as monomers or form complexes with outer membrane and periplasmic 
fusion proteins (95).  MATE family members can be either Na+ or H+ antiporters (98).  In 
gram-negative bacteria, RND transporters are the predominant and most clinically 
relevant family in conferring antimicrobial resistance (95). RND transporters are 
typically a tripartite system consisting of an inner membrane protein, a periplasmic fusion 
protein, and an outer membrane protein that are encoded as an operon.  Occasionally 
operons are found without the outer membrane protein such as the AcrAB-TolC pump of 
E. coli and the MexAB-OprM pump of Pseudomonas aeruginosa (95, 99, 100). Loss of a 
single component in a RND system will prevent function of the entire pump (93).  The 
broad substrate range of RND transporters provides a major mechanism to mediate 
multidrug resistance (101). Thus, RND transporters often mask the function of MFS and 
MATE transporters, which share a similar, but slightly reduced substrate range than the 
RNDs (96, 98). SMR transporters are a subgroup of the drug metabolite superfamily and 
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are found only in prokaryotes. Cationic drugs are the substrate of this H+ antiporter 
system (102).  
C. jejuni is predicted to contain 14 putative efflux pumps, (103, 104).  Two RND 
family pumps, CmeABC (Cme for Campylobacter multidrug efflux) and CmeDEF, and a 
MFS family transporter CmeG have been characterized (105-108). CmeG has roles in 
both oxidative stress and antimicrobial resistance (105).  Mutation of cmeG increases 
susceptibility to ciprofloxacin, erythromycin, tetracycline, gentamycin, rifampicin, 
ethidium bromide, cholic acid, and hydrogen peroxide (105).  
CmeABC is comprised of an inner membrane protein (CmeB), a periplasmic 
fusion protein (CmeA), and an outer membrane protein (CmeC) transcribed from a 3-
gene operon (cmeABC) (72). The sequence of cmeABC is variable, but the operon is 
conserved in both C. jejuni and C. coli (24, 109). CmeABC is required for colonization 
due to its role in bile resistance (71, 72). Bile, one of the substrates for CmeABC, induces 
cmeABC expression (71, 89).  Other substrates for CmeABC include structurally diverse 
antimicrobials including fluoroquinolones, tetracyclines, and macrolides (72).  
 Expression of cmeABC is regulated by CmeR, a TetR family repressor (91).  
CmeR is located upstream of the cmeABC operon and transcribed in the same direction 
(91).  Binding by CmeR to a 16-base inverted repeat within the cmeABC promoter region 
represses expression (91). CmeR also serves as pleiotropic regulator modulating the 
function of 27 other genes (110).  One of these genes, Cj0561c, is tightly regulated by 
CmeR and strongly induced by bile (90, 110).  
 CmeR has an N-terminal DNA binding domain and a C-terminal ligand-binding 
domain, and functions as a dimer (111).  Bile interacts with the ligand-binding domain of 
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CmeR and inhibits the binding of CmeR to its target promoters, resulting in increased 
expression of cmeABC and Cj0561c (89, 90, 110). This induction mechanism is due to 
the fact that binding of bile to the ligand pocket induces a conformational change in the 
DNA-binding domain of CmeR, releasing CmeR from the target promoter (89, 112).  
Different bile salts (conjugated and non-conjugated) had varied, yet substantial levels of 
induction of cmeABC expression (89). Interestingly, taurocholate (a conjugated bile 
compound) induced cmeABC expression in the absence of CmeR(89), suggesting that  a 
CmeR-independent mechanism also exists in bile-mediated induction of cmeABC (89).   
 CmeDEF is considered a secondary efflux pump and has synergistic roles with 
CmeABC (106). Although CmeDEF is also composed of an inner membrane protein 
(CmeF), a periplasmic fusion protein (CmeE), and an outer membrane protein (CmeD), it 
is not regulated by CmeR (107). CmeDEF contributes to resistance of various 
antimicrobials, detergents and bile salts at a modest level (106). Interestingly, mutation of 
both cmeF and cmeB was not possible in C. jejuni strain 11168, but was successful in 
strains 81-176 and 21190. However, the double mutation reduced growth of strains 81-
176 and 21190. These results suggest a role for CmeABC and CmeDEF in cell viability 
(106).   
 
Antimicrobial resistance 
Antimicrobial resistance of bacteria has been recognized as a major public health 
problem (113).  Bacterial resistance to antimicrobials can be mediated by both intrinsic 
and adaptive mechanisms.  Intrinsic resistance is inherent to the organism, such as lack of 
antimicrobial target, while development of adaptive resistance involves mutations or 
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acquisition of resistance genes (104, 113). Antibiotics are used for both human and 
veterinary medicine as well as animal production.  The extensive usage of antibiotics 
serves as the selection force for the development and spread of antibiotic-resistant 
bacteria and is responsible for the antibiotic resistance problem seen today (113).  In 
conventional food animal production systems, antimicrobials have been used for both 
growth promotion and therapeutic purpose (114).  For growth promotion, all animals of a 
herd or flock are treated with a subtherapeutic level of drug, in feed or water, in the 
absence of disease.  The mechanisms underlying growth promotion by antimicrobials are 
unknown (115).  This subtherapeutic level of treatment provides a constant, low level of 
selection pressure, allowing proliferation of organisms resistant to the drug. In Europe, 
restriction on the use of antimicrobials for growth promotion in food animals began in 
1986 (114).  Restrictions varied by country and drug until 2006 when all antimicrobials 
for growth promotion were banned in the European Union (114, 116).  In the United 
States, fluoroquinolones were used for poultry production before 2005, but have been 
banned since then due to concerns of antimicrobial resistance to these drugs (117).   
Antimicrobial resistance mechanisms in Campylobacter are well documented for 
aminoglycosides, tetracyclines, macrolides, and fluoroquinolones (104). 
Aminoglycosides bind to the 16S rRNA within the small ribosomal subunit of bacteria 
and blocks assembly of the 30S and 50S subunits, preventing protein synthesis (118). 
Resistance to aminoglycosides in Campylobacter is mediated by aphA genes encoding 
3’-O-aminoglycoside phosphotransferase (104, 113).   This enzyme adds phosphate 
groups to the 3' hydroxyl group in aminoglycosides, causing inactivation (104, 113).   
Three genes have been described in Campylobacter mediating aminoglycoside resistance 
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including aphA-1, aphA-3, and aphA-7, which can be found on the chromosome or 
plasmids (119-122). Resistance to aminoglycosides, represented by gentamycin, in C. 
jejuni was < 1% in U.S. (123), but the resistance rate is much higher in some other 
countries (124-126) .  
Tetracyclines bind to 16S rRNA within the small ribosomal subunit, inhibiting the 
elongation phase of protein synthesis (118). There are multiple tetracycline resistance 
mechanisms in bacteria, but tetracycline resistance in Campylobacter is mediated by 
Tet(O), a ribosomal protection protein (104, 113).  After tetracycline has bound to the 
ribosome inhibiting elongation, Tet(O) binds to the ribosomal A site and induces a 
confirmational change that disrupts tetracycline binding and allows protein synthesis to 
continue (104, 127).  Tet(O) can be found on the chromosome or on a plasmid (128).  
The tetracycline class is widely used in animal production in the U.S. and tetracycline 
resistance is highly prevalent in Campylobacter. For example, the National Antimicrobial 
Resistance Monitoring System (NARMS) Executive Report indicated that tetracycline 
resistance in C. jejuni was 43% for all isolates in 2010 with resistance generally higher in 
isolates from turkeys and chickens (123). Tetracyclines are the only approved drug to 
prevent infectious causes of abortion in sheep in the U.S. (36).  However, a tetracycline-
resistant C. jejuni clone [carrying the tet(O) gene] responsible for the majority of sheep 
abortion in the U.S. was recently described, limiting the usefulness of this class of 
antibiotics for preventing abortion (22, 49).   
Macrolides target the 23S rRNA in the large ribosomal subunit, blocking 
translocation of the peptide chain during protein synthesis (118, 129).  Macrolide 
resistance in C. jejuni is mediated by mutations in the 23S rRNA genes and the L4 and 
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L22 ribosomal proteins (130-134).  C. jejuni carries 3 copies of the 23S rRNA genes 
(135, 136).  For stable macrolide resistance, at least 2 of the copies must carry the 
mutation (134). These resistance-conferring mutations occur at nucleotide positions 2074, 
2075, or rarely both (131, 134, 137).  Resistance mediated by mutation at nucleotide 2075 
is more common than the 2074 mutation, but mutations at both positions can confer high-
level resistance (129, 131, 134).  Mutations of the ribosomal proteins L4 and L22 by 
amino acid substitution and amino acid insertion result in a moderate-level macrolide 
resistance (130).   According to NARMS’ data, C. jejuni resistance to macrolides was < 
2% in 2010 in the U.S. (123), but the resistance rate is much higher in some other 
countries (124-126, 138-142). 
Fluoroquinolones target DNA gyrase, a type II topoisomerase necessary for DNA 
supercoiling and required for DNA replication (118).  Fluoroquinolones form a complex 
with DNA gyrase on the DNA strand being replicated, causing double stranded DNA 
breakage (143, 144).  DNA gyrase is encoded by gyrA and gyrB. In Campylobacter 
several mutations in GyrA have been described influencing the level of fluoroquinolone 
resistance (145, 146).  Among the reported GyrA mutation, the Thr-86-Ile change confers 
high-level resistance to fluoroquinolones (103). This mutation affects the DNA 
supercoiling activity of GyrA and contributes to the increased fitness in fluoroquinolone-
resistant C. jejuni (103, 147).   
In addition to the mechanisms discussed above, efflux pumps also play important 
roles in antibiotic resistance in Campylobacter. As the major multidrug efflux pump in 
Campylobacter, CmeABC extrudes diverse antibiotics including tetracyclines, 
macrolides, aminoglycosides, and fluoroquinolones (72).  Thus CmeABC plays a 
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synergistic role with other resistance mechanisms in conferring antibiotic resistance (103, 
148, 149).   Additionally, CmeABC facilitates the emergence of spontaneous mutants 
resistant to ciprofloxacin under selection pressure (150), contributing to the development 
of fluoroquinolone resistance. NARMS data indicated that fluoroquinolone resistance is 
20-22% for Campylobacter cultured from animal, retail meat, and humans samples from 
the U. S.(123), but the resistance rate is higher in some other countries (124-126, 139, 
141). 
 
 
Oxidative stress response and defense 
An enteric microaerobic organism, C. jejuni is susceptible to oxidative stress created 
by internal and environmental sources (151).  Superoxide (O2-), hydrogen peroxide 
(H2O2), and hydroxyl radicals (OH), are some of the reactive oxygen species (ROS) that 
induce oxidative stress (151, 152). C. jejuni requires low levels of oxygen for optimal 
growth and can utilize oxygen as a terminal electron acceptor during aerobic respiration 
(153). Aerobic respiratory enzymes contain redox cofactors necessary for electron 
transfer and these co-factors can be autoxidized to produce ROS (152). Superoxide is 
generated as a byproduct of auto-oxidation of respiratory chain co-factors (151, 152). In 
addition, the presence of unbound ferrous iron (Fe2+) in the cytoplasm can trigger the 
Fenton reaction producing hydroxyl radicals (151, 152).  Intracellular hydrogen peroxide 
is produced as a byproduct of NADH reductase reactions and during the breakdown of 
superoxide (154).  
ROS are also encountered upon attachment to epithelial cells and invasion of the 
intestinal epithelium and lamina propia (29, 60, 75).  Production of hydrogen peroxide by 
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intestinal cells was demonstrated after adhesion and invasion of C. jejuni (75).   Invasion 
of the intestinal tissue brings Campylobacter into contact with macrophages and 
neutrophils, which produce nitric oxide, hydrogen peroxide, and superoxide (82).  
Secondary reactions can produce hydroxyl radicals (82).   
ROS damage cells by oxidizing proteins, lipids and DNA, causing disruption of 
bacterial metabolism, membrane integrity, signaling and replication (155). Superoxide 
and hydrogen peroxide can oxidize iron sulfur proteins releasing ferric (Fe3+) iron from 
the protein into the cytoplasm and inactivating the protein (155). The cytoplasm of 
bacteria is a reduced environment (152, 155).   This causes reduction of free ferric iron to 
ferrous iron via the Haber-Weiss reaction (Equation 1) (152, 155).  Ferrous iron then 
enters the Fenton reaction (Equation 2) and perpetuates the production of ROS (152, 
155).  As ROS continue to oxidize cellular components, organic hydroperoxides are 
generated, causing further oxidative damage (155).   
 (Eq. 1) Haber-Weiss reaction: Fe3+ + O2- → Fe2+ + O2     
(Eq. 2) Fenton reaction: Fe2+ + H2O2    →!! Fe3+ + OH + OH-   
 To minimize the effects of ROS, bacteria encode oxidative stress regulators to 
coordinate the response of oxidative stress genes.  In E. coli, OxyR and SoxRS, mediate 
this response with additional contributions by RpoS and Fur (151).  OxyR and SoxRS 
regulate the response to hydrogen peroxide and superoxide, respectively (151).  RpoS is a 
general stress response regulator and Fur is an iron responsive regulator (151). These 
regulators modulate the expression of genes encoding superoxide dismutase, catalase and 
alkyl hydroperoxide reductase that detoxify superoxides and peroxides (151).  There are 
no enzymes to detoxify hydroxyl radicals (152). 
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In E. coli there are multiple catalase, alkyl hydroperoxide reductase, and superoxide 
dismutase genes, but C. jejuni contains only one of each (151, 156-158).  Superoxide 
dismutase (sodB) provides resistance to superoxide and peroxides (Equation 3) (158). 
Catalase (katA) and alkyl hydroperoxide reductase (ahpC) provide resistance to peroxides 
(Equation 4) (156, 157).  Catalase is specific for hydrogen peroxide while ahpC breaks 
down organic hydroperoxides (156, 157).  
(Eq. 3) Superoxide detoxification: 2O2-  + 2H+  →!! H2O2 + + O2  
(Eq. 4) Peroxide detoxification: 2H2O2 → O2  +  H2O -  
C. jejuni does not contain OxyR, SoxRS, or RpoS (159).  PerR, Fur, Cj1556, and 
CosR contribute to regulation of oxidative stress response genes (160-165). PerR is a Fur 
homolog regulating the response to iron and peroxide stress (163, 164).  PerR represses 
ahpC and katA(163, 164). Fur is an iron responsive regulator that also negatively 
regulates katA (163, 165, 166). Cj1556, a regulator of oxidative and aerobic stress, 
positively regulates katA, ahpC and perR while negatively regulating sodB (162). CosR, 
an orphan response regulator, negatively regulates ahpC while positively regulating sodB 
and katA (160, 161).   
 
CosR as an oxidative stress response regulator 
Garénaux et. al. first recognized the role of CosR (Cj0355c) in oxidative stress 
response in a proteomic study examining the response of C. jejuni to paraquat, a 
generator of superoxide radicals (167). In that study, genes involved in oxidative stress 
response, redox, and virulence were overexpressed while CosR was downregulated (167).  
Attempts to knockout CosR were unsuccessful and it was classified as an essential gene 
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(88, 167).  The lethal effects of cosR mutagenesis were circumvented by gene inhibition 
using peptide nucleic acid (PNA) by Hwang et. al. 2011(160). 
PNA is a synthetic DNA mimic able to bind complementary DNA or RNA 
following Watson-Crick binding principles (168, 169).  Nielsen et. al. designed PNA to 
be homomorphous to DNA with the exception of the deoxyribose backbone (169).  2-
Aminoethylglycine units form the non-charged polyamine backbone of PNA, replacing 
the deoxyribose sugars (169). PNA binds optimally to DNA or RNA in an anti-parallel 
manner with the amino terminal of PNA directed to the 3’ end of the DNA or RNA (168, 
170). PNA has been used for inhibiting gene expression in both eukaryotic and 
prokaryotic systems (170). Target inhibition by PNA occurs at the level of translation in 
bacteria (170, 171).  
In C. jejuni PNA has been used to successfully inhibit protein expression from 
cmeA and cosR (160, 161).  cmeA-specific PNA inhibited CmeA expression, impairing 
the function of the CmeABC efflux pump (172).   The decreased pump function was 
reflected as an increase in antimicrobial susceptibility (72, 172). cosR-specific PNA 
reduced the expression of CosR while still maintaining the viability of C. jejuni (160). 
Using PNA inhibition, it was found that CosR regulates 93 genes in C. jejuni (161). 
Notably, CosR regulates sodB, ahpC, and katA by binding to a 21-base pair binding site 
within the promoter region of these genes (160, 161). SodB activity was increased while 
KatA activity decreased with inhibition of CosR, indicating the negative and positive 
regulation of the respective genes (160, 161). Thus, inhibiting CosR increases resistance 
to oxidants in accordance with its role as a negative regulator of many oxidative stress 
defense genes (160).  However, resistance is dependent on the type of oxidant.  When 
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exposed for 1 hour to equal amounts of paraquat and hydrogen peroxide, paraquat was 
more effective than hydrogen peroxide in killing C. jejuni independent of CosR levels 
(160). This is likely explained by the fact that paraquat treated cells reduced gene and 
protein expression of CosR, but hydrogen peroxide did not (160).  Hydrogen peroxide-
mediated cell death was suggested to be independent of CosR (160).  
 
Oxidative stress and efflux pumps 
Many bacterial regulators sense oxidative stress through redox reactions of residues. 
The thiol group of cysteine is readily susceptible to redox reactions and can be oxidized 
to form disulfide bonds or sulfonic acid or undergo S-nitrosyllation or S-alkylation (173). 
Regulatory proteins containing metal ion binding sites utilize metals, such a iron (Fe2+), 
zinc (Zn 2+), or manganese (Mn2+), to oxidize histidine residues (155).  The oxidative 
stress regulator families OxyR and OhrR contain cysteine residues that can be modified 
by redox reactions while PerR is a metal responsive regulator containing critical histidine 
residues (155, 173).  
 OxyR redox modulation is still under study but it is believed to occur through two 
mechanisms: general or selective (173).  In the general mechanism two cysteine residues 
are oxidized to form an intramolecular disulfide bond inducing a conformational change 
(173).  The selective mechanism involves a single cysteine modification that can vary.  
The variation in the modification presumably allows selection of certain genes, resulting 
in differential gene expression (155, 173). Interestingly, OxyR is functional in both the 
oxidized and reduced states acting as a repressor and activator (155).   
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The OhrR family is a subgroup of the MarR family that includes MgrA and SarZ of 
Staphylococcus aureus (155).  Proteins may contain one or two cysteines that function in 
redox reactions.  For proteins with a single cysteine, oxidation produces a mixed disulfide 
bond with a free thiol group or forms a cyclic amide that interferes with DNA binding 
activity (155).  The proteins with two cysteines undergo intermolecular disulfide binding 
(155).  
PerR is a member of the metal responsive Fur family (155, 163). PerR contains two 
metal binding sites, one for Zn2+ and the second for Fe2+ or Mn2+ (155).  The preference 
for Fe2+ or Mn2+ is not understood (155). Three histidine residues and two aspartate 
residues align the metal ions within the binding site resulting in a protein confirmation 
that stabilizes the DNA binding domains (155).  In this confirmation PerR binds to DNA, 
repressing gene expression (155). Disassociation is mediated by oxidation of a histidine 
residue (155). Hydrogen peroxide is reduced by Fe2+ generating a hydroxyl radical (155).  
The hydroxyl radical oxidizes a histidine, usually H37, disrupting the metal binding site 
confirmation, and PerR dissociates from the DNA (155).   
Kohanski et. al. hypothesized that bactericidal antibiotics induce bacterial cell death 
through oxidative stress (174). An increase in hydroxyl radical production was observed 
after treatment with bactericidal, but not bacteriostatic antibiotics.  Addition of a radical 
quencher increased the viability of cells treated with bactericidal drugs.  This killing by 
bactericidal drugs involved intracellular iron from iron-sulfur cluster proteins.  In 
addition, NADPH levels decreased after bactericidal drug treatment. Blockage of the 
TCA cycle also reduced death in cells treated with bactericidal antibiotics (174). 
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Based on these findings, Kohanski et. al. proposed the following mechanism for 
bactericidal antibiotics, including fluoroquinolones, aminoglycosides, and β-lactams,  to 
mediate cell death (174).   Treatment with bactericidal antibiotics leads to an increase in 
NADPH consumption as NADPH is converted to NAD+, producing superoxide (174, 
175). Superoxide oxidizes iron sulfur proteins, releasing ferric iron that also reacts with 
superoxide via the Haber-Weiss reaction to produce ferrous iron.  Excess ferrous iron 
production drives the Fenton reaction increasing hydroxyl radicals (174). Hydroxyl 
radical damage results in cellular death.  
 However, two recent studies independently disputed the mechanism proposed by 
Kohanski et. al. (176, 177).  Liu and Imlay were unable to demonstrate increased iron or 
hydrogen peroxides levels that were postulated to drive the Fenton reaction (176).  In 
addition, respiratory chain function was observed to decrease or remain the same after 
bactericidal drug treatment (176).  Also catalase and peroxidase genes were not activated 
during antimicrobial treatment (176). In another study, Keren et. al. were not able to 
correlate hydroxyl radical formation with cell death caused by antibiotics (177).  They 
also found similar levels of killing under aerobic and anaerobic conditions (177).   Both 
studies concluded that ROS were not involved in antibiotic-mediated cell death.   
In spite of the controversy over ROS as a mechanism of antibiotic-mediated killing of 
bacteria, oxidative stress appears to affect many cellular processes including antibiotic 
efflux systems.  The pleiotropic regulators MexR of Pseudomonas aeruginosa, MgrA and 
SarZ of Staphylococcus aureus, and AsrR of Enterococcus faecium sense oxidative stress 
(178-181). MexR and MgrA are regulators of efflux pumps (182-185) and oxidation has 
been shown to affect their binding to promoter DNA (178, 180).  In addition, the efflux 
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pumps CmeG of C. jejuni, AcrAB of Salmonella enterica serovar Typhimurium, and P55 
of Mycobacterium tuberculosis were found to be responsive to oxidative stress (105, 186, 
187).  AcrAB appears to have multiple pathways to respond to oxidants (186). CmeG 
contributes to oxidative stress resistance as inactivation of cmeG increased the 
susceptibility of C. jejuni to hydrogen peroxide (105). In addition, CmeABC of C. jejuni 
was recently described to be repressed by CosR and that the cmeABC promoter contains a 
CosR binding site upstream of the CmeR binding site (161). These findings suggest that 
oxidative stress response and antibiotic efflux systems are intertwined or linked, but the 
detailed mechanisms for the interaction and how efflux systems contribute to defense 
against oxidative stress are largely unknown. 
 
Control of Campylobacter 
 
Control of Campylobacter has focused primarily on the broiler industry as 
chicken meat or meat products are the most common source of infection for humans (42). 
Campylobacter is highly prevalent in live birds and colonizes in high numbers.  Thus, 
intervention on farm or at pre-slaughter will have a great impact on control of 
Campylobacter.  In general, biosecurity, immunologic approaches, and antimicrobial 
alternatives have been used for intervention (42).  Biosecurity focuses on restriction, 
barriers, and sanitation and is widely used on farms (37, 42). Access to birds is restricted 
by limiting the number of persons onto the farm or into the house (52, 188), limiting the 
number of visits into house (189, 190), and pest control (189, 191-193). Pest control 
applies not only to poultry house, but also to feed to prevent contamination with feces 
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from other animals or wild birds (194). Barriers methods include footbaths, clothing 
changes, or showering for entry/exit of house (37, 188).  Basic sanitation of feed and 
watering devices as well as decontamination and disinfection of houses and equipment 
between groups of birds are also used (188). Biosecurity measures are limited by 
practicality, cost, and consistency of implementation (37, 42).   
Immunological interventions rely on host defenses to exclude or reduce 
Campylobacter from the avian intestinal tract (42). Attenuated, killed, and subunit 
vaccines have been studied, but no commercial product is currently available (42).   The 
ideal Campylobacter vaccine in poultry would be delivered orally, stimulate immunity to 
kill or reduce Campylobacter in the intestinal tract, and have no effect on humans 
consuming the food product (42, 195). In addition, the 6-week growth cycle of broilers 
requires a vaccine that induces immunity quickly (42). Live attenuated vaccines are a 
concern for potential reversion to pathogenicity.  Killed vaccines tested so far have not 
achieved the expected level of reduction (195).  Several subunit vaccines have appeared 
promising, but need additional work (195-197).  
Other intervention methods include competitive exclusion and improving poultry 
genetics.  Competitive exclusion involves treatment of flocks with defined cultures or 
crude intestinal extracts (198). Several competitive exclusion products are commercially 
available, but efficacy is variable (42, 194). The bacteria comprising these mixtures may 
or may not be identified (194, 198).  Concerns exist for the potential transmission of 
pathogens and/or antimicrobial resistance in undefined cultures (42, 198). Some poultry 
lines show differences in resistance to colonization by Campylobacter (199-201). Studies 
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into the chicken immune response are ongoing for selective breeding to improve 
resistance to Campylobacter (200, 202-204).   
Bacteriocins and bacteriophages are potential alternatives to antimicrobials (42).  
Bacteriophages, viruses of bacteria, kill susceptible bacteria.  Current concerns for using 
bacteriophages are the potential for bacteria to develop resistance to the bacteriophage 
and the transmission of antimicrobial resistance or virulence genes by phages (42). 
Bacteriocins are antimicrobial peptides produced by bacteria, such as members of 
Lactobacillus, Paenibacillus, Enterococcus, Lactococcus, Pediococcus, Carnobacterium, 
Escherichia, Bacillus, Staphylococcus, Pseudomonas and Clostridium, to kill other 
bacteria (42).   The exact mechanism of killing is unknown, but disruption of bacterial 
membranes through pore formation is one suggested mechanism (42, 205).  Bacteriocins 
have shown promise in producing high level reductions of Campylobacter levels ranging 
from 2-6 logs in poultry (42, 206). Additionally, bacteriocins do not induce cross-
resistance to other bacteriocins or antimicrobials and antimicrobial resistance does not 
confer bacteriocin resistance (205, 207).  Also, since bacteriocins are likely produced in 
humans and animals by their own microflora and they are susceptible to proteases, 
bacteriocins are not expected to cause toxicity in humans (205).  Several bacteriocins 
have been described to reduce Campylobacter levels in chickens and turkeys (42, 205, 
208-210), but commercialization of the product has not happened. 
For postharvest control of Campylobacter, the focus is on limiting cross 
contamination. To promote emptying of the gastrointestinal tract, feed is withdrawn for 
8-12 hours prior to processing (194).  This limits fecal contamination of the crates and 
birds during transportation, preventing cross contamination from farm to processing plant 
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(194). Once in the plant, scalding loosens feathers and reduces surface pathogens (211).    
Inside–out bird washers rinse carcasses after evisceration to remove fecal material that 
may have been released from the intestinal tract (211).   Carcass chilling is usually 
through immersion in water with sanitizers, and the type of sanitizer used is dependent on 
current regulations for chemicals in food (194).  However, air chilling is common in 
Europe (194).  Temperature of water, length of time for chilling, pressure, water flow, 
cleanliness of water source and sanitizer concentration all impact the effectiveness of 
these methods (194, 211).  Freezing is another control method, but is precluded in 
production of fresh poultry products (194).  Irradiation, although effective in reduction of 
pathogens (212), is not commonly used due to public perception of irradiation safety 
(194). 
 
Summary 
 
 Campylobacter jejuni is an important zoonotic pathogen and a main cause of 
foodborne disease. Its ability to survive bile, ROS, antimicrobials, host defenses and 
varying environmental conditions highlights the adaptability and resilience of the 
organism.  However, resistance to fluoroquinolone and macrolide drugs is problematic as 
these are drugs of choice for treatment of campylobacteriosis.  Drug specific 
antimicrobial resistance mechanisms, particularly those for fluoroquinolones and 
macrolides, are synergized by the multidrug efflux pump CmeABC. CmeABC is 
essential for colonization and also appears to have a role in oxidative stress, being 
repressed by CosR, an oxidative stress regulator. Improved understanding of the 
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pathobiology of C. jejuni may facilitate development of better Campylobacter control 
mechanisms.  The following chapters examine the mechanisms influencing expression of 
the CmeABC efflux pumps in Campylobacter jejuni and its interaction with an oxidative 
stress regulator named CosR. 
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Abstract 
  
 The CmeABC multidrug efflux transporter of Campylobacter jejuni plays a key 
role in antimicrobial resistance. CmeR, a transcriptional repressor, maintains transporter 
expression at a basal level. Overexpression of CmeABC has been observed in laboratory-
generated mutants, but it is unknown if this phenotype occurs naturally in C. jejuni and if 
it has any functional consequences.  Expression of cmeABC was examined in natural 
isolates obtained from broiler chickens, turkeys and humans, to determine the genetic 
mechanisms and role of cmeABC differential expression in antimicrobial resistance.   
Phenotypic classification of 64 C. jejuni isolates as overexpression (OEL) or wild-type 
expression level (WEL) of cmeABC, determined by immunoblotting and real time RT-
PCR comparisons with strain NCTC 11168, identified 43 isolates as OEL. Representative 
mutations of the cmeABC promoter and/or CmeR-coding sequence were analyzed using 
electrophoretic mobility shift assays and transcriptional fusion assays. Reduced CmeR 
binding to the mutated cmeABC promoter sequences or decreased CmeR levels increased 
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cmeABC expression. Amino acid substitutions in CmeR did not affect cmeABC promoter 
binding and some OEL isolates harbored no mutations in known regulatory elements, 
suggesting that cmeABC is also regulated by unidentified mechanisms.  Overexpression 
of cmeABC did not affect the susceptibility of C. jejuni to most tested antimicrobials 
except for chloramphenicol, but promoted the emergence of ciprofloxacin-resistant 
mutants under antibiotic selection. These results link CmeABC overexpression in natural 
C. jejuni isolates to various mutations and this phenotypic change promotes the 
emergence of antibiotic-resistant mutants under selection pressure.  Thus, differential 
expression of CmeABC may facilitate Campylobacter adaptation to antibiotic treatments.   
  
Introduction 
 
Multidrug efflux pumps play key roles in bacterial physiology, conferring 
intrinsic and acquired resistance to diverse toxic compounds.  There are multiple types of 
drug efflux systems in bacteria, but in gram negative bacteria, the resistance-nodulation- 
cell division (RND) family of efflux pumps is of primary importance for antimicrobial 
resistance (1).  ArcAB-TolC, MexAB-OprM, and MexXY-Z in Escherichia coli and 
Pseudomonas aeruginosa are examples of well-characterized RND efflux pumps that 
extrude bile salts, organic cations, detergents, and various classes of antimicrobials (2-5).  
These efflux pumps have been associated with intrinsic and acquired resistance to 
antimicrobial compounds.  CmeABC, also a member of the RND family, is the 
predominant efflux pump in Campylobacter jejuni (6) and plays a key role in the 
resistance to structurally diverse compounds, such as bile salts, ciprofloxacin, 
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erythromycin, ethidium bromide, and various detergents (6, 7).   Synergistic effects of 
CmeABC with other resistance mechanisms (such as target gene mutations) contribute to 
high-level resistance to macrolides, tetracyclines, and fluoroquinolones in Campylobacter 
(8-11).  Due to its significant role in bile resistance, CmeABC is essential for 
Campylobacter colonization and adaptation in the intestinal tract of animals (7) . 
CmeABC is comprised of an inner membrane transporter (CmeB), a periplasmic 
fusion protein (CmeA), and an outer membrane protein (CmeC). The three components 
are encoded by a three-gene operon (6).  Transcription of this operon is repressed by 
CmeR, a TetR family transcriptional regulator (12).   The cmeR gene is located 
immediately upstream of the cmeABC operon. The CmeR protein contains a C-terminal 
ligand-binding domain and a N-terminal DNA-binding domain (7). The DNA-binding 
domain interacts specifically with a 16-base inverted repeat within the promoter region of 
the cmeABC operon (13).  This binding inhibits the transcription of the cmeABC operon. 
However, mutation of CmeR or alteration of the promoter sequences affects the binding 
of CmeR, resulting in increased expression of CmeABC (12, 14). Additionally, cmeABC 
expression is inducible by bile and this induction is through the interaction of bile with 
the ligand-binding pocket of CmeR, which triggers a conformational change in the DNA-
binding domain, releasing CmeR from the cmeABC promoter (15, 16). 
Gastroenteritis caused by Campylobacter is estimated to affect 845,024 people 
and cause 8,463 hospitalizations per year in the United States (17). C. jejuni and C. coli 
are the most common Campylobacter species associated with foodborne disease and are 
commensals in avian species (particularly poultry), swine, and ruminants (18).  
Campylobacter contamination frequently occurs with poultry meat and unprocessed milk. 
 
 
 
 
 
66 
Thus, undercooked poultry and unpasteurized milk are common vehicles for foodborne 
transmission of Campylobacter to humans (18, 19).  Clinically, campylobacteriosis is 
manifested as diarrhea, abdominal cramps, and fever, which typically resolves in 1 week 
without medical intervention. However, when antimicrobial treatment is indicated with 
severe or prolonged cases, or in immuncompromised patients, fluoroquinolones and 
macrolides are the drugs of choice (18, 20). Increasing resistance to these antibiotics in 
Campylobacter is problematic, especially to fluoroquinolones, as Campylobacter is 
highly adaptable to fluoroquinolone treatment and acquisition of mutations associated 
with fluoroquinolone resistance does not impose a fitness cost on this organism (21-23). 
In all clinically relevant antibiotic resistance, CmeABC plays an important role as 
inactivation of cmeABC rendered Campylobacter much more susceptible to various 
antimicrobials (6).   
Considering the significance of CmeABC in Campylobacter pathobiology, its 
varied expression levels are expected to affect antimicrobial resistance. Under toxic 
conditions or in the adaptation to harsh environments, enhanced expression of cmeABC 
may confer a survival advantage on Campylobacter.  The advantage may occur directly 
through increased extrusion of toxic substrates, which reduces their harmful effect and 
increased frequency of emergence of antimicrobial resistant mutants.  Although 
inactivation of cmeABC or overexpression of this efflux pump has been examined under 
experimental conditions by using insertional mutagenesis or stepwise selection of 
mutants on antibiotic containing plates (12, 14), it is unknown if differential expression 
of cmeABC occurs in naturally occurring isolates and if the differential expression has 
any functional consequences. In this study, we investigated the expression of cmeABC in 
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C. jejuni isolates from turkeys, chickens, and humans, examined the mechanisms 
associated with the differential expression, and measured the functional consequences 
associated with the differential expression.  
 
Materials and Methods 
 
Bacterial Strains and Growth Conditions  
Sixty four naturally occurring Campylobacter isolates were randomly selected 
from conventionally raised broiler chickens (24), conventionally raised turkeys (24), and 
clinical diarrheal cases of humans.  Eight of the human isolates including E46972, 
H30769, H49024, S13530, T37957A, X77136, M402 and W11805 were used in a 
previous study (25). Other human isolates were F6501, W14861, H52022, X60179, 
T59822, M63885, H2958, X39768, W64861, W28752, M76927, M37523, M33323, 
M32506, F15871, M36292, S47645, X7199, W52546.  The 20 broiler isolates, 17 turkey 
isolates, and 27 human isolates were confirmed to be C. jejuni using the reported mapA 
and 16S rRNA primers (26, 27). Key PCR primers used in this study are listed in Table 1. 
In addition to these isolates, several laboratory strains were also used, including NCTC 
11168 (28), 81-176 (29), 81-176ΔcmeR  (12), 11168ΔcmeR (12) and the quality control C. 
jejuni strain ATCC 33560 (30, 31), which are listed in Table 2. All strains were routinely 
cultured in Mueller Hinton (MH) agar or MH broth (Difco, Detroit, MI) at 42°C under 
microaerobic conditions (5%O2, 10%CO2, 85%N2).  Media were supplemented with 
kanamycin at 30 µg/mL or chloramphenicol at 4 µg/mL when needed. 
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E. coli strains (Table 2) DH5α (Invitrogen), DH5αpMW10 (32), DH5αpRK2013 
(33), XL1-Blue (Agilent), and JM109 (Agilent) were cultured at 37°C.  Luria-Bertani 
(LB) broth or agar (Difco) was supplemented with 30 µg/mL of kanamycin or 100 µg/mL 
of ampicillin when needed. 
 
Immunoblotting  
Isolates were initially screened for CmeABC expression by immunoblotting with 
polyclonal antibodies against CmeABC.  All clinical C. jejuni isolates, NCTC 11168 and 
11168ΔcmeR were cultured in MH broth.  Samples were pelleted, and re-suspended in 
SDS loading buffer for a final concentration of 5 x 109 CFU/mL.  The protein samples 
were analyzed by SDS-PAGE and immunoblotting as described previously using 
antibodies against CmeA, CmeB, CmeC (6) and MOMP (9). Bands for CmeA, CmeB, 
and CmeC from the clinical isolates were compared to those of NCTC 11168 and 
11168ΔcmeR by visual inspection and densitometric analysis using the AlphaEaseFC 
Software (Version 3.2.3 Rev C; Innotech).  
Primary classification as wild type-level (WEL) or overexpression level (OEL) of 
CmeABC was based on analysis of CmeB by densitometry and CmeA was utilized as a 
secondary factor for the classification.  The 64 clinical C. jejuni isolates were analyzed on 
8 immunoblots with NCTC 11168 and 11168ΔcmeR used as controls for WEL and OEL, 
respectively. The threshold for CmeABC overexpression based on densitometric analysis 
was a 2-fold increase for the CmeB band in relation to the expression level in NCTC 
11168. Each immunoblot was examined individually to ensure the threshold for 
overexpression was met. This phenotypic classification was further confirmed by 
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measuring the cmeB transcript using real time RT- PCR.  OEL isolates showed 
overexpression of CmeB on immunoblotting and/or real time RT-PCR expression of 
cmeB.   CmeA expression based on a threshold of 2-fold for overexpression was used for 
isolates that remained between the two phenotypic groups after real time cmeB 
expression levels were analyzed. 
The expression level of CmeR was also evaluated by immunoblotting in selected 
clinical isolates that harbored mutations in the cmeR gene.  The whole cell samples were 
prepared from isolates M63885, CT9:7, CB2:6, CB2:8, CB2:11, S13530, T37957A, 
X7199, CT2:2, NCTC 11168, and 11168ΔcmeR.  Samples were loaded onto a 12% SDS 
PAGE gel for electrophoresis in Lameilli buffer at 80 V for 30 minutes followed by 200V 
for 60 minutes.  The gel and PVDF membrane were equilibrated in Towbin transfer 
buffer for 30 minutes, assembled onto the transfer apparatus, and transferred at 60 V for 
40 minutes in Towbin transfer buffer.  The membrane was blocked in blocking buffer 
(5% skim milk with 0.01% Tween-20 in PBS) at 4°C on a rocker. Then it was incubated 
with rabbit anti-CmeR diluted 1:100 in blocking buffer for 90 minutes at room 
temperature on a rocker.  The membrane was washed 3 times for 10 minutes in washing 
buffer (0.01% Tween-20 in PBS) and further incubated with goat anti-rabbit IgG 
conjugated with horseradish peroxidase (KPL) (1:1000 in blocking buffer) for 1 hour at 
room temperature.  After three washings, the membrane was developed with the 4CN 
Horseradish Peroxidase Substrate system (KPL).  Densitometric analysis for CmeR was 
performed in the same manner for CmeABC. 
SDS-PAGE and immunoblotting were also performed for the recombinant mutant 
CmeR named rCmeR-tr to determine if the protein was recognizable by CmeR 
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antibodies.  This recombinant protein was derived from mutations in strain CT2:2 (Table 
3).  The recombinant CmeR named rCmeRSS was used as a control. Both rCmeRSS and 
rCmeR-tr were loaded at 400 ng onto a 12% SDS-PAGE gel. Electrophoresis and 
immunoblotting were performed using the same methods used for immunoblotting of 
CmeR in clinical isolates. 
 
Real time RT-PCR  
Transcription of cmeB and cmeR was detected by real time RT-PCR to confirm 
the results of immunoblotting.  RNA was isolated from 24-hour cultures of clinical 
isolates, NCTC 11168, and 11168ΔcmeR as described previously (13).  Real time RT-
PCR was performed for all isolates for cmeB and for selected isolates for cmeR as 
described previously (12, 13, 16, 34). The primers used for real time RT-PCR are shown 
in Table 1. Relative expression based on NCTC 11168 was calculated with the Pfaffl 
Method (35).  Overexpression of cmeB was defined as greater or equal to 3 fold of NCTC 
11168 expression.  cmeB expression measured by RT-PCR was compared with  the result 
of immunoblotting for final determination of a CmeABC phenotype.  For those isolates 
where RT-PCR and immunoblotting data did not align, less weight was given to real time 
RT-PCR data due to reported variability in cmeB coding sequence (36). 
 
DNA Sequencing  
DNA sequencing was performed to determine if isolates were carrying mutations 
in cmeR, the Cj0369c-cmeR promoter or the cmeABC promoter.  All clinical isolates 
classified as having a phenotype of CmeABC overexpression, some selected clinical 
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isolates with the wild-type expression levels, and 81-176 were amplified with RIGA-F 
and RIGA-R primers  (Table 1) for sequence analysis of the region between cmeR to the 
5’end of cmeA, which covers the whole ORF of cmeR and the entire promoter of cmeABC.  
Additionally, the predicted promoter region of Cj0369c-cmeR (the two genes share a 
single promoter located upstream of Cj0369c) was examined to determine if mutations in 
the promoter region were involved in differential CmeR expression. The Cj0369c-cmeR 
promoter was amplified with Cj0370-F and Cj0368c-R (Table 1). 
 
Electrophoretic mobility shift assays (EMSA)   
EMSA was used to assess the binding of CmeR to the cmeABC promoter 
sequences from various clinical isolates.  These clinical isolates were observed to contain 
sequence polymorphisms within the cmeABC promoter region.  A recombinant CmeR 
named rCmeRSS (37) with cysteines 69 and 166  replaced with serine was used for 
EMSA as described previously (12, 38). The Cys-Ser substitution does not affect the 
binding activity, but significantly improves the stability of recombinant CmeR as the Cys 
residues are sensitive to oxidation during in vitro binding assay. The 170-bp cmeABC 
promoter sequences were amplified from genomic DNA of NCTC 11168, 81-176, CT3:7, 
CT1:1, CT1:9, CT9:20,  and X7199 with primers GSF and GSR1(12) (Table 1).  The 
amplified products were purified (QIAquick PCR Purification kit, Qiagen) and then 
labeled with DIG-11-dd-dUTP using the DIG Oligonucleotide 3’ End Labeling kit 
(Roche). The labeled promoter DNA were used as probes in EMSA.   
The cmeABC promoter probes were named for their strain of origin: 11168, 81-
176, CT3:7, CT1:1, CT1:9, CT9:20 and X7199.  Promoter probes from clinical isolates 
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(CT3:7, CT1:1, CT1:9, CT9:20 and X7199) were compared with the promoter probes of 
11168 or 81-176 (laboratory strains), depending on their similarity to the CmeR binding 
site in the two laboratory strains. The CmeR-binding site contains an A to T substitution 
in the 81-176 strain compared to 11168, which is considered a naturally occurring 
variation (12).  
The promoter probes (0.05 pmol each) were incubated with 0, 60, 120, and 180 ng 
of rCmeRSS in 22 µL of binding buffer according to the method of Alekshun et. al. and 
Lin et. al. 2005 (12, 38). The reaction mixtures were incubated for 30 minutes at room 
temperature and Promega DNA loading buffer was added to each reaction. Samples were 
separated by electrophoresis at 200V for 45 minutes on a 6% polyacrylamide gel in 
0.25X TBE Buffer and transferred to a positively charged nylon membrane by vacuum 
(12).  Chemiluminescent detection using alkaline phosphatase-conjugated anti-DIG 
antibody and CDP-Star (Roche) was performed as previously described (12).  
 
Construction of promoter fusions and β- galactosidase assays   
The observed sequence polymorphisms in the promoter sequences of cmeABC 
were assessed for their impact on cmeABC transcription by constructing transcriptional 
fusions with a promoter-less lacZ gene. Genomic DNA templates (NCTC 11168, 81-176, 
CT1:1, CT 1:9, CT9:20, CT3:7, M32506 and X7199) were used for amplification of a 
578-bp sequence containing the cmeABC promoter with primers PF (12) and PX (Table 
1). These PCR products were purified (QIAquick PCR Purification kit), digested with 
XbaI and BamHI (Promega), and re-purified using the QIAquick kit.  Vector pMW10 
(32) was purified (QIAprep Spin Miniprep kit, Qiagen) from DH5αpMW10 (Table 2), 
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digested with the same enzymes, and re-purified.  Vector and PCR product inserts were 
ligated with T4 ligase (Roche) and transformed into DH5α.  Transformants were selected 
on LB agar plates supplemented with kanamycin (30 µg/mL).  Plasmid constructs (Table 
2) were purified from DH5α and sequenced with pMW10-F and pMW10-R (Table 1) to 
confirm the appropriate sequences and fusion.  
To transfer the plasmids into C. jejuni, tri-parental mating using C. jejuni 81-176, 
E. coli DH5αpRK2013 (33), and the various DH5α pMW10 transcriptional fusion 
constructs was performed as described previously (33). After transfer into C. jejuni 81-
176, plasmids pMW11168, pMW81-176, pMW1:1, pMW1:9, pMW3:7, pMW9:20, 
pMWM32506, and pMWX7199 (Table 2) were purified and electroporated into 81-
176ΔcmeR. The empty vector, pMW10, was also transferred to 81-176 and 81-176ΔcmeR 
by the same methods and used as a background control.  Cultures were grown for 20 
hours in MH broth supplemented with kanamycin (30 µg/mL), then β-galactosidase 
assays were performed as described previously (39). Three independent experiments 
were conducted. Student’s t-test with Welch’s correction was used to compare the 
expression data from various promoters and was done using GraphPad InStat® (Version 
3.06) with the significance level set at 0.05. 
Sequence polymorphisms were also observed in the Cj0369c-cmeR promoter.  To 
determine if these mutations affected CmeR expression, a second set of promoter fusions 
was created using the same method.  Briefly, primers 370BamH-F and 369XbaI-R1 
(Table 1) were used to amplify a 238-base pair segment containing the Cj0369c-cmeR 
promoter from genomic DNA templates of NCTC 11168, 81-176 and X7199.  
Construction of plasmids, transformation into DH5α and sequencing was performed as 
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described above.  Plasmid constructs pMW11168-R, pMW81-176-R and pMWX7199-R 
were electroporated into C. jejuni 81-176 (Table 2).  The empty vector, 81-176pMW10, 
from the prior assay was used as a background control.   β-galactosidase assays for 3 
independent experiments and statistical analysis were performed as described in the 
assays with the cmeABC promoters.  
 
Construction, purification, and functional analysis of various CmeR variants 
Sequence polymorphisms were detected in CmeR among the analyzed isolates. 
To determine if the sequence variations affected the DNA binding activity of CmeR, we 
generated various forms of recombinant CmeR using site-directed mutagenesis. Plasmid 
pQECmeRSS (37) was used as a template for site directed mutagenesis, which was done 
using the Stratagene QuikChange II  kit.  Site-specific primers (Table 1) were used to 
produce the amino acid changes in CmeR from isolates CT2:2, M63885, CT9:7, and 
T37597A.  All amino acid substitutions, corresponding nucleotide sequences and protein 
names are listed in Table 3.  
Isolate M63885 contains 2 amino acid substitutions in CmeR, which were 
introduced simultaneously into the pQECmeRSS template. The M63R17-F and M63R17-
R primers were used to mutate the threonine to isoleucine at residue 3 and the M63475-F 
and M63475-R primers were used to mutate the glutamate to lysine at residue 159. This 
mutated plasmid was named pQECmeR-IK.  Isolates CT9:7 and T37957A both contain a 
single amino acid substitution in CmeR.  Primers T97547G-F and T97547G-R were used 
to change the proline to arginine at residue 159 as observed in strain CT9:7, creating the 
plasmid named pQECmeR-R.  Primers T3X250A-F and T3X250A-R introduced the 
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glutamate to lysine substitution at residue 84 as observed in strain T37957A.  This 
plasmid was named pQECmeR-K. Isolate CT2:2 contains 2 amino acid substitutions in 
CmeR and a nucleotide insertion.  This mutated CmeR was created using 2 rounds of 
mutagenesis.  The T insertion after nucleotide 583 was introduced into template 
pQECmeRSS with primers T22583-F1 and T22583-R1 along with the first amino acid 
substitution at residue 144, a glycine to alanine substitution, with primers r431GA-F and 
r431GA-R to create an intermediate plasmid.  The mutations were confirmed in the 
intermediate plasmid prior to introduction of the final mutations.   In the second round of 
mutagenesis, this intermediate was used as a template to introduce the final amino acid 
change, a serine to glycine substitution at residue 207 with primers r619621-F and 
r619621-R to create plasmid pQECmeR-tr. 
  All mutations were introduced into the respective templates by one cycle of 95°C 
for 30 seconds followed by 16 cycles of 95°C for 30 seconds, 55°C for 30 seconds, and 
68°C for 4 minutes. The amplified product was cooled on ice for 2 minutes before Dpn-I 
digestion of parental DNA at 37°C for 1 hour.   Each product was transformed into 
JM109 or XL1-Blue (Agilent) and the transformants were selected on LB agar 
supplemented with ampicillin (100 µg/mL).  The specific mutations were confirmed by 
sequencing with primers pQETypeIII/IV-F and pQEReverse-R (Table 1).   
 The CmeR variants including rCmeR-tr, rCmeR-R, rCmeR-K, and rCmeR-IK 
were induced and purified from their respective E. coli strains (Table 2) under native 
conditions (40).  After purification, proteins were desalted using PD-10 desalting 
columns (GE Healthcare).  Proteins of rCmeR-tr and rCmeR-K were concentrated in PBS 
using Amicon Centricon YM-10 Columns (Millipore).  
 
 
 
 
 
76 
 For functional analysis, EMSA was used to assess the ability of the mutated 
versions of CmeR to bind to the cmeABC promoter. Binding by the purified mutant 
proteins rCmeR-tr, rCmeR-R, rCmeR-K or rCmeR-IK was compared to binding by the 
rCmeRSS protein. The 11168 cmeABC promoter probe (0.05 pmol) was incubated with 
0, 60, 120, and 180 ng of rCmeRSS or one of the mutant rCmeR proteins in 22µL of 
reaction buffer according to the method of Alekshun et. al. and Lin et. al. 2005 (12, 38). 
The reaction mixtures were incubated for 30 minutes at room temperature and Promega 
DNA loading buffer was added to each reaction.  Electrophoresis, transfer, and detection 
were performed using the same methods as described for the EMSA assay.   
 
Antimicrobial susceptibility testing  
Agar dilution test was performed in MH agar and MH agar supplemented with 
12,500 µg/mL of sodium choleate according to the CLSI-recommended method (31).  
Ciprofloxacin, kanamycin, erythromycin, tetracycline, ampicillin, clindamycin, 
chloramphenicol, ethidium bromide, sodium choleate, cholic acid and taurocholic acid 
were tested.  In addition to the 21 WEL and 43 OEL clinical isolates, 3 laboratory strains 
classified as WEL isolates, NCTC 11168, ATCC33560, and 81-176, were also tested.  At 
least 2 experiments were performed for each isolate.  Distribution of the minimum 
inhibitory concentration (MIC) around the median was tested with the Brown Forsythe 
test (SAS version 9.2) comparing the 43 OEL and 24 WEL isolates. The significance 
level set at 0.05. 
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Fluctuation Assays 
Fluctuation assays were performed to assess if CmeABC expression levels 
affected the spontaneous mutation rate to ciprofloxacin in C. jejuni.  The assays were 
conducted using the methods described by Luria and Delbrück (41) with some 
modifications (42-46). Selected WEL isolates (NCTC 11168, 81-176, CB8:14, CT10:18, 
H2958, CB6:8) and OEL isolates (CT9:7, CB4:22, M76297, CT9:14, CB3:1, T37957A, 
11168ΔcmeR, 81-176ΔcmeR) were cultured on antimicrobial-free MH plates, adjusted to 
108 CFU/mL in MH broth, and serially diluted to 104. Thirty-six parallel cultures of 200 
µL were inoculated on a 96-well plate and incubated for 24 hours. Total cell counts were 
determined by plating on antimicrobial free MH agar while spontaneous mutant counts 
were plated on MH agar supplemented with 4 µg/mL of ciprofloxacin. 
Total cell counts for each set of cultures (36 parallel cultures) were estimated 
from 5 random wells.  The 5 wells were selected using the Random Integer Set Generator 
(Random.org).   From each of these wells, a 10 µL sample of culture was removed and 
serially diluted to 10-7.   A 90 µL sample from the 10-5, 10-6, and 10-7 dilutions was spread 
to MH agar. Plates were incubated for 2 days for total CFU counts. Counts from the 5 
random wells were averaged to determine the total count for each set of 36 parallel 
cultures. 
  To determine the number of spontaneous mutants, all 36 wells were plated to 
MH agar containing 4 µg/mL of ciprofloxacin.  Plates were checked after 2 days for 
colony size and incubated for an additional day to ensure colonies were large enough for 
counting. Mutation rate was calculated by the Ma-Sandri-Sarkar Maximum Likelihood 
Estimator method using the Fluctuation Analysis Calculator (47). Average mutation rates 
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for WEL and OEL were log transformed and compared with the Student’s t-test using 
GraphPad InStat® (Version 3.06) with the significance level set at 0.05. 
 
In vitro ciprofloxacin treatment  
Inactivation of CmeABC reduced the emergence of ciprofloxacin-resistant 
mutants in C. jejuni under antibiotic selection, while inactivation of cmeR (resulting in 
overexpression of cmeABC) increased mutant emergence, suggesting that expression 
levels of CmeABC influences the emergence of antibiotic resistant mutants. To assess if 
differential expression of cmeABC in naturally occurring isolates affects their adaptation 
to antibiotic treatment, we examined the emergence frequencies of ciprofloxacin-resistant 
mutants in isolates of different CmeABC phenotypes. Three WEL (CB6:8, F15871, 
CT10:18) and three OEL isolates (T37957A, CT7:20, CB8:14) were used for this 
experiment, which were cultured on non-selective media (MH agar) and then treated with 
4 µg/mL of ciprofloxacin using the method of Han et. al. 2008 (48) with some 
modifications.  Briefly, MH broth supplemented with 4 µg/mL of ciprofloxacin was 
inoculated to an initial concentration of 107 CFU/mL in a 20 mL of culture with 3 
replicates per isolate. Cultures were incubated for 3 days.  Samples (0.5 mL) were taken 
on days 0, 1, 2, and 3 - post inoculation for enumeration of ciprofloxacin-resistant mutant 
and total cell counts. Total counts were cultured on MH agar according to the plate drop 
method (49) for days 0, 1, 2, and 3.  For days 0 to 2 mutants were counted by direct 
plating 100 µL of culture onto MH-ciprofloxacin (4 µg/mL) agar in duplicate and 
according to the plate drop method (49) onto MH-ciprofloxacin (4 µg/mL) agar.  For day 
3, total plate counts and mutants were all determined by the plate drop method. The serial 
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dilutions used in the plate drop method were dilutions 10-2 to 10-7 for day 0 and 10-3 to 
10-8 for days 1 to 3.  Two independent experiments were performed for each isolate. The 
cell counts were calculated for each culture and log transformed. Data analysis was 
performed with Graph Pad Prism® (Version 6.0c) with multiple unpaired t-tests and 
Holm-Šídák method for multiple comparisons.  The significance level was set at 0.05.  
In the second experiment, cultures were inoculated to an initial density of 106 
CFU/mL. Samples were collected in the same manner as the first experiment.  For each 
day total counts were cultured on MH agar according to the plate drop method (49).  
Mutants were counted by direct of plating 100 µL of culture to MH-ciprofloxacin (4 
µg/mL) agar in duplicate and serial dilutions for plate drop method (49) onto MH-
ciprofloxacin (4 µg/mL) agar.  The serial dilutions used in the plate drop method were 
dilutions 10-2 to 10-7 for day 0 and 10-3 to 10-8 for days 1 to 3. Two independent 
experiments were performed for each isolate.  Data analysis was performed as described 
in the prior experiment. 
 
Results 
 
Phenotypic classification of isolates 
 Initial screening for phenotypic classification of CmeABC expression was done 
through immunoblotting (Fig.1) and real time RT-PCR for expression of cmeB. Analysis 
of the 64 C. jejuni isolates for cmeB expression identified 43 isolates with overexpression 
levels (OEL) of CmeABC and 21 isolates with wild-type expression levels (WEL) of 
CmeABC.  The region spanning from cmeR to cmeA was sequenced for all OEL isolates, 
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4 of the WEL isolates, and C. jejuni strain 81-176 to identify genetic mutations that were 
potentially involved in mediating the differential cmeABC expression. All isolates except 
1 OEL isolate harbored mutations in the sequenced region compared to the same region 
in strain NCTC 11168.   
To refine the identification of mutations mediating differential cmeABC 
expression, the cmeABC promoter was analyzed for mutations unique to the OEL isolates 
and cmeR was analyzed for DNA polymorphisms resulting in amino acid changes. The 
CmeR binding site of the cmeABC promoter contains an A to T substitution at base 10 of 
the 16 base inverted repeat in strain 81-176 (Fig. 2A) that is considered a natural 
variation (81-176 variation) (6).  Among the clinical isolates, 34 carried this mutation. 
Isolates that contained only the 81-176 variation in the CmeR binding site were excluded 
from further analysis.   There were 14 OEL isolates carrying mutations within the CmeR 
binding site of the cmeABC promoter other than the 81-176 A to T substitution (Figure 
2A).  These isolates also carried amino acid mutations in CmeR. All of the observed 
amino acid mutations were also seen in isolates with no mutations in the cmeABC 
promoter. These 14 isolates were categorized as cmeABC promoter mutants.    
Analysis of cmeR for DNA polymorphisms found numerous mutations leading to 
amino acid changes in CmeR. DNA polymorphisms that did not result in amino acid 
changes in CmeR were excluded. Three isolates harbored unique mutations in CmeR 
(Table 3). Other OEL isolates carried amino acid changes in CmeR that were also seen in 
WEL isolates. Five OEL isolates and one WEL isolate with a unique combination of 
substitutions at residues 144, 183 and 207 were also selected for analysis (Table 3). None 
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of these isolates, except X7199, had mutations in the cmeABC promoter.  Together these 
9 clinical isolates were categorized as cmeR mutants.    
 
Mutation of the CmeR binding site affects cmeABC expression in clinical isolates 
Figure 2A illustrates the region of the cmeABC promoter containing the CmeR 
binding site.  Two categories of substitutions were observed in the CmeR binding site: 5 
isolates with a G to A substitution at base 2 of the inverted repeat and 7 isolates with an 
A to G substitution at base 14.  The 81-176 variation is found in 7 isolates carrying the 
substitution at base 14 and one isolate carrying the substitution at base 2.  Two isolates 
carrying the 81-176 variation and a 5 base deletion in the cmeABC promoter were 
detected.   The last 3 bases of the CmeR binding site and the following 2 bases are absent 
in isolate CT9:20 (Fig 2A). Isolate X7199 has a 5 base deletion 5’ to the CmeR binding 
site in addition to an A to G substitution at base 14 of the CmeR binding site (Fig 2A).  
These 14 isolates are considered cmeABC promoter mutants. 
From the cmeABC promoter mutants, 6 representative sequences were selected for 
analysis by EMSA and transcriptional fusion (Fig. 2A).  The promoters from the isolates 
X7199 and CT9:20 were selected for their unique deletions. The M32506 and CT3:7 
promoters both contain the 14 A to G mutations, while the CT3:7 promoter also contains 
the 81-176 variation. The CT1:1 and CT1:9 promoters carry the 2 G to A mutation.   
The ability of CmeR to bind to the mutant cmeABC promoter sequences was 
assessed by EMSA. The selected mutant cmeABC promoter sequences from clinical 
isolates were paired with either the 11168 promoter (promoter from strain NCTC 11168) 
(Fig. 2B, panels I to III, lanes 1 to 4) or 81-176 promoter (Fig. 2B, panels IV to VI, lanes 
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1 to 4) for use in EMSA based on the presence or absence of the A to T 81-176 variation 
in the CmeR binding site.  Five of the 6 mutant promoters, CT1:1, CT1:9, M23506, 
CT3:7, and CT9:20 (Fig 2B, panels I, II, III, V, and VI respectively, lanes 5 to 8) showed 
decreased binding to rCmeRSS as manifested by the increased amounts of unbound probe 
and/or decreased amounts of  probe- rCmeRSS complexes.  The CT1:1 (Fig. 2B, panel I, 
lanes 5 to 8), CT1:9 (Fig. 2B, panel II, lane 5 to 8) promoters showed increased amounts 
of free probe.  The M32506 (Fig. 2B, panel III, lane 5 to 8), CT3:7 (Fig 2B,  panel V, 
lane 5 to 8), and CT9:20 (Fig. 2B, panel VI, lane 5 to 8) probes display decreased 
intensity in the CmeR-DNA complexes and increased amounts of free probe.  The 
CT9:20 cmeABC promoter  (Fig. 2B, panel VI, lanes 5-8) showed the largest reduction in 
CmeR binding as indicated by the reduced intensity of rCmeRSS-DNA complexes (Fig. 
2B, panel VI lanes 7-8) and increased free probe amount compared to the 81-176 probe. 
The X7199 promoter displayed no difference in binding to rCmeRSS compared to the 81-
176 promoter (Fig. 2B, panel IV).  These results suggest that most of the examined 
mutations in the cmeABC promoter sequence affected binding by CmeR. 
To further quantify the effect of the promoter mutations on cmeABC expression, 
transcriptional fusion of the mutant cmeABC promoters to the promoterless lacZ gene 
was performed in the presence and absence of CmeR.  In the 81-176 wild-type 
background, CmeR is expressed and binds to the cmeABC promoter, repressing its 
transcription.  The 81-176ΔcmeR strain is an isogenic mutant that does not express CmeR, 
resulting in a loss of repression for the cmeABC promoter.  Without this repressor, 
cmeABC is overexpressed.  Transcription from the 11168 promoter in the 81-176 wild-
type background (CmeR is present) was defined as the basal level of cmeABC 
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transcription and used as a control.  In the presence of CmeR (81-176 wild-type 
background) (Fig. 3A), all examined cmeABC promoters including 81-176 have 
significantly increased (p<0.05) transcription compared to basal levels.  Expression from 
the 81-176 promoter increased 2.4-fold (p = 0.0096), the CT1:1 promoter increased 4.6-
fold (p = 0.0232), the CT1:9 promoter increased 5.5-fold (p = 0.0073), the CT3:7 
promoter increased 5.6-fold (p = 0.0425), the M32506 promoter increased 6.3-fold (p = 
0.0036), and the X7199 promoter increased 5.4-fold (p = 0.0150) over basal transcription 
levels.  These increases are indicative of decreased repression by CmeR due to the 
mutations in the cmeABC promoters. Notably, the CT9:20 promoter with the deletion of 
the last 3 bases of the CmeR binding site, had the highest increase in transcription at 8-
fold (p = 0.0208) over the basal levels, consistent with its most obvious reduction in 
binding by CmeR on EMSA.   
Transcription from the CT1:1 and CT1:9 promoters, with the same sequence but 
carried in different isolates, was not significantly different. This indicates that choosing a 
single representative isolate is sufficient to evaluate the other isolates in the group.  The 
transcription from the X7199 and CT3:7 promoters is not significantly different, although 
there is 5-base pair deletion upstream of the CmeR binding site in the X7199 promoter.  
This result suggests that the substitutions in the CmeR binding site alone (represented by 
CT3:7) is sufficient to alter expression of cmeABC.  
In the absence of CmeR, transcription for all promoters except X7199, was not 
significantly different (p >0.05) compared to the 11168 promoter (Fig. 3B).   
Interestingly, transcription from the X7199 promoter was significantly increased 2.2-fold 
(p = 0.0472) over 11168 in the absence of CmeR and represents a 14.1-fold (p = 0.0154) 
 
 
 
 
 
84 
increase over the basal transcription level.  Comparatively, the 11168 promoter increased 
6.3-fold (p = 0.014) over basal levels while the 81-176 promoter increased 6.0-fold (p 
<0.0001).  This suggests that the additional increase for the X7199 promoter does not 
involve CmeR.  Comparisons for each promoter showed the deletion of CmeR 
significantly increased expression  (p <0.05) of the cmeABC promoters form 11186, 81-
176 and M32506 (Fig 3C).  Transcription in the absence of CmeR  (81-176 ΔcmeR 
background) showed a 6.3-fold increase for the 11168 promoter (p = 0.014) and a 2.5-
fold increase for the 81-176 promoter (p = 0.0039) and a 2.6-fold increase for the X7199 
promoter (p = 0.0367) (Fig 3C). The smaller change for the 81-176 and X7199 promoters 
compared to the 11168 promoter is likely due to already elevated expression in the wild-
type background mediated by the CmeR binding site mutations.  Transcription from the 
M32506 promoter, surprisingly, was statistically significant (p = 0.0410) in the absence 
of CmeR compared to the wild-type.  However this 0.8-fold difference is not biologically 
significant and is the same for the CT9:20 promoter (Fig. 3C). Examination of M32506 
transcription revealed this was likely due to a single, low level measurement in the wild-
type background. Compared to their transcription in the wild-type background, the 
expression of CT1:1, CT1:9, CT3:7,  and CT9:20 promoters were not significantly 
different (p > 0.05), suggesting that inactivation of cmeR did not further increase 
transcription from these promoters or M32506 (Fig. 3C).  
 
Varied expression levels of cmeR in clinical isolates 
 Several DNA polymorphisms were detected in the cmeR gene of clinical isolates, 
resulting in amino acid changes in this regulatory protein (Table 3). Immunoblotting of 
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whole cell proteins was performed to determine the CmeR expression level from 8 OEL 
isolates and 1 WEL isolate harboring representative mutations. The anti-CmeR antibody 
detected the CmeR protein from 8 of the 9 cmeR mutants (Fig. 4A).  The remaining cmeR 
mutant isolate (CT2:2) did not produce a band reactive with the antibody (Fig. 4B, lane 
2), suggesting that the CmeR protein was not translated in this isolate.  CT2:2 contained a 
T insertion after base 583 in cmeR, resulting in a frame shift and premature truncation 
(Table 3).  Additional immunoblotting failed to detect any portion of the truncated CmeR 
from CT 2:2.   
 To confirm the results of immunoblotting, cmeR expression was evaluated by real 
time RT-PCR.  Real time expression levels of cmeR varied dramatically among the 9 
isolates. Expression ranged from 0.006 to 33 fold of that in NCTC 11168 (Table 3), 
however this was not correlated with CmeR expression levels on immunoblotting 
(densitometric data not shown). Expression levels of cmeR from CT2:2 were negligible at 
0.006 fold of that in NCTC 11168, consistent with the lack of protein expression as 
detected by immunoblotting.   
 cmeR and Cj0369c form a two-gene operon and share a single promoter located in 
front of Cj0369c (13).  The predicted promoter for the Cj0369c-cmeR operon contains an 
inverted repeat with two half sites separated by a 12-base spacer that may represent an 
unknown regulatory mechanism (13).  Sequence analysis of this region was performed on 
several isolates to determine if mutations occurred and if they could be correlated with 
the varying cmeR expression levels identified by real time RT-PCR. Mutations of the 
Cj0369c-cmeR promoter were found in some isolates after comparison to the sequence of 
NCTC 11168 and were divided into 2 groups (data not shown).  The first group carried a 
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single base deletion one base 5’ to the second half site of the inverted repeat in strains 81-
176, T37957A, and E46972. The second group, consisting of isolates X7199, W52546, 
and S13530, contained a T insertion in the second half site of the inverted repeat after the 
eighth base and a G to A substitution at base 5 of the spacer.  The Cj0369c-cmeR 
promoter from CT2:2 had no mutations, suggesting that transcription from this promoter 
is unlikely the source of the decreased production as observed by immunoblotting and 
real-time PCR.    
 Transcriptional fusion of representative Cj0369c-cmeR promoters from strains 81-
176, X7199, and NCTC 11168 was performed to determine if the observed 
polymorphisms affected transcription. The 81-176, NCTC 11168, and X7199 promoters 
produced low levels of transcription (Miller units in the range 2-16), which were not 
significantly different (p > 0.05) (data not shown), suggesting that these mutations were 
not associated with the expression levels of cmeR. However, this was not consistent with 
the real time cmeR expression data (Table 3).  The mutations observed in the Cj0369c-
cmeR promoter for X7199 and the S13530 were identical but, cmeR expression was 10.9 
and 0.2 fold of NCTC 11168 respectively.   The reason for this discrepancy is unclear.   
 
Truncation, but not amino acid substitution affected CmeR binding to the cmeABC 
promoter  
 The amino acid changes in CmeR observed in clinical isolates were categorized 
into 5 groups represented by the 9 cmeR mutant isolates (Table 3). Site-directed 
mutagenesis and recombinant CmeR production were performed for 3 representative 
isolates with amino acid substitutions and a single isolate with substitution and truncation 
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of CmeR (Table 3). The 4 proteins produced were named rCmeR-tr, rCmeR-IK, rCmeR-
K and rCmeR-R.  The rCmeR-IK from M63885 contains 2 amino acid substitutions at 
residues 6 and 159 replacing threonine with isoleucine and glutamate with lysine, 
respectively.  The rCmeR-K from T37957A and rCmeR-R from CT9:7 contain single 
amino acid substitutions of the glutamate at residue 84 for lysine in rCmeR-K and the 
proline 183 residue for arginine in rCmeR-R.  The rCmeR-tr from isolate CT2:2 contains 
a glycine to alanine substitution at residue 144 and a nucleotide insertion after base 583 
resulting in pre-mature truncation of CmeR to 193 amino acids (the full-length CmeR is 
210 amino acids). The S207G substitution observed in CT2:2 occurs downstream of the 
truncation and was not expected to affect CmeR function.  rCmeR-tr was detected by 
immunoblotting with the anti-CmeR antibody and presented as a band of 23 kD (Fig. 5A, 
lane 3), slightly smaller than the full-length rCmeRSS at  24kD (Fig. 5A, lane 2), 
consistent with the predicted truncation.   
  EMSA was performed with all 4 mutant proteins to assess the binding to the 
NCTC 11168 cmeABC promoter (11168 promoter). The rCmeR-R, rCmeR-IK, or 
rCmeR-K proteins bound to the cmeABC promoter in a manner similar to the rCmeRSS 
control (data not shown).  However, rCmeR-tr failed to bind to the cmeABC promoter at 
all tested concentrations (Fig. 5B, lanes 5-8) suggesting that the truncation abolished the 
ability to bind promoter DNA. 
 
Differences in antimicrobial susceptibility 
In vitro antimicrobial susceptibilities did not differ between the OEL and WEL 
isolates in the presence or absence of bile for most of the tested antimicrobials except for 
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chloramphenicol.  Without bile, the median MIC for chloramphenicol was 4 µg/mL for 
both the OEL and WEL isolates (Table 4). However, the distribution of MICs around the 
median was significantly different between the two phenotypic groups (p < 0.05). The 
WEL isolates had chloramphenicol MICs of 2 to 4 µg/mL with 67% of the isolates at 4 
µg/ml, while the OEL isolates had MICs ranging from 2 to 16 µg/mL with 21% of the 
isolates at 8 and 16 µg/mL (Table 4).  With bile in the testing media, the MIC distribution 
between the two phenotypes was also significantly different (p <0.05) (Table 4). 
Although the median remains at 4 µg/mL for both groups, 81% of the OEL isolates were 
at this MIC, while 58% of the WEL isolate were at this MIC. Both OEL and WEL 
isolates have MIC ranges of 2 to 8 µg/mL after addition of bile. Compared to the non-bile 
media, addition of bile shifted the MIC to the upper end for WEL isolates and shifted the 
MIC to the median the for OEL isolates.     
 
Emergence of ciprofloxacin-resistant mutants 
 The spontaneous mutation rate to ciprofloxacin was examined for selected isolates 
using the fluctuation assay, which was not significantly different between OEL and WEL 
isolates (data not shown).  However, OEL isolates showed increased emergence of 
ciprofloxacin-resistant (CipR) mutants during in vitro treatment (Fig. 6).  Two 
experiments were performed with the initial inoculum levels of 107 and 106 CFU/mL, 
respectively.  For the inoculums at 107 CFU/mL, there were no significant difference in 
the mean numbers of pre-existing CipR mutants between the WEL and OEL cultures on 
day 0 (Fig. 6A).  CipR populations from both WEL and OEL cultures expanded over days 
1 to 3.  The mean CipR mutant populations were 0.9 logs higher for OEL on day 1, 1.5 
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logs higher on day 2, and 2 logs higher than WEL on day 3. However, the means were 
not significantly different between the OEL and WEL groups (p > 0.05). 
 For the inoculum of 106 CFU/mL, the means for pre-existing CipR mutants on day 
0 were not significantly different for the WEL and OEL cultures.  The mean CipR mutant 
numbers on day 1 were 2 logs (p = 0.0175) higher than the mutants in the WEL cultures.  
This trend continued on days 2 and 3 with OEL means being 3.7 logs (p = 0.0053) and 
4.2 logs (p = 0.0016) higher than the WEL means, respectively. These results indicate 
OEL cultures produced significantly higher numbers of CipR mutants than the WEL 
cultures during ciprofloxacin treatment.    
 
Discussion 
 
 This study demonstrates that differential expression of CmeABC naturally occurs 
in Campylobacter isolates derived from different host species.  The differential 
expression was linked to multiple mechanisms including mutations in the cmeABC 
promoter region and coding sequences of CmeR as well as decreased expression of 
CmeR, the repressor for the cmeABC operon. Additionally, there are unidentified 
mechanisms that also modulate cmeABC expression as some OEL isolates did not have 
any mutations in the known regulatory elements for cmeABC. Differential expression of 
cmeABC was linked to altered antimicrobial susceptibility and enhanced the emergence 
of CipR mutants under antibiotic selection.  These findings suggest that differential 
expression of CmeABC is selected under natural conditions and may facilitate 
Campylobacter adaptation to various environments. 
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Of the 64 isolates examined in this study, 43 (67%) were phenotypically classified 
as OEL isolates.  CmeABC is normally repressed by CmeR, which binds to the promoter 
region of cmeABC (12). Thus, mutations in CmeR and/or the cmeABC promoter sequence 
were investigated to determine the genetic basis associated with overexpression of 
cmeABC in these clinical isolates. Those mutations that occurred in the CmeR binding 
site or resulted in amino acid changes in CmeR and were absent from the majority of the 
WEL isolates were selected for detailed analysis. Additionally, those isolates harboring 
the same mutation as the one in the CmeR binding site of strain 81-176 were excluded 
from analysis as this mutation has been characterized previously (12). Using these 
selection criteria, we selected 14 isolates harboring promoter mutations and 9 isolates 
harboring CmeR mutations for detailed analysis. 
Most of the detected amino acid substitutions in CmeR did not affect its function 
as determined by EMSA. However, a single nucleotide insertion at the 3’end of the cmeR 
gene resulted in a frame-shift and presumably led to truncation of the CmeR protein in 
CT2:2.  CmeR was not detected by immunblotting in CT2:2 (Fig. 4B) and the cmeR 
transcript level was also significantly reduced. Additionally, CT2:2 did not contain any 
mutations in the predicted  Cj0369c-cmeR promoter region, excluding the possibility that 
lack of cmeR expression was due to altered transcription initiation.  These findings 
suggest that the single nucleotide insertion could have destabilized the cmeR transcript or 
the frame shift rendered the CmeR protein unstable in C. jejuni, leading to the lack of 
CmeR in this isolate. However, a recombinant version of the truncated CmeR (rCmeR-tr) 
was successfully generated (Fig. 5A), suggesting that this truncated CmeR is stable in the 
E. coli host.  Interestingly, rCmeR-tr failed to bind to the promoter DNA of cmeABC as 
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determined by EMSA (Fig. 5B), suggesting that even if this truncated version is made in 
C. jejuni, it would not be able to control the expression of cmeABC. The lack of CmeR 
production and the inability of the truncated CmeR to bind to promoter DNA fully 
explain the overexpression of cmeABC in isolate CT2:2.   
It is interesting that rCmeR-tr lost the ability to bind DNA despite the fact that the 
truncation occurred in the C-terminal end of CmeR and the DNA-binding domain 
remained intact. The truncation occurred in the α10 helix of CmeR.  CmeR functions as 
dimer in vivo and the crystal structure of CmeR identified that α helices 6, 8, 9, and 10 
are involved in dimer formation (12, 15, 50). Thus, the truncation in rCmeR-tr likely 
affects dimer formation and ultimately the function of CmeR. This result suggests that the 
C-terminal sequence of CmeR is also important for its interaction with target DNA. 
Recently, C. jejuni ATCC 33560, a quality control strain used for antimicrobial 
susceptibility testing in C. jejuni, was found to contain a frame shift mutation in cmeR, 
which led to truncation of the CmeR protein (51). The truncation occurs in α helix 8 of 
CmeR and presumably results in non-functional CmeR (51).  Together, these findings 
indicate that frame-shift mutations in CmeR occur under natural conditions. As CmeR is 
a pleiotropic regulator (regulating other genes in addition to cmeABC) (13), truncation of 
CmeR likely affects multiple functions in C. jejuni. 
The majority of the mutations in the cmeABC promoter were found to affect 
cmeABC expression.  The cmeABC promoter contains a 16 base inverted repeat that 
serves as the specific binding site for CmeR (12).  Mutations in the CmeR binding site 
within the cmeABC promoter have been described previously after in vitro stepwise 
selection with erythromycin (14) and ciprofloxacin (12). This study is the first to describe 
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the occurrence of this type of mutation in C. jejuni isolates from natural sources and 
various hosts including humans, turkeys, and chickens. These mutations inhibited binding 
by CmeR, resulting in increased transcription from the cmeABC promoter.  This was 
demonstrated by reduced binding of the mutant promoters by CmeR on EMSA (Fig. 2B, 
panels I, II, III,V, and VI) and increased transcription of cmeABC as determined by 
transcriptional fusion assays (Fig. 3). In addition to the substitution, deletions within the 
CmeR binding site were found in one isolate, CT9:20.  This promoter showed the greatest 
inhibition of CmeR binding on EMSA and the largest increase in transcription in the 
presence of CmeR (Fig. 3A). These findings indicate that mutations in the cmeABC 
promoter commonly occur and these mutations influence the expression of this multidrug 
efflux pump.  
 Multiple mutations were also identified in a single isolate. For example, isolate 
X7199 harbored a substitution in the CmeR binding site and a 5 base deletion upstream 
of the CmeR binding site (Fig. 2A). This isolate also contained mutations in cmeR (Table 
3).  The cmeABC promoter in this isolate was identical to the promoter in CT3:7 except 
for a 5-base pair deletion upstream of the CmeR binding site (Fig. 2A).  While the CT3:7 
promoter demonstrated reduced binding to CmeR on EMSA (Fig. 2B, panel V), the 
X7199 promoter had similar binding as the 81-176 cmeABC promoter (Fig. 2B, panel 
IV). However, both the X7199 and CT3:7 cmeABC promoters demonstrated similar, 
elevated expression by transcriptional fusion assay compared with the 11168 promoter in 
the presence of CmeR (Fig. 3A).  This discrepancy between the results of EMSA and 
transcriptional fusion suggests that the EMSA assay has a lower sensitivity than the 
transcriptional fusion assay, or alternatively, there is another regulatory mechanism that 
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also modulates cmeABC expression. Indeed, when the X7199 promoter was examined in 
the absence of CmeR using transcriptional fusion (Fig. 3B), its expression was 
significantly increased compared to its own expression level in the presence of CmeR 
(Fig. 3C).  This result is consistent with the EMSA result and suggests that the X7199 
promoter is still under the repression by CmeR.   
In some isolates, the OEL phenotype was not linked to the known mechanisms 
modulating cmeABC expression as there were no mutations detected in CmeR or the 
promoter region. Additionally, even though some isolates harbored mutations in CmeR, 
these mutations did not affect the function of CmeR. Furthermore, the regulation of the 
X7199 promoter cannot be fully explained by a CmeR-dependent mechanism. These 
findings suggest that there may be additional regulatory mechanisms modulating 
cmeABC expression.  Previously, Lin et. al. 2005 also described a CmeR-independent 
mechanism modulating cmeABC expression (16).  Bile is a known inducer of CmeABC 
and mediates increased expression by altering the confirmation of CmeR, resulting in 
disassociation of CmeR from the cmeABC promoter (15, 16).  It was noticed that in the 
absence of CmeR, the expression of cmeABC was further induced by taurocholate, 
suggesting this bile compound induced expression of cmeABC through a CmeR- 
independent mechanism (16).  Taken together, observations from this study and previous 
reports suggest that multiple mechanisms modulate the expression of cmeABC.    
 The functional consequence of cmeABC overexpression was evaluated in relation 
to antimicrobial treatments.  Antimicrobial susceptibility was unaffected by cmeABC 
overexpression for most of the tested antibiotics, with the exception of chloramphenicol.  
This was not surprising as a previous study using genetic manipulation revealed that 
 
 
 
 
 
94 
overexpressing cmeABC by inactivating cmeR had a modest effect on MICs, but 
inactivation of cmeABC significantly increased the susceptibility of C. jejuni to 
antibiotics (6, 12).  For chloramphenicol, the OEL isolates displayed a larger range of 
MIC values than WEL isolates, with more MICs distributed above the median value 
(Table 4). This suggests that overexpression of CmeABC had an effect on the MIC 
distribution of chloramphenicol. Interestingly, when chloramphenicol MIC was measured 
in the presence of bile, the MICs of the WEL isolates shifted above the median value, 
while the MICs of the OEL isolates shifted toward the median value. This difference is 
probably due to the fact that bile is an inducer for cmeABC and the possibility that 
induction was more prominent in the WEL isolates than in the OEL isolates.  For the 
OEL isolates, cmeABC was already overexpressed due to less inhibition by CmeR or 
other unidentified mechanisms. Thus, the bile-mediated induction through CmeR is 
expected to be less effective in the OEL isolates than in the WEL isolates.   
 Fluoroquinolone resistance in Campylobacter is mediated by DNA gyrase 
mutations and the function of CmeABC (6, 8, 9). These two mechanisms function 
synergistically in mediating resistance to fluoroquinolones (9). Additionally, CmeABC 
promotes the emergence of fluoroquinolone-resistant mutants under antibiotic selection 
(8, 23). In this study, we examined the correlation between the OEL phenotype and 
ciprofloxacin resistance. It was found that the basal spontaneous mutation rate was not 
affected by overexpression of cmeABC as measured by the fluctuation assay.  However, 
the OEL isolates showed higher level of emergence of CipR mutants under antibiotic 
selection (Fig. 6).  This was consistently shown by using two inoculation doses (106 and 
107 CFU/mL). For the 107 CFU/mL inoculum, the difference between the OEL and WEL 
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groups were obvious, but were not statistically significant. For the 106 CFU/mL 
inoculum, the numbers of CipR mutants from the OEL isolates were significantly higher 
than those from the WEL mutants. The lack of statistical significance with the 107 
CFU/mL inoculum was probably due to the presence of pre-existing CipR mutants in the 
inoculum (Fig. 6) that somewhat reduced the difference between the OEL and WEL 
groups. Thus, reducing the inoculum to 106 CFU/mL allowed clear detection of 
differences between the two groups. These results suggest that the OEL phenotype may 
facilitate Campylobacter to adapt to fluoroquinolone treatment by promoting the 
emergence of resistant mutants. This finding has practical implication as fluoroquinolone 
antibiotics are used for both human medicine and animal production. Thus, the detection 
of a large number of C. jejuni with an OEL phenotype from different host species might 
be the result of antibiotic usage that has served as a selection force for the OEL 
phenotype. 
 In summary, this study reveals that overexpression of CmeABC commonly occurs 
in C. jejuni isolates derived from various host species.  The overexpression is mediated 
by multiple mechanisms including mutations in the cmeABC promoter sequence and in 
the CmeR coding sequence. Additionally, results from this study suggest that there are 
other unidentified mechanisms that modulate the expression of CmeABC. 
Overexpression of cmeABC promotes the development of resistant mutants upon 
treatment with fluoroquinolone antibiotics and may contribute to the survival and 
persistence of C. jejuni in animal reservoirs where antibiotics are commonly used. These 
findings provide new insights into the adaptive mechanisms of C. jejuni and further 
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highlight the potential to control antibiotic resistant Campylobacter by targeting 
CmeABC.  
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TABLE 1: Oligonucleotide primers used for PCR and real time RT-PCR1 
Primer Sequence Source or 
Reference 
PCR    
  RIGA2-F CAAGTTTAGCAGGGTAAGTAA This study  
  RIGA2-R   TAAATTAAAAGCAGGAGAACAAG This study  
  16srRNA-F AATCTAATGGCTTAACCATTA (26) 
  16srRNA-R GTAACTAGTTTAGTATTCCGG (26) 
  mapA-F GAGTGCTTGTGCAACTAAAC (27) 
  mapA-R ATAGCATCTTGAGTTGCTCC (27) 
  GSF CTAAATGGAATCAATAGCTCC (12) 
  GSR1 GCACAACACCTAAAGCTAAAA (12) 
  PF AAAAGGATCCTAAATGGAATCAATAGCTCC (BamHI) (12) 
  PX GCGGCATTTGTATTTCTAGAGCTTCTTCT (XbaI) This study 
  pMW10-F ATCTGCCTCCTCATCCTCTTCAT This study 
  pMW10-R ATTCAGGCTGCGCAACTGTT This study 
  M63R17-F ATGAACTCAAATAGAATACCATCACAAAAAGTT This study 
  M63R17-R AACTTTTTGTGATGGTATTCTATTTGAGTTCAT This study 
  M63R475-F TATATGAAAAAAAATGCAAAAAAACTTGCTGTTCTTT This study 
  M63R456-R AAAGAACAGCAAGTTTTTTTGCATTTTTTTTCATATA This study 
  T3X250A-F CCAAAACACAAGAAATTAAAAATGGCACTTTAAAA This study 
  T3X250A-R TTTTAAAGTGCCATTTTTAATTTCTTGTGTTTTGG This study 
  T97547G-F AATGTTTTAATTAACGCTGCTTTGAAAAATAAAAAAG This study 
  T97547G-R CTTTTTTATTTTTCAAAGCAGCGTTAATTAAAACATT This study 
  T22583-F1 GAACATGTTTGAATTTGTTGTAAATGTTTTT This study 
  T22583-R1 AAAAACATTTACAACAAATTCAAACATGTTC This study 
  r431GA-F CTATAACATACTTATGGATTTTTTCAAGCAACAAA This study 
  r431GA-R TTTGTTGCTTGAAAAAATCCATAAGTATGTTATAG This study 
  r619621-F AATGGAATCAATGGATCCAAAGCTTAA This study 
  r619621-R TTAAGCTTTGGATCCATTGATTCCATT This study 
  pQETypeIII/IV-F CG GATAACAATT TCACACA G Promega 
  pQEReverse-R GTTCTGAGGTCATTACTGG Promega 
  Cj0370-F1 CAGTCCTCACCACCTTTCT This study 
  Cj0368c-R AGGCCACTGCTTTGATT This study 
 370BamH-F CAGTCGGATCCACCTTTC (BamHI) This study 
 369XbaI-R1 AAATATCGTTTTTTTCTAGAGTTTGTAAT (XbaI) This study 
   
Real time RT-PCR   
  16S-F TACCTGGGCTTGATATCCTA (34) 
  16S-R GGACTTAACCCAACATCTCA (34) 
  cmeB-F ACGATTCAACCTTTTCCCAGC (34) 
  cmeB-R TTTGCTACTTGAGCAATCGCTTC (34) 
  F3 ATTTTCAATCAACCAGAAGCTG (16) 
  R3 TCCAATTGGCAAGATGTCTATC (16) 
1Restriction sites are indicated by underlined sequence 
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TABLE 2: Bacterial strains or plasmids used in this study 
Plasmid or Strain Description Source 
Plasmids   
     pMW10 E. coli – Campylobacter shuttle vector 
carrying promoter-less lacZ, KanR 
(32) 
     pMW11168 pMW10 carrying the cmeABC promoter 
from NCTC11168 fused to lacZ, KanR 
This study 
     pMW81-176 pMW10 carrying the cmeABC promoter 
from 81-176 fused to lacZ, KanR 
This study 
     pMWX7199 pMW10 carrying the cmeABC promoter 
from X7199 fused to lacZ, KanR 
This study 
     pMWM32506 pMW10  carrying the cmeABC promoter 
from isolate M32506 fused to lacZ, KanR  
This study 
     pMW1:1 pMW10 carrying the cmeABC promoter 
from isolate CT1:1 fused to lacZ, KanR 
This study 
    pMW1:9 pMW10 carrying the cmeABC promoter 
from isolate CT1:9 fused to lacZ, KanR 
This study 
     pMW3:7 pMW10 carrying the cmeABC promoter 
from isolate CT3:7 fused to lacZ, KanR 
This study 
     pMW9:20 pMW10 carrying  the cmeABC promoter 
from isolate CT9:20 fused to lacZ, KanR 
This study 
     pMW11168-R pMW10 carrying the Cj0369c-cmeR  
promoter from NCTC 11168 fused to 
lacZ, KanR 
This study 
     pMW81-176-R pMW10 carrying the Cj0369c-cmeR  
promoter from 81-176 fused to lacZ, 
KanR 
This study 
     pMWX7199-R pMW10 carrying the Cj0369c-cmeR  
promoter from  isolate X7199 fused to 
lacZ, KanR 
This study 
     pQE30 Expression vector for N-terminal 6-His 
tagged proteins, AmpR 
Qiagen 
     pQECmeRSS pQE30 carrying CmeR with the C69S and 
C166S mutations  
(37) 
     pQECmeR-K pQE30 carrying CmeRSS with the E84K 
mutation, AmpR 
This study 
     pQECmeR-R pQE30 carrying CmeRSS with the P183R 
mutation, AmpR  
This study’ 
     pQECmeR-IK pQE30 carrying CmeRSS with the T6I 
and E159K mutations, AmpR  
This study’ 
     pQECmeR-tr pQE30 carrying CmeRSS with the 
G144A and S207G amino acid mutations.  
Also carries T insertion at nucleotide 583 
causing frame shift after amino acid 193, 
AmpR  
This study’ 
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TABLE 2: continued 
Plasmid or Strain Description Source 
Campylobacter jejuni strains   
     NCTC 11168 Wild type; genome sequence known (1) 
     11168ΔcmeR Derivative of NCTC 11168, cmeR::cat (2) 
     ATCC 33560 C. jejuni quality control strain (3, 4) 
     81-176 Wild type; isolated from a human (5) 
     81-176pMW10 Derivative of 81-176 carrying pMW10 This Study 
     81-176pMW11168 Derivative of 81-176 carrying 
pMW11168 
This Study 
     81-176pMW81-176 Derivative of 81-176 carrying pMW81-
176 
This Study 
     81-176pMWX7199 Derivative of 81-176 carrying 
pMWX7199 
This Study 
     81-176pMWM32506 Derivative of 81-176 carrying 
pMWM32506 
This Study 
     81-176 pMW1:1 Derivative of 81-176 carrying pMW1:1 This Study 
     81-176 pMW1:9 Derivative of 81-176 carrying pMW1:9 This Study 
     81-176 pMW3:7 Derivative of 81-176 carrying pMW3:7 This Study 
     81-176 pMW9:20 Derivative of 81-176 carrying pMW9:20 This Study 
     81-176ΔcmeR  Derivative of 81-176, cmeR::cat (2) 
     81-176ΔcmeR pMW10 Derivative of 81-176ΔcmeR carrying 
pMW10 
This Study 
     81-176ΔcmeR pMW11168 Derivative of 81-176ΔcmeR carrying 
pMW11168 
This Study 
     81-176ΔcmeR pMW81-176 Derivative of 81-176, cmeR::cat carrying 
pMW81-176 
This Study 
     81-176ΔcmeR pMWX7199 Derivative of 81-176ΔcmeR carrying 
pMWX7199 
This Study 
     81-176ΔcmeR pMWM32506 Derivative of 81-176ΔcmeR carrying 
pMWM32506 
This study 
     81-176ΔcmeR pMW1:1 Derivative of 81-176ΔcmeR carrying 
pMW1:1 
This study 
     81-176ΔcmeR pMW1:9 Derivative of 81-176ΔcmeR carrying 
pMW1:9 
This study 
     81-176ΔcmeR pMW3:7 Derivative of 81-176ΔcmeR carrying 
pMW3:7 
This study 
     81-176ΔcmeR pMW9:20 Derivative of 81-176ΔcmeR carrying 
pMW9:20 
This study 
     81-176pMW11168-R Derivative of 81-176 carrying 
pMW11168-R 
This study 
     81-176pMW81-176-R Derivative of 81-176 carrying       
pMW81-176-R  
This study 
     81-176pMWX7199-R Derivative of 81-176 carrying 
pMWX7199-R 
This study 
   
Escherichia coli strains   
     DH5α F-Φ80lacZΔM15 Δ(lacZYA-argF) U169 
recA1 endA1 hsdR17 (tκ,-mκ+) phoA 
supE44λ- thi-1 gyrA96 relA1 
Invitrogen 
     DH5αpRK2013 IncP KmR Tra RK2+ ΔrepRK2 repE1+ (6) 
     DH5αpMW10 DH5α derivative carrying pMW10 (7) 
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TABLE 2: continued 
Plasmid or Strain Description Source 
E. coli strains, continued   
     JM109 e14-(McrA-) recA1 endA1 gyrA96 thi-1 
hsdR17(tκ-mκ+) supE44 relA1 Δ(lac-
proAB) [F’ traD36 proAB lacqZΔM15] 
Agilent  
     XL-1 Blue recA1 endA1 gyrA96 thi-1 hsdR17 
supE44 relA1 lac [F’ proAB lacIqZΔM15 
Tn10 (Tetr) 
Agilent 
     JM109pQECmeRSS Derivative of JM109 carrying 
pQECmeRSS AmpR 
(1) 
     JM109pQECmeR-K Derivative of JM109 carrying  
pQECmeR-K, AmpR  
This study 
     JM109pQECmeR-R Derivative of JM109 carrying 
 pQECmeR-R, AmpR  
This study 
     JM109pQECmeR-IK Derivative of JM109 carrying pQECmeR-
IK, AmpR 
This study 
     XL1-Blue pQECmeR-tr Derivative of XL1-Blue carrying 
pQECmeR-tr, AmpR 
This study 
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TABLE 3: Mutation, expression, and phenotypes of CmeR in selected C. jejuni isolates  
Clinical 
 Isolate 
cmeR Expression 
Fold Change* 
Nucleotide 
Mutation 
Amino Acid 
Mutation 
Recombinant 
Protein 
Binding to cmeABC 
promoter 
CT2:2 0.006 G431A G144A rCmeR-tr No 
  583 T insertion Truncation after 
193 
  
  A619G S207G   
  C621A Silent   
      
M63885 0.845 C17T T6I rCmeR-IK Yes 
  G475A E159K   
      
T37957A 33.107 G250A E84K rCmeR-K Yes 
      
CT9:7 0.378 C547G P183R rCmeR-R Yes 
      
CB2:8 1.117 G431A G144A Not tested Not tested 
CB2:11 0.327 C547G P183R   
CB2:6** 0.806 A619G S207G   
S13530 0.184 C621A silent   
X7199 10.861     
*In relative to the expression level in NCTC 11168 
**Isolate is phenotypically classified as WEL 
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TABLE 4:  Chloramphenicol MIC distribution (% for each MIC) among the tested 
isolates   
MIC 2 µg/mL 4 µg/mL 8 µg/mL  16 µg/mL 
MH agar     
     WEL 33 67 0 0 
     OEL 42 37 19 2 
     
MH agar with ox-bile1     
     WEL 33 58 8 0 
     OEL 16 81 2 0 
1Ox bile 12,500 µg/mL 
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FIGURE 1: Differential expression of CmeABC in clinical Campylobacter jejuni 
isolates.  Expression was determined by immunoblotting of whole cell proteins from 
NCTC 11168 (lane 1), clinical isolates (lanes 2-11), and 11168ΔcmeR (lane 12) with anti-
CmeB, anti-CmeC, anti-CmeA, and anti-major outer membrane protein (MOMP) 
antibodies. These broiler isolates in lanes 2 to 11 are CB1:6, CB1:14, CB 1:18, CB2:6, 
CB2:8, CB2:11, CB3:1, CB3:5, CB 3:14, and CB3:21.  Isolates CB2:8, CB2:11, CB 3:1, 
CB3:5, CB3:14 and CB3:21 (lanes 6-11) were designated as having overexpression levels 
of CmeABC and isolates CB1:6, CB1:14, CB 1:18, and CB2:6 (lanes 2-5) as having 
wild-type levels of CmeABC.  The major outer membrane protein (MOMP) was used as 
an internal control.   
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FIGURE 2: Binding of CmeR to variants of the cmeABC promoter in different isolates. 
(A) Sequence alignment of the cmeABC promoter region illustrating the 16-base inverted 
repeat of the CmeR binding site shown in lowercase letters. The strain names are listed 
on the left of each sequence.  All mutations differing from the 11168 promoter are 
highlighted in bold. (-) indicates a deleted base. (B) EMSA showing the binding of 
rCmeRSS to different promoter variants. The control probes include the NCTC 11168 
probe (lanes 1-4) in panels I-III and the 81-176 probe (lanes 1-4) in panels IV to VI.  The 
variant promoter probes include CT1:1 (panel I, lanes 5-8), CT1:9 (panel II, lanes 5-8), 
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B    1    2    3     4     5    6    7    8  
VI 
I 
III 
II 
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P
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   1    2    3     4     5    6    7    8  
   1    2    3     4     5    6    7    8  
   1    2    3     4     5    6    7    8  
   1    2    3     4     5    6    7    8  
   1    2    3     4     5    6    7    8  
C 
P P
C 
P
C 
P
C 
P
C 
      11168: AAATTTTtgtaataaaaattacaAT 
     81-176: AAATTTTtgtaataaatattacaAT 
  CT1:1: AAATTTTtataataaaaattacaAT  
  CT1:9: AAATTTTtataataaaaattacaAT 
      CT3:7: AAATTTTtgtaataaatattgcaAT 
     M32506: AAATTTTtgtaataaaaattgcaAT 
      X7199: A-----TtgtaataaatattgcaAT 
     CT9:20: AAAATTTtgtaataaatatt-----  
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FIGURE 2 continued: M32506 (panel III, lanes 5-8), X7199 (panel IV, lanes 5-8), CT3:7 
(panel V, lanes 5-8), and CT9:20 (panel VI, lanes 5-8). For each probe, the amount of 
rCmeRSS used for the each reaction was 0 (lanes 1 and 5), 60 (lanes 2 and 6), 120 (lanes 
3 and 7), and 180 ng (lanes 4 and 8), respectively. The rCmeRSS-DNA complexes are 
indicated with a “C” and the unbound promoter probe is indicated with a “P”.
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FIGURE 3: Effect of various mutations in CmeR and the promoter region on 
transcription of cmeABC as measured by transcriptional fusions and β-galactosidase 
assays. The names of the promoters are indicated under each panel.  Each promoter was 
assayed in the wild-type 81-176 background (A) and the 81-176ΔcmeR background (B). 
The data represent means with standard deviation from three independent experiments. 
A 
B 
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FIGURE 3 continued: The relative difference in transcription (fold change) due to 
repression by CmeR for each promoter is shown in (C) and was determined by 
comparison of transcription in the absence of CmeR (B) to the presence of CmeR (A).  
The unpaired Student’s t-test with Welch’s correction was used for comparison of the 
means with significance set at 0.05.
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FIGURE 4: Expression of CmeR in various isolates and its correlation with CmeABC 
expression.  (A) Immunoblotting of whole cell proteins from NCTC 11168 (lane 1), 
clinical isolates (lanes 2-9), and 11168ΔcmeR (lane 10) with the anti-CmeR antibody. 
The clinical isolates in lanes 2 to 9 are M63885, CT9:7, CB2:6, CB2:8, CB2:11, S13530, 
T37957A, and X7199, respectively.  (B) Immunoblotting of whole cell proteins from 
11168ΔcmeR (lane 1), CT2:2 (lane 2), and NCTC 11168 (lanes 3) with anti-CmeR, anti-
CmeB, and anti-CmeA antibodies.   
A 
B 
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FIGURE 5: The inability of the recombinant CmeR from isolate CT2:2 to bind to the 
promoter DNA of cmeABC. (A) Immunoblotting of purified rCmeRSS (lane 2; wild-type 
CmeR with C69 and C166 replaced with serine) and rCmeR-tr (lane 3; truncated CmeR 
after residue 193 from isolate CT2:2) with the anti-CmeR antibody.  Lane 1 is the protein 
standard ladder. (B) EMSA showing binding of the 11168 cmeABC promoter by 
rCmeRSS (lanes 1-4) and rCmeR-tr (lanes 5-8). Proteins were added at 0, 60 (lanes 2 and 
6), 120 (lanes 3 and 7), 180 ng (lanes 4 and 8). The locations of protein-DNA complexes 
and the probe are indicated. 
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FIGURE 6: Emergence of ciprofloxacin-resistant mutants from WEL (circle) and OEL 
(triangle) isolates during treatment with ciprofloxacin.  In panel A, the experiment was 
performed with an initial inoculum of 107 CFU/ml of each isolate, while in panel B, the 
inoculum was 106 CFU/mL for each isolate. The culture medium was MH broth 
containing 4 µg/mL of ciprofloxacin.  Three WEL and OEL isolates were used in each 
experiment with cultures prepared in triplicate. Each point represents the number of 
ciprofloxacin-resistant mutants from a single culture. Bars represent mean log10CFU/mL 
for each group.  Means for each phenotypic group were compared for each day with 
A 
B 
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FIGURE 6 continued: multiple unpaired Student’ t-tests and Holm-Šídák method for 
multiple comparisons.  The significance level was set at 0.05.
  
 
 
112 
References 
 
1. Nikaido H, Pagès JM. 2012. Broad-specificity efflux pumps and their role in 
multidrug resistance of Gram-negative bacteria. FEMS Microbiol Rev 36:340-
363. 
2. Li XZ, Nikaido H, Poole K. 1995. Role of mexA-mexB-oprM in antibiotic efflux 
in Pseudomonas aeruginosa. Antimicrob Agents Chemother 39:1948-1953. 
3. Poole K, Krebes K, McNally C, Neshat S. 1993. Multiple antibiotic resistance 
in Pseudomonas aeruginosa: evidence for involvement of an efflux operon. J 
Bacteriol 175:7363-7372. 
4. Okusu H, Ma D, Nikaido H. 1996. AcrAB efflux pump plays a major role in the 
antibiotic resistance phenotype of Escherichia coli multiple-antibiotic-resistance 
(Mar) mutants. J Bacteriol 178:306-308. 
5. Aires JR, Köhler T, Nikaido H, Plésiat P. 1999. Involvement of an active efflux 
system in the natural resistance of Pseudomonas aeruginosa to aminoglycosides. 
Antimicrob Agents Chemother 43:2624-2628. 
6. Lin J, Michel L, Zhang Q. 2002. CmeABC functions as a multidrug efflux 
system in Campylobacter jejuni. Antimicrob Agents Chemother 46:2124-2131. 
7. Lin J, Sahin O, Michel LO, Zhang Q. 2003. Critical role of multidrug efflux 
pump CmeABC in bile resistance and in vivo colonization of Campylobacter 
jejuni. Infect Immun 71:4250-4259. 
8. Luo N, Sahin O, Lin J, Michel LO, Zhang Q. 2003. In vivo selection of 
Campylobacter isolates with high levels of fluoroquinolone resistance associated 
with gyrA mutations and the function of the CmeABC efflux pump. Antimicrob 
Agents Chemother 47:390-394. 
9. Ge B, McDermott PF, White DG, Meng J. 2005. Role of efflux pumps and 
topoisomerase mutations in fluoroquinolone resistance in Campylobacter jejuni 
and Campylobacter coli. Antimicrob Agents Chemother 49:3347-3354. 
10. Cagliero C, Mouline C, Cloeckaert A, Payot S. 2006. Synergy between efflux 
pump CmeABC and modifications in ribosomal proteins L4 and L22 in 
conferring macrolide resistance in Campylobacter jejuni and Campylobacter coli. 
Antimicrob Agents Chemother 50:3893-3896. 
11. Gibreel A, Wetsch NM, Taylor DE. 2007. Contribution of the CmeABC efflux 
pump to macrolide and tetracycline resistance in Campylobacter jejuni. 
Antimicrob Agents Chemother 51:3212-3216. 
  
 
 
113 
12. Lin J, Akiba M, Sahin O, Zhang Q. 2005. CmeR functions as a transcriptional 
repressor for the multidrug efflux pump CmeABC in Campylobacter jejuni. 
Antimicrob Agents Chemother 49:1067-1075. 
13. Guo B, Wang Y, Shi F, Barton Y, Plummer P, Reynolds D, Nettleton D, 
Grinnage-Pulley T, Lin J, Zhang Q. 2008. CmeR functions as a pleiotropic 
regulator and is required for optimal colonization of Campylobacter jejuni in vivo. 
J Bacteriol 190:1879-1890. 
14. Cagliero C, Maurel M, Cloeckaert A, Payot S. 2007. Regulation of the 
expression of the CmeABC efflux pump in Campylobacter jejuni: identification 
of a point mutation abolishing the binding of the CmeR repressor in an in vitro-
selected multidrug-resistant mutant. FEMS Microbiol Lett 267:89-94. 
15. Lei HT, Shen Z, Surana P, Routh MD, Su CC, Zhang Q, Yu EW. 2011. 
Crystal structures of CmeR-bile acid complexes from Campylobacter jejuni. 
Protein Sci 20:712-723. 
16. Lin J, Cagliero C, Guo B, Barton Y, Maurel M, Payot S, Zhang Q. 2005. Bile 
salts modulate expression of the CmeABC multidrug efflux pump in 
Campylobacter jejuni. J Bacteriol 187:7417-7424. 
17. Centers for Disease Control and Prevention. 2011. 15 June 2013, posting date. 
Estimates of Foodborne Illness in the United States. Centers for Disease Control 
and Prevention National Center for Emerging and Zoonotic Infectious Diseases 
and Division of Foodborne, Waterborne, and Environmental Diseases, Atlanta, 
GA. (18 June 2013 accessed) http://www.cdc.gov/foodborneburden/2011-
foodborne-estimates.html. 
18. Janssen R, Krogfelt KA, Cawthraw SA, van Pelt W, Wagenaar JA, Owen 
RJ. 2008. Host-pathogen interactions in Campylobacter infections: the host 
perspective. Clin Microbiol Rev 21:505-518. 
19. Taylor EV, Herman KM, Ailes EC, Fitzgerald C, Yoder JS, Mahon BE, 
Tauxe RV. 2013. Common source outbreaks of Campylobacter infection in the 
USA, 1997-2008. Epidemiol Infect 141:987-996. 
20. Ross AG, Olds GR, Cripps AW, Farrar JJ, McManus DP. 2013. 
Enteropathogens and chronic illness in returning travelers. N Engl J Med 
368:1817-1825. 
21. Luo N, Pereira S, Sahin O, Lin J, Huang S, Michel L, Zhang Q. 2005. 
Enhanced in vivo fitness of fluoroquinolone-resistant Campylobacter jejuni in the 
absence of antibiotic selection pressure. Proc Natl Acad Sci U S A 102:541-546. 
  
 
 
114 
22. Han J, Wang Y, Sahin O, Shen Z, Guo B, Shen J, Zhang Q. 2012. A 
fluoroquinolone resistance associated mutation in gyrA Affects DNA supercoiling 
in Campylobacter jejuni. Front Cell Infect Microbiol 2:21. 
23. Yan M, Sahin O, Lin J, Zhang Q. 2006. Role of the CmeABC efflux pump in 
the emergence of fluoroquinolone-resistant Campylobacter under selection 
pressure. J Antimicrob Chemother 58:1154-1159. 
24. Luangtongkum T, Morishita TY, Ison AJ, Huang S, McDermott PF, Zhang 
Q. 2006. Effect of conventional and organic production practices on the 
prevalence and antimicrobial resistance of Campylobacter spp. in poultry. Appl 
Environ Microbiol 72:3600-3607. 
25. Akiba M, Lin J, Barton YW, Zhang Q. 2006. Interaction of CmeABC and 
CmeDEF in conferring antimicrobial resistance and maintaining cell viability in 
Campylobacter jejuni. J Antimicrob Chemother 57:52-60. 
26. Linton D, Lawson AJ, Owen RJ, Stanley J. 1997. PCR detection, identification 
to species level, and fingerprinting of Campylobacter jejuni and Campylobacter 
coli direct from diarrheic samples. J Clin Microbiol 35:2568-2572. 
27. Linton D, Owen RJ, Stanley J. 1996. Rapid identification by PCR of the genus 
Campylobacter and of five Campylobacter species enteropathogenic for man and 
animals. Res Microbiol 147:707-718. 
28. Parkhill J, Wren BW, Mungall K, Ketley JM, Churcher C, Basham D, 
Chillingworth T, Davies RM, Feltwell T, Holroyd S, Jagels K, Karlyshev AV, 
Moule S, Pallen MJ, Penn CW, Quail MA, Rajandream MA, Rutherford 
KM, van Vliet AH, Whitehead S, Barrell BG. 2000. The genome sequence of 
the food-borne pathogen Campylobacter jejuni reveals hypervariable sequences. 
Nature 403:665-668. 
29. Black RE, Levine MM, Clements ML, Hughes TP, Blaser MJ. 1988. 
Experimental Campylobacter jejuni infection in humans. J Infect Dis 157:472-
479. 
30. McDermott PF, Bodeis SM, Aarestrup FM, Brown S, Traczewski M, 
Fedorka-Cray P, Wallace M, Critchley IA, Thornsberry C, Graff S, Flamm 
R, Beyer J, Shortridge D, Piddock LJ, Ricci V, Johnson MM, Jones RN, 
Reller B, Mirrett S, Aldrobi J, Rennie R, Brosnikoff C, Turnbull L, Stein G, 
Schooley S, Hanson RA, Walker RD. 2004. Development of a standardized 
susceptibility test for Campylobacter with quality-control ranges for 
ciprofloxacin, doxycycline, erythromycin, gentamicin, and meropenem. Microb 
Drug Resist 10:124-131. 
31. Clinical and Laboratory Standards Institute. 2008. Performance Standards for 
Antimicrobial Disk and Dilution Susceptibility Tests for Bacteria Isolated from 
  
 
 
115 
Animals; Approved Standard-Third Edition.  CLSI document M31-A3 Wayne, 
Pennsylvania. 
32. Wösten M, Boeve M, Koot M, van Nuenen A, van der Zeijst B. 1998. 
Identification of Campylobacter jejuni promoter sequences. J Bacteriol 180:594-
599. 
33. Miller WG, Bates AH, Horn ST, Brandl MT, Wachtel MR, Mandrell RE. 
2000. Detection on surfaces and in Caco-2 cells of Campylobacter jejuni cells 
transformed with new gfp, yfp, and cfp marker plasmids. Appl Environ Microbiol 
66:5426-5436. 
34. Hao H, Yuan Z, Shen Z, Han J, Sahin O, Liu P, Zhang Q. 2013. Mutational 
and transcriptomic changes involved in the development of macrolide resistance 
in Campylobacter jejuni. Antimicrob Agents Chemother 57:1369-1378. 
35. Pfaffl MW. 2001. A new mathematical model for relative quantification in real-
time RT-PCR. Nucleic Acids Res 29:e45. 
36. Cagliero C, Cloix L, Cloeckaert A, Payot S. 2006. High genetic variation in the 
multidrug transporter cmeB gene in Campylobacter jejuni and Campylobacter 
coli. J Antimicrob Chemother 58:168-172. 
37. Oakland M, Jeon B, Sahin O, Shen Z, Zhang Q. 2011. Functional 
characterization of a lipoprotein-encoding operon in Campylobacter jejuni. PLoS 
One 6:e20084. 
38. Alekshun MN, Kim YS, Levy SB. 2000. Mutational analysis of MarR, the 
negative regulator of marRAB expression in Escherichia coli, suggests the 
presence of two regions required for DNA binding. Mol Microbiol 35:1394-1404. 
39. Miller JH. 1992. A short course in bacterial genetics: a laboratory manual and 
handbook for Escherichia coli and related bacteria. Cold Spring Harbor 
Laboratory Press, Cold Spring Harbor, NY. 
40. Qiagen. 2003. The QIAexpressionist, A handbook for high lelevel expresson and 
purification of 6x His-tagged proteins, Third ed. Qiagen Worldwide. 
41. Luria S, Delbrück M. 1943. Mutations of Bacteria from Virus Sensitivity to 
Virus Resistance. Genetics 28:491-511. 
42. Crane G, Thomas S, Jones M. 1996. A modified Luria-Delbrück fluctuation 
assay for estimating and comparing mutation rates. Mutat Res 354:171-182. 
43. Rosche W, Foster P. 2000. Determining mutation rates in bacterial populations. 
Methods 20:4-17. 
  
 
 
116 
44. Pope C, O'Sullivan D, McHugh T, Gillespie S. 2008. A practical guide to 
measuring mutation rates in antibiotic resistance. Antimicrob Agents Chemother 
52:1209-1214. 
45. Foster P. 2006. Methods for determining spontaneous mutation rates. Methods 
Enzymol 409:195-213. 
46. Wang G, Wilson TJ, Jiang Q, Taylor DE. 2001. Spontaneous mutations that 
confer antibiotic resistance in Helicobacter pylori. Antimicrob Agents Chemother 
45:727-733. 
47. Hall BM, Ma CX, Liang P, Singh KK. 2009. Fluctuation analysis CalculatOR: a 
web tool for the determination of mutation rate using Luria-Delbruck fluctuation 
analysis. Bioinformatics 25:1564-1565. 
48. Han J, Sahin O, Barton YW, Zhang Q. 2008. Key role of Mfd in the 
development of fluoroquinolone resistance in Campylobacter jejuni. PLoS Pathog 
4:e1000083. 
49. Chen CY, Nace GW, Irwin PL. 2003. A 6 x 6 drop plate method for 
simultaneous colony counting and MPN enumeration of Campylobacter jejuni, 
Listeria monocytogenes, and Escherichia coli. J Microbiol Methods 55:475-479. 
50. Gu R, Su CC, Shi F, Li M, McDermott G, Zhang Q, Yu EW. 2007. Crystal 
structure of the transcriptional regulator CmeR from Campylobacter jejuni. J Mol 
Biol 372:583-593. 
51. Hyytiäinen H, Hänninen ML. 2012. Quality control strain Campylobacter jejuni 
ATCC 33560 contains a frameshift mutation in the CmeR regulator. Antimicrob 
Agents Chemother 56:1148. 
 
  
 
 
117 
CHAPTER 4: INTERACTION OF COSR AND CMER IN MODULATING THE 
EXPRESSION OF CMEABC AND ROLE OF CYSTEINE OXIDATION IN COSR 
SENSING OF OXIDATIVE STRESS 
 
To be submitted to the Journal of Bacteriology 
Tara Grinnage-Pulley and Qijing Zhang 
Department of Veterinary Microbiology and Preventive Medicine, Iowa State University, 
College of Veterinary Medicine, Ames IA 50011, United States of America 
 
 
Abstract 
 
 During transmission and intestinal colonization, Campylobacter jejuni, a major 
foodborne human pathogen, experiences oxidative stress. CosR, a response regulator in 
C. jejuni, modulates oxidative stress response and defense and represses expression of the 
CmeABC multidrug efflux pump.  CmeABC, a key component in the resistance to toxic 
compounds including antimicrobials and bile salts, is also under negative regulation by 
CmeR, a TetR family transcriptional regulator.  How CosR interacts with CmeR in 
controlling cmeABC expression and how CosR senses oxidative stress are still unknown. 
To answer these questions, we conducted various experiments utilizing electrophoretic 
mobility shift assays, transcriptional fusion assays, and immunoblotting.  CosR and 
CmeR bound independently to two separate sites of the cmeABC promoter, 
simultaneously repressing cmeABC expression.   This dual binding of CosR and CmeR 
required 17 bp between the two binding sites as mutations that shortened the distance 
enhanced cmeABC expression. Additionally, the single cysteine residue (C218) of CosR 
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was sensitive to oxidation, which altered the DNA-binding activity of CosR, dissociating 
CosR from the cmeABC promoter. Replacement of C218 with serine rendered CosR 
insensitive to oxidation, confirming the role of C218 in sensing oxidative stress and 
providing a mechanism for CosR-mediated response to oxidative stress. These findings 
reveal an interactive role of CosR and CmeR in modulating cmeABC expression and 
identify a previously unrecognized mechanism that explains overexpression of cmeABC 
in response to oxidative stress. CmeR and CosR mediated differential expression of 
cmeABC in response to different signals may facilitate adaptation of Campylobacter to 
various environmental conditions.  
 
Introduction 
 
Campylobacter jejuni is a microaerophilic, gram-negative pathogen causing 
foodborne gastroenteritis in humans.  In some animal species, such as birds, C. jejuni is a 
commensal organism well adapted to the enteric environment. Colonization in the 
intestines requires C. jejuni to be resistant to the antimicrobial action of bile.  The 
CmeABC multidrug efflux pump is one of the known mechanisms required for intestinal 
colonization (1).  CmeABC is a tripartite efflux system composed of the inner membrane 
protein CmeB, the periplasmic fusion protein CmeA, and the outer membrane protein 
CmeC (2).  This three-gene operon is regulated by a TetR family regulator named CmeR 
(3), which binds to a 16-base inverted repeat within the cmeABC promoter and inhibits 
the expression of cmeABC (3).  CmeABC is an important player for antibiotic resistance 
and is the predominant mechanism for bile resistance in C. jejuni, making it essential for 
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intestinal colonization (1, 2, 4).  The expression of cmeABC is inducible by bile, and the 
induction is mediated by the binding of bile to CmeR, which triggers a conformational 
change in the DNA-binding domain of CmeR, thereby releasing CmeR from the 
promoter and increasing the pump expression (4, 5).  
As a microaerobic organism, Campylobacter is sensitive to atmospheric oxygen 
and to oxidative stresses from host immune systems including hydrogen peroxide 
produced by intestinal epithelium (6).  Hydrogen peroxide is one of the reactive oxygen 
species (ROS) that induce oxidative damage to cells (7, 8). Other ROS include 
superoxide and hydroxyl radicals. Oxidative stress is one of the mechanisms the immune 
system employs to defend against pathogens (8). Recent studies have identified the 
orphan response regulator CosR as an oxidative stress response regulator in C. jejuni, 
modulating the expression of oxidative stress response and resistance genes including 
katA, sodB, and ahpC (9, 10). Interestingly, CosR also represses the expression of 
CmeABC by binding to a region in the cmeABC promoter containing a CosR binding site 
(10).  This finding suggests a link between the oxidative stress response and antibiotic 
efflux system in Campylobacter. Regulation of antibiotic efflux pumps has been 
previously linked to oxidative stress in other bacteria. For example, MexR of 
Pseudomonas aeruginosa senses oxidative stress through two cysteine residues (11).   
The reduced form of MexR serves as a repressor for the MexAB-OprM efflux pump, but 
once oxidized, MexR is dissociated from the promoter, leading to overexpression of 
MexAB-OprM (11, 12). Collectively, these observations suggest that oxidative stress 
response and antibiotic efflux systems are intertwined in bacteria.  
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  HP1043 is a homologue of CosR found in Helicobacter pylori (13). CosR can 
functionally substitute for HP1043 when expressed in H. pylori from the HP1043 
promoter (13).  HP1043 forms a dimer and contains 2 cysteine residues that modulate its 
regulatory function (13-15). CosR contains a single cysteine residue (C218) that 
corresponds to C215 of HP1043. Based on the HP1043 sequence and its crystal structure, 
the single cysteine residue of CosR likely resides in the dimer interface (15).  It has been 
known that oxidation of cysteine residues at the dimer interface affects the conformation 
and function of regulatory proteins (16, 17), but it is unknown if modification of C218 in 
CosR modulates its binding activities to promoter DNA. 
Previous work suggested that CmeABC is also likely regulated by a CmeR-
independent mechanism, because cmeABC was further induced by bile in the absence of 
CmeR (4). The excess induction in the absence of CmeR was attributed to an unknown 
mechanism regulating cmeABC expression (4). Additionally, our recent work studying 
various cmeABC promoter mutations further indicated that multiple regulators may bind 
to the promoter sequence of cmeABC (18). These observations and the recent publication 
on CosR binding to the promoter of CmeABC (10) suggest that the regulation of cmeABC 
is complex and likely involves interaction of multiple regulators. Therefore, we 
hypothesize that CosR and CmeR function as a dual mechanism in modulating the 
expression of CmeABC and that C218 in CosR serves as a sensor for oxidative stress. To 
test this hypothesis, we examined the interactive role of CosR and CmeR in the 
regulation of cmeABC and the effect of cysteine oxidation on the function of CosR. 
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Material and Methods 
 
Bacterial strains and growth conditions  
C. jejuni strains X7199 (19), NCTC 11168 (20), 81-176 (21), 81-176ΔcmeR (3), 
and 11168ΔcmeR (3) were used in this study (Table 1) and they were routinely cultured 
on Mueller Hinton (MH) agar or in MH broth (Difco, Detroit, MI) at 42°C under 
microaerobic conditions (5% O2, 10% CO2, 85% N2). Media was supplemented with 
kanamycin at 30 µg/mL or chloramphenicol at 4 µg/mL as needed.   
Escherichia coli strains DH5α  (Invitrogen) and JM109 (Agilent Technologies) 
were routinely cultured at 37°C with Luria-Bertani (LB) broth or LB agar (Difco), which 
was supplemented with 30 µg/mL kanamycin or 100 µg/mL ampicillin when needed. 
 
Recombinant CosR construction and purification 
Recombinant CosR was produced using the pQE30 (Qiagen) expression system. 
Amplification of the cosR (Cj0355c) sequence from NCTC 11168 was performed with 
primers Cj0355c-F1 and Cj0355c-R1 (Table 2).  This PCR product and the pQE30 
plasmid were digested with BamHI and KpnI (Promega).  The digested PCR product and 
pQE30 were purified using the QIAquick PCR purification and QIAprep Spin Miniprep 
kits (Qiagen), respectively. The vector and insert were then ligated with T4 ligase 
(Roche) and transformed into E. coli JM109.  The transformants were selected on LB 
agar supplemented with ampicillin (100 µg/mL). The plasmid was purified from 
transformant JM109pQECj0355c (Table 1) and was sequenced to confirm there were no 
mutations in the cloned Cj0355c gene. The recombinant CosR, named rCosRWT, was 
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induced and purified from JM109pQECj0355c under native conditions as described in 
the QIAExpresssionist (22).  Following purification, the protein was desalted with a PD-
10 desalting column (GE Healthcare).  
To mutate the single cysteine residue (C218) in CosR, pQECj0355c was used as a 
template for site directed mutagenesis of cosR.  Primers CosR652-F and CosR652-R  
(Table 2) were designed to introduce a T to A substitution at nucleotide 652, resulting in 
the replacement of cysteine residue 218 by serine.  The QuikChange II Site-Directed 
Mutagenesis kit (Agilent Technologies) was used to introduce the mutation by one cycle 
of 95°C for 30 seconds followed by 16 cycles of 95°C for 30 seconds, 55°C for 30 
seconds, and 68°C for 4 minutes. The amplified product was cooled on ice for 2 minutes 
before Dpn-I digestion of parental DNA at 37°C for 1 hour.  The product, 
pQECj0355c652 (Table 1), was then transformed into E. coli strain JM109 and the 
transformants were selected on LB agar supplemented with ampicillin (100µg/mL).  The 
specific mutation was confirmed by sequencing.  This mutated version of CosR was 
named rCosRC218S and was purified using the same method as with rCosRWT.   
 
Electrophoretic mobility shift assays (EMSA)  
EMSA was used to assess binding of CosR to the cmeABC promoter or its 
derivatives.  Primers GSF and GSR1 (3) (Table 2) were used to amplify a 170-bp region 
of the cmeABC promoter from strains 81-176, NCTC 11168 (named 11168 promoter) and 
X7199 as described previously (18).  An internal fragment of cmeA was amplified with 
primers AF and AR (Table 2) and was used as a negative control probe (3).  A 14-base 
pair deletion between the CosR and CmeR binding sites of cmeABC was designed based 
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on the sequence of 81-176 and this probe was named P14D.   A pUC57 vector carrying 
the P14D sequence was synthesized (Genscript) and then amplified using the GSF and 
GSR1 primers (3) (Table 2).  All probes were purified with QIAquick PCR purification 
kit and labeled with DIG-11-dd-UTP as described previously (3).  
To assess the binding specificity of CosR to the cmeABC promoter, the 11168 
promoter probe or the cmeA probe (0.05 pmol) were mixed with 250 ng of rCosRWT or 
rCosRC218S in reaction buffer (14.4 µL total) according to the method of Alekshun et. 
al. (23) and Lin et. al. 2005 (3). A control reaction was prepared with the 11168 promoter 
probe without addition of protein. Reactions were incubated for 30 minutes at room 
temperature. Promega DNA loading buffer was added to each reaction and then the 
reaction was run at 200V for 45 minutes on a 6% polyacrylamide gel in 0.25X TBE 
buffer.  Transfer to a positively charged membrane by vacuum and detection of DIG with 
CDP Star (Roche) were performed as previously described (3). 
 To assess the effect of oxidation on binding of CosR to the cmeABC promoter, 
the 11168 promoter probe (0.05 pmol) was mixed with 250 ng of rCosRWT or 
rCosRC218S, incubated for 30 minutes at room temperature, and then hydrogen peroxide 
was added to the reactions at final concentrations of 0, 5, 10, or 20 nM (final volume 14.4 
µL).  Reactions were incubated for an additional 30 minutes at room temperature.   
Electrophoresis, transfer and detection were performed as described above.  
To determine if CosR and CmeR interfere with each other in binding to the 
cmeABC promoter, dual binding EMSA assays were performed using promoter DNA that 
had varied lengths of spacing between the CmeR-binding site and the CosR-binding site.  
Dual binding of CosR and CmeR utilized 81-176 cmeABC promoter probe which has 17- 
  
 
 
124 
base pairs between the CmeR and CosR binding site as a full length promoter control.  
The second probe containing a reduced distance between the CmeR and CosR binding 
sites was either the promoter probe of X7199, which has a 5 base-pair deletion, or probe 
P14D with a 14 base pair deletion.  Each probe (0.05 pmol) was incubated with 200 ng of 
rCmeRSS alone, 400 ng of rCosRC218S alone, or both rCmeRSS and rCosRC218S at 
200 ng and 400 ng, respectively, in the reaction mixture (14.4 µL). A control reaction was 
prepared for each probe without the protein. Reactions were incubated at room 
temperature for 30 minutes.  Promega DNA loading buffer was added to each reaction, 
which was then run at 200V for 55 minutes on a 6% polyacrylamide gel in 0.25X TBE 
buffer.  Transfer and detection were performed as described above. 
 
Immunoblotting  
To determine if inhibition of CosR affects expression of CmeABC, 
immunoblotting was performed using cultures that were incubated with the anti-CosR 
peptide nucleic acid (PNA). The PNA (KFFKFFKFFK-O-CATTTGTTCTATCCTT) (9) 
was obtained from PNA Bio, Inc.  C. jejuni NCTC 11168 and 11168ΔcmeR were grown 
on MH agar and then adjusted in MH broth to OD600 ~0.07.  Cultures were incubated 
with and without the anti-CosR PNA at a final concentration of 1.5 µM with shaking at 
180 rpm for 8 hours at 42 °C under microaerobic conditions (9).  After incubation, 
cultures were adjusted to 1.5 x 108 cells, centrifuged, and re-suspended in 1X SDS 
loading buffer to 1.5 x 106 cells/µL.  SDS-PAGE and immunoblotting for CmeA and 
CmeB were performed as described by Lin et. al. 2002 (2). Densitometric analysis was 
performed on the immunoblots using AlphaEaseFC Software (Version 3.2.3 Rev C; 
  
 
 
125 
Innotech). !
 
Transcriptional fusion and β-galactosidase assay  
Various cmeABC promoters were fused to the promoter-less lacZ gene in pMW10 
(24). Construction of strains 81-176 and 81-176ΔcmeR containing the plasmids pMW10, 
pMW11168, pMW81-176, and pMWX7199 was described previously (Table 1) (18).  
Plasmids pMW11168, pMW81-176, and pMWX7199 contained the cmeABC promoter 
from NCTC 11168, 81-176, and X7199, respectively, fused to the lacZ reporter gene, 
while pMW10 contains the reporter gene, lacZ, without a fused promoter. Plasmid 
pMW561 carries the Cj0561c promoter from strain NCTC 11168. Cj0561c is repressed 
by CmeR, not CosR, serving as a negative control for the effect of anti-CosR PNA.  
pMW561 (25) was extracted from 11168W7pMW561 (25) (Table 1) using the QIAprep 
Spin Miniprep kit and transformed into DH5α.  Tri-parental mating was used to transfer 
the plasmid into C. jejuni strains 81-176 and 81-176ΔcmeR (26). 
Overnight cultures of 81-176 or 81-176ΔcmeR with pMW10 (24), pMW11168, 
pMW81-176, pMWX7199, or pMW561 were grown on MH agar supplemented with 
kanamycin (30 µg/mL) and then harvested in MH broth with kanamycin. Cultures were 
adjusted in MH-kanamycin broth to OD600 ~0.07 and aliquoted to two tubes.  The first 
tube was incubated with 1.5 µM anti-CosR PNA and the second was incubated without 
the anti- CosR-PNA.  All tubes were incubated by shaking at 180 rpm for 8 hours at 42 
°C under microaerobic conditions (9).  -galactosidase assays were performed in 
triplicate samples for three independent experiments (27). Means were calculated and 
statistical analysis was performed using Student’s t-test with Welch’s corrections 
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(GraphPad InStat® Version 3.06). The repressive effects (fold changes) for each 
regulator were statistically analyzed between promoters by log2 transformation of the 
transcriptional data and one-way analysis of variance (ANOVA) in SAS (version 9.3).  
 
Results 
 
CosR binds specifically to the cmeABC promoter  
EMSA was used to demonstrate the specific binding of CosR to the cmeABC 
promoter. As shown in Figure 1, the control reaction containing the 11168 promoter 
probe (Fig. 1, lane 1) and no CosR demonstrated the migration of unbound 11168 
promoter probe at the lower end of the gel.  In the presence of rCosRWT or rCosRC218S, 
DNA-protein complexes were formed and migrated above the unbound probe (Fig. 1, 
lanes 2 and 3).  No complexes were seen with the control probe (cmeA internal fragment)  
(Fig. 1, lanes 4 and 5), indicating that CosR did not bind to the internal cmeA fragment.  
The result is consistent with the finding described by Hwang et. al. 2012 (10) and 
indicates that CosR binds specifically to the cmeABC promoter. 
Notably, the rCosRC218S-DNA band (Fig. 1, lane 3) was darker than the 
rCosRWT-DNA band (Fig. 1, lane 2), indicating stronger binding of the DNA probe by 
rCosRC218S. The two rCosR proteins differ in one amino acid, with cysteine 218 
replaced by serine in rCosRC218S.  Cysteine residues are sensitive to oxidation, while 
serine is not susceptible to oxidation (16).  The EMSA reactions were carried out under 
aerobic conditions and the reduced binding of rCosRWT compared to rCosRC218S 
suggested that this protein was subject to oxidation under aerobic conditions.  Repeated 
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EMSAs showed rCosRWT was always less active than rCosRC218S in DNA binding 
assayed under the in vitro condition (data not shown), suggesting a potential role of 
cysteine oxidation in modulating the function of CosR. 
 
Oxidation of C218 in CosR reduced DNA binding 
To further demonstrate the effect of C218 oxidation on DNA binding, hydrogen 
peroxide was used to treat the reactions in the EMSA assay. As shown in Figure 2, the 
binding of the cmeABC promoter by rCosRWT decreased as hydrogen peroxide 
concentration increased (lanes 2-5). At 20 nM of hydrogen peroxide (Fig. 2, lane 5), the 
binding of rCosRWT to the DNA probe was totally inhibited and the unbound probe was 
at the level of the free probe control (Fig. 2, lane 1). In contrast, the promoter binding by 
rCosRC218S was not affected by treatment with hydrogen peroxide (Fig. 2, lanes 6-9).  
These results indicated that the C218 in CosR was sensitive to hydrogen peroxide and 
oxidation of this residue interfered with CosR binding to promoter DNA. 
 
Dual binding of the cmeABC promoter by CosR and CmeR 
 The cmeABC promoter contains binding sites for both CmeR and CosR (9, 10) 
(also see Fig. 3A).  To determine if binding of one protein interferes with binding of the 
other, promoter sequences with various lengths between the two binding sites were used 
as probes in EMSA.  Both the 11168 and 81-176 cmeABC promoter probes had 17 bp 
between the CosR and CmeR binding sites (Fig. 3A).  This distance was reduced to 12 bp 
in the promoter from strain X7199 (Fig. 3A), a human isolate, while the P14D probe 
contained only 3 bp between the binding sites (Fig. 3A).  
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Each promoter probe was incubated with rCmeRSS or rCosRC218S individually 
or in combination.  Evaluation of individual protein binding showed that rCosRC218S 
bound equally well to the 81-176 (Fig. 3B and C, lane 2), X7199 (Fig. 3B, lane 7), and 
P14D (Fig. 3C, lane 7) promoter probes. However, binding of rCmeRSS to the promoter 
probes varied (Fig. 3A and B, lanes 2 and 6). rCmeRSS binding to the 81-176 cmeABC 
promoter produced 2 banding patterns:  in Figure 3C (lane 2), there are 3 distinct bands 
representing the rCmeRSS-DNA complexes, while in Figure 3B (lane 2) the upper band 
of the rCmeRSS-DNA complexes produced a wide streak, blurring the edges of the band 
with a shadow effect. Binding of rCmeRSS to the X7199 promoter produced 3 distinct 
dark bands (Fig. 3B, lane 6), while rCmeRSS binding to the P14D probe yielded 3 light 
bands (Fig. 3C, lane 6), suggesting reduced interaction between the protein and the P14D.  
This indicates that the cmeABC promoter binding by CmeR, but not CosR, is affected by 
spatial arrangement of the CosR and CmeR binding sites.  
Evaluation of the cmeABC promoter for binding by the rCosRC218S and 
rCmeRSS proteins when added in combination demonstrated simultaneous binding of 
rCosRC218S and rCmeRSS to the promoter probe. Dual binding to the 81-176 promoter 
probe produced 3 dark bands that shifted higher than those from a single protein binding 
(Fig. 3B and C, lane 4), while binding to probe X7199 produced 3 lighter bands (Fig. 3B, 
lane 8). Dual binding of rCosRC218S and rCmeRSS to P14D also created 3 bands, but 
the bands were thinner in width (Fig. 3C, lane 8) compared to the 81-176 promoter (Fig. 
3C, lane 4).  The decrease in band size or intensity is indicative of reduced binding.  
Binding was not affected by the order of protein addition to the probes (data not shown). 
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These results suggest that reducing the distance between the binding sites of CosR and 
CmeR interferes with dual binding by CosR and CmeR.  
 
CmeR and CosR independently modulate CmeABC expression in vivo  
Based on the results of EMSA, CosR and CmeR can bind to the cmeABC 
promoter simultaneously, constituting a dual mechanism for regulating the expression of 
cmeABC.  To further understand the interaction of these two regulators in modulating 
cmeABC expression, immunoblotting was used to assess the expression of this efflux 
pump under different conditions. Since cosR appears to be an essential gene and cannot 
be inactivated in Campylobacter, we used anti-CosR PNA to assess its impact on 
cmeABC expression in C. jejuni. The wild-type NCTC 11168 and its isogenic cmeR 
mutant (11168ΔcmeR) were grown with or without the PNA, and the whole cell proteins 
were analyzed by immunoblotting using anti-CmeA, anti-CmeB, and anti-major outer 
membrane protein (MOMP) antibodies (Fig. 4). MOMP was used as a control as its 
expression is not affected by CosR (9, 10) and CmeR (3, 25).  Indeed, MOMP showed 
similar levels of expression under all culture conditions (Fig. 4).  In contrast, the 
expression of CmeA and CmeB increased in the absence of CmeR or presence of the 
anti-CosR PNA (Fig. 4), and the effects were further quantified by densitometric analysis.   
 In the 11168ΔcmeR strain (Fig. 4, lane 3), cmeR deletion resulted in a 2.1-fold 
increase in CmeB and a 2.7-fold increase in expression of CmeA compared to the 
expression level in wild-type 11168 (Fig. 4, lanes 1). This represents the effect of CmeR 
on cmeABC expression in the presence of CosR.  Treating the cultures with the anti-CosR 
PNA also increased the expression of cmeABC (Fig. 4, lanes 2 and 4).   When treated 
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with the PNA (Fig. 4, lanes 2 and 4), expression of CmeB increased 1.2- fold in both the 
wild-type 11168 and the 11168ΔcmeR cultures relative to the untreated cultures (Fig. 4, 
lanes 1 and 3).  For CmeA, its expression increased 1.3-fold over the untreated culture 
(Fig. 4, lane 1) in wild-type 11168.  This represents the effect of CosR in the presence of 
CmeR.  A similar effect was observed in the 11168ΔcmeR culture treated with the anti-
CosR-PNA (Fig. 4, lane 4) as expression of CmeA increased 1.5-fold (densitometric data 
not shown) over the untreated 11168ΔcmeR culture (Fig. 4, lane 3). The increased 
expression of CmeB and CmeA in the wild-type background in the presence of the PNA 
indicates that CosR is able to repress the efflux pump expression in the presence of 
CmeR, consistent with the EMSA finding that CosR and CmeR bound to the cmeABC 
promoter simultaneously. In addition, the similar effects of CosR in both the wild-type 
and cmeR mutant backgrounds indicate that CosR functions independently and is not 
affected by CmeR.   
 
CosR functions as a secondary transcriptional regulator of cmeABC 
Additionally, in vivo transcriptional fusion assays were performed to assess 
cmeABC expression under various conditions.  Plasmids containing the cmeABC 
promoter from strains NCTC 11168 (11168 promoter), 81-176, or X7199 (Fig. 3A) were 
fused to a promoterless lacZ gene. These plasmids were transferred into wild-type 81-176  
(Fig. 5A) and 81-176ΔcmeR (Fig. 5B), which were then cultured and treated with the 
anti-CosR PNA (Fig. 5). The effect of CmeR and CosR on transcription was determined 
by comparison of the same promoter under various conditions.  Inactivation of CmeR 
resulted significant increases (p < 0.05) in cmeABC transcription: 4.6-fold for the 11168 
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promoter, 3.7-fold for the 81-176 promoter, and 2.6-fold for the X7199 promoter as 
determined by comparing 81-176ΔcmeR with the wild-type 81-176 in the absence of the 
anti-CosR PNA (Fig. 5).  In cultures treated with the anti-CosR PNA (81-176ΔcmeR and 
81-176), the loss of CmeR also had a significant  (p < 0.05) effect on cmeABC 
transcription with 3.5-, 2.3-, and 2.1-fold increases for the 11168, 81-176, and X7199 
promoters, respectively.  These two sets of fold changes represent the levels of CmeR 
inhibition on cmeABC expression in the presence of CosR (Table 3) and under CosR 
suppression (Table 4), respectively for each promoter. These effects further confirm that 
CmeR functions independently of CosR.   
The independent repression of CosR was confirmed by comparison of cultures 
treated with anti-CosR PNA and without anti-CosRPNA for each promoter.  Inhibiting 
cosR in wild-type 81-176 (with a functional CmeR) caused a significant (p < 0.05) 
increase in transcription of all tested promoters (Fig. 5A). For the 11168, 81-176, and 
X7199 promoters, the increases were 1.8-, 2.1-, and 1.7-fold, respectively which indicates 
that CosR functions as a repressor for cmeABC in the presence of CmeR, consistent with 
the immunoblotting result (Fig. 4). The transcriptional fusions were also evaluated in the 
81-176ΔcmeR background (Fig. 5B).  In the absence of CmeR, inhibition of CosR further 
increased the transcription of the cmeABC promoters compared to the non-treated 
controls, but this was not statistically significant.  Inhibition of cosR resulted in a 1.4- 
fold increase for the 11168 and 81-176 promoters and 1.3-fold for the X7199 promoter. 
These two sets of fold changes represent the levels of CosR inhibition on cmeABC 
expression in the presence of CmeR (Table 3) and in the absence of CmeR (Table 4), 
respectively for each promoter. The lower magnitude of inhibition on cmeABC by CosR 
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compared with CmeR suggests that CmeR functions as a primary regulator and CosR as a 
secondary regulator for cmeABC.    
 
Reduced spacer length affects dual binding of the cmeABC promoter by CmeR and 
CosR!
EMSA demonstrated that dual binding of CmeR and CosR to the cmeABC 
promoter was influenced by the length of the spacer between the two promoter binding 
sites on EMSA (Figure 3). Transcriptional fusion assays confirmed that transcription of 
cmeABC was significantly (p < 0.05) increased for each promoter when CosR was 
inhibited and CmeR was inactivated (81-176ΔcmeR, with anti-CosR PNA).  
Transcriptional increases of 6.3-, 4.9-, and 3.5- fold for the 11168, 81-176, and X7199 
promoters, respectively, were observed and these increases represent the collective 
effects of CosR and CmeR (Table 4).  Notably, the collective effect on transcription was 
significantly lower (p = 0.0102) for the X7199 promoter than the 11168 promoter. 
Mutations in the CmeR binding site and/or the spacer between the CosR and CmeR 
binding sites, but not the CosR binding sites are seen in the promoters in Figure 3A. The 
transcriptional effects of CosR, 1.8-, 2.1, and 1.7- fold in the presence of CmeR (Table 3) 
and 1.4 and 1.3-fold in the absence of CmeR (Table 4), were not significantly different 
among the promoters, suggesting that repression of these promoters by CosR is not 
influenced by the spacer region, consistent with the EMSA results (Fig. 3B and C). 
Examination of individual effect of CmeR for each promoter showed that the 
effect is similar (p > 0.05) for the 81-176 and X7199 promoter at 2.3- and 2.1-fold, but 
both are significantly (p < 0.05)  reduced from the 3.5-fold effect for the 11168 promoter 
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(Table 4).  This decrease is consistent with the mutations in the CmeR binding site of the 
X7199 and 81-176 promoters.  Interestingly, in the presence of CosR, the effect of CmeR 
for the X7199 promoter was only 2.6-fold compared to 4.6- and 3.7-fold for the 11168 
and 81-176 promoter (Table 3).  These effects are similar (p > 0.05) for the full length 
promoters 81-176 and 11168, but significantly lower (p < 0.05) for the X7199 compared 
to either of the full length promoters. This suggests repression of cmeABC by CmeR is 
reduced by the shortened space between the binding sites in the presence of CosR for the 
X7199 promoter. 
To confirm this effect of CmeR was related to the decreased distance between the 
binding sites and not mutations in the CmeR binding site, transcription levels in the 
presence of dual regulators (wild-type 81-176 without CosR-PNA) were compared 
between the full length and shortened promoters (Fig. 5A). Transcription from the X7199 
promoter showed a 2.9-fold (p <0.01) increase over the 11168 promoter compared to the 
1.4-fold (p > 0.05) increase of the 81-176 promoter over the 11168 promoter. To confirm 
the larger increase for the X7199 promoter was not solely due to the mutations in the 
CmeR binding site, transcription from the X7199 cmeABC promoter was compared to the 
81-176 promoter and showed a 2.1-fold increase over the 81-176 promoter in the 
presence of both repressors (Fig. 5A).  Thus even with mutations in the CmeR binding 
site in both promoters, repression by CmeR is further reduced for the X7199 promoter. 
Taken together, these results indicate that reduction of the spacer length between the 
binding sites decreases the binding by CmeR during dual repression of cmeABC by 
CmeR and CosR and leads to increased cmeABC levels.  
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The effects of each regulator individually and collectively was also analyzed for 
the possibility of an additive or synergistic effect during dual binding. Addition of the 
calculated individual effects for CmeR and CosR, determined that the sum of the 
individual effects for each promoter was 4.9-fold for the 11168 promoter, 3.7-fold for the 
81-176 promoter, and 3.4-fold for the X7199 promoter (Table 3). The difference between 
the collective effect (6.3-, 4.9-, and 3.5-fold) and sum the individual effects (4.9- , 3.7-, 
and 3.4-fold) was not significantly different at 1.4- 1.2-, or 0.1-fold for the 11168, 81-
176, and X7199 promoters respectively (Table 3).  Notably the magnitude of this effect 
was smallest for the shortened X7199 promoter, although this was not statistically 
significant compared to the full-length promoters (Table 3).  The inability to detect a 
statistical difference between the promoters for this value may be due to the indirect 
measurement of this value.  However, the presence of a difference between the sum and 
collective effects suggests there might be a synergy between CmeR and CosR in 
repressing cmeABC in the full-length promoters.  
 
CosR specifically inhibits CosR in vivo  
To confirm that CosR is specific for inhibiting expression of cmeABC, the 
Cj0561c promoter was also examined in the presence of the anti-CosR PNA. Cj0561c is 
known to be repressed by CmeR (25, 28), but there is no evidence that it is regulated by 
CosR. As shown in Figure 5A, expression from the Cj0561c promoter did not differ 
significantly with or without the CosR PNA in the wild-type 81-176 background.  A 
similar result was obtained in the 81-176ΔcmeR background (Fig. 5B).  This indicates 
that inhibiting CosR did not affect the expression of Cj0561c, confirming the specificity 
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of CosR to cmeABC. In contrast, when transcription of Cj0561c was compared between 
wild-type 81-176 and 81-176ΔcmeR, a significant (p < 0.01) increase in transcription was 
observed in the 81-176ΔcmeR backgrounds regardless of the CosR levels, confirming that 
deletion of cmeR increases the transcription of Cj0561c.  The ability of CosR to inhibit 
cmeABC transcription, but not Cj0561c transcription demonstrates that CosR specifically 
regulates cmeABC.  
 
Discussion 
 
The multidrug efflux pump CmeABC is well known for its roles in antimicrobial 
resistance and bile resistance (1, 2, 4, 29-33).  This efflux system is under negative 
regulation by CmeR (3-5, 25, 34-36). Recently, CosR, an oxidative stress response 
regulator, was also found to modulate the expression of cmeABC (10).   In this study we 
demonstrate that CosR and CmeR bind simultaneously to the promoter sequence of 
cmeABC and function as a dual regulatory mechanism for this efflux pump.  The 
interaction of CosR and CmeR with the promoter DNA does not depend on each other, 
but the spacing between the two binding sites for the two regulators influences CmeR 
repression during dual binding of the cmeABC promoter. In addition, we found that the 
sole cysteine (C218) of CosR is sensitive to cysteine oxidation and it likely serves as a 
mechanism for CosR to sense oxidative stress. These findings provide new information 
on the complex regulatory mechanisms of CmeABC and the diverse signals that may 
modulate the expression and function of this predominant efflux system in C. jejuni.  
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Both CmeR and CosR have a specific binding site in the cmeABC promoter (3, 9).  
CosR was described to recognized to a 21 base binding site, ttaAanAaAAaTtAtagaTTt, 
which occurs in multiple promoters (9), and this CosR binding site is found within the 
cmeABC promoter region (10) upstream of the CmeR binding site (3).  The inability of 
CosR to bind to the cmeA internal fragment on EMSA (Fig. 1) or to influence Cj0561c 
expression as measured by transcriptional fusion (Fig. 5) was correlated with the lack of 
this specific binding site within cmeA and the promoter of Cj0561c. The specific 
interaction of CosR with the binding site was recently demonstrated by the DNA 
footprinting assay using the katA promoter (10). CosR positively regulates katA, but katA 
is also negatively regulated by PerR and Fur, peroxide and iron responsive regulators (37-
40).  The katA promoter contains multiple binding sites for PerR and holo-Fur regulators 
in addition to the CosR binding site (10, 41).  CosR binds to the CosR-specific binding 
site, which does not overlap with the sites for other regulators (10). A similar situation 
occurs in the cmeABC promoter, where CosR and CmeR bind to two separate sites (Fig. 
3A). 
The CosR binding site resides 17 bases upstream of the CmeR binding site within 
the cmeABC promoter. Dual regulation of the cmeABC promoter by CosR and CmeR was 
demonstrated in vitro by EMSA (Fig. 3) and was confirmed by in vivo expression using 
immunoblotting (Fig. 4) and transcriptional assays (Fig. 5).  An interesting finding of this 
study is that the dual binding of the cmeABC promoter by CmeR and CosR is influenced 
by the distance between the two binding sites.  The cmeABC promoter from NCTC 11168 
was used as a reference and the wild-type control for expression.  The other promoters, 
including 81-176, X7199, and P14D, contained various mutations in the CmeR binding 
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site or in the spacer between the two binding sites (Fig. 3A). Specifically, the 81-176 
promoter contained an A to T substitution in the CmeR binding site, but had the full-
length (17 bp) spacer between the CmeR and CosR binding sites.  The X7199 promoter 
and the constructed P14D probe had the same A to T substitution, but the spacer length in 
the two promoter sequences were reduced to 12 and 3 bp, respectively.  In addition, the 
X7199 promoter had an A to G substitution at base 14 of the CmeR binding site.  This 
additional substitution in the CmeR binding site of the X7199 promoter did not affect 
CmeR binding on EMSA (Fig. 3B, lane 6) or transcription of cmeABC compared to the 
81-176 promoter when CmeR was present and cosR was inhibited by the PNA 
(individual effects of CmeR, Table 4).  Both the X7199 and P14D promoters displayed 
reduced dual binding by CmeR and CosR, with the greatest reduction in binding observed 
when the spacer was reduced to only 3 bp (Fig. 3B and C). The collective effect of CmeR 
and CosR on cmeABC transcription was also the lowest for the X7199 promoter (Table 5).  
These results suggest a steric interference between CosR and CmeR in their interaction 
with the promoter DNA. The reduction in spacer was confirmed to increase transcription 
of cmeABC from the X7199 promoter (Fig. 5). This was shown by comparing the 
transcriptional rates between the 81-176 promoter and the X7199 promoter in the 
presence of both CmeR and CosR (Fig. 5A and Table 3).  Both promoters had 
substitutions in the CmeR binding site, but transcription from the X7199 promoter was 
significantly higher than that of the 81-176 promoter, attributing the difference to the 
deletion in the spacer region. In addition, the effect of CmeR repression was similar 
between the 81-176 and X7199 promoters when CmeR was evaluated alone (Table 4), 
but reduced for the X7199 promoter when the effect of CmeR was measured in the 
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presence of CosR (Table 3).  This result suggests that maximal repression of cmeABC by 
CmeR and CosR requires at least 17 bp between the regulator binding sites. 
The effect of the spacer length on the binding of CosR and CmeR was further 
demonstrated by using an artificial DNA probe, P14D, in which the majority of the 
spacer sequence was deleted (Fig. 3A). This significant shortening of the spacer even 
reduced the binding of P14D by CmeR alone (Fig. 3C), while binding of the X7199 
promoter by CmeR was not affected by the 5 bp deletion (Fig. 3B).  Additionally, 
shortening the spacer sequence did not affect the binding of CosR to the X7199 and 
P14D promoter probes (Fig. 3B and C; lane 7). However, both probes showed decreased 
complexes during dual binding by CosR and CmeR (Fig. 3A and 3B; lane 8). Based on 
these findings, it can be speculated that the spacer sequence facilitates CmeR binding to 
its binding site, but is not required for CosR to interact with its binding site. Thus when 
both CosR and CmeR bind to the X7199 promoter, CosR may create a steric hindrance 
for CmeR binding, resulting in reduced binding by CmeR and consequently enhanced 
transcription of cmeABC (Fig. 5).  This observation further supports the notion that a 
sufficient length of the spacer is required for maximum inhibition of CosR and CmeR. 
In addition to the dual binding, we also demonstrated that CosR functions 
independently of CmeR as a secondary repressor for cmeABC. The transcriptional fusion 
assay indicated that the level of CosR repression in the presence of CmeR was similar for 
the 11168, 81-176, and X7199 promoters (Fig. 5 and Table 3), demonstrating the ability 
of CosR to provide additional repression when CmeR is present. The effect of CosR 
repression in the absence of CmeR was also similar for all tested promoters, confirming 
that the spacer length did not affect the function of CosR (Fig. 5 and Table 4).   
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The observed magnitude of CosR repression on cmeABC was lower than that of 
CmeR, indicating CosR functioned as a secondary regulator for cmeABC.  However, this 
finding is based on PNA inhibition of cosR, which did not completely abolish CosR.  
This also limited our ability to evaluate the additive or synergistic effects of CosR and 
CmeR on cmeABC expression.  The small difference between the collective and sum of 
individual effects of 1.2- and 1.4 -fold for the 81-176 and 11168 promoters in comparison 
with the 0.1-fold of the X7199 promoter is suggestive of a synergistic effect. But this 
possibility requires further investigation. The inhibition of CosR represents a limitation of 
this study due to the essential nature of CosR to C. jejuni (9, 42), which prevents deletion 
of this gene from C. jejuni as we did with cmeR. Without a way to delete the gene, the 
magnitude of inhibition of CosR on cmeABC expression and the synergistic effect of dual 
CmeR and CosR repression must be interpreted precautiously. 
 Many genes in the CosR regulon are involved in the oxidative stress response (9, 
10).  Under oxidative stress, reactive oxygen species (ROS) cause oxidative damage to 
cellular components, reducing growth, and at high levels, can cause cell death. Thus, 
CosR-mediated response and defense against oxidative stress is important for 
Campylobacter physiology. Although the role of CosR has been defined, how it senses 
oxidative stress is not known.  Examination of the CosR sequence identified a single 
cysteine residue, C218, which is predicted to be localized at the dimer face. Cysteine 
residues are known sites subject to modification by ROS, reactive nitrogen species, and 
reactive electrophilic species and are involved in redox sensing by regulatory proteins 
(11, 16, 17, 43). In this study, we demonstrated that C218 in CosR is sensitive to 
oxidative stress and oxidation of this cysteine disassociated CosR from the cmeABC 
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promoter (Fig. 2, lanes 1 to 5).  This result suggests that cysteine modification affects the 
function of CosR. This conclusion is further supported by findings in other studies, in 
which expression of cmeABC was induced under oxidative stress (10).  As CosR 
modulates the expression of multiple genes in C. jejuni (10), altered function of CosR by 
cysteine modification would conceivably affect the expression of multiple genes involved 
in oxidative stress response and defense. Thus, cysteine oxidation likely serves as a 
mechanism for sensing oxidative stress by CosR, which may help Campylobacter to deal 
with oxidative stress. 
The nature of C218 modification and how it affects the function of CosR is still 
unknown. Cysteine oxidation can result in disulfide bond formation, which often alters 
protein conformation and modulates DNA binding activity (16).  OxyR, MgrA, AsrR, 
and MexR are regulators that utilize cysteine oxidation as a mechanism to regulate DNA 
binding (11, 16, 44, 45). Considering the similarity in regulatory mechanisms between 
CosR and other regulators, here we propose that oxidation of C218 in CosR results in 
disulfide bond formation and conformational changes in the protein, inhibiting its ability 
to bind to the cmeABC promoter. This model will be examined in future studies. 
CosR positively regulates katA and ahpC, but negatively regulates others genes 
such as sodB, dps, and cmeABC (9, 10).  OxyR, a well characterized oxidative stress 
regulator present in other bacteria but absent in C. jejuni, has been shown to acts as an 
activator and repressor for katA in Pseudomonas aeruginosa (46).  OxyR can be modified 
to multiple oxidation and activation states, which mediate the opposing effects (46). 
Results from two-dimensional gel analysis suggest CosR undergoes protein modifications 
in C. jejuni as CosR was identified as three parallel spots (9).  The nature of the 
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modification is unknown, but evidence suggests that CosR may not be modified by 
phosphorylation as both CosR and HP1043 (an otholog of CosR in H. pylori) lack the 
conserved aspartate residue that is required for phosphorylation (9, 15, 47).  Regardless 
of the nature of the modification, we speculate that the three modified forms of CosR 
may have different functions providing both repression and activation of genes in the 
regulon (9, 10). This possibility remains to be examined in future work.   
Although CosR and CmeR co-repress cmeABC, the two regulators respond to 
different signals. CosR senses and responds to oxidative stress, while CmeR responds to 
bile (4, 5), salicylate (36), and possibly other unidentified compounds. As a 
microaerophilic zoonotic pathogen prevalent in food producing animals, Campylobacter 
frequently encounters environmental stresses such as antimicrobials, bile, and oxidative 
challenges (6, 48). Campylobacter utilizes multiple mechanisms for environmental 
adaptation, but CmeABC is a key player for antibiotic resistance and intestinal 
colonization by mediating resistance to antimicrobials and bile (1, 3, 4, 25). Findings 
from this study suggest that CmeABC is also involved in oxidative stress response via a 
CosR-mediated mechanism. How CmeABC contributes to oxidative stress defense is 
unknown and remains to be examined in future studies. Nevertheless, the sophisticated 
mechanisms of regulation and the newly discovered role in oxidative stress response 
further signify the importance of this efflux system in Campylobacter pathobiology and 
indicate that its functions are more diverse than previously expected.  All together, these 
observations further justify CmeABC as a potential target for the development of anti-
Campylobacter interventions. 
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TABLE 1: Bacterial strains or plasmids used in this study 
Plasmid or Strain Description Source 
Plasmids   
     pMW10 E. coli – Campylobacter shuttle vector carrying 
promoterless lacZ, KanR 
(24) 
     pMW11168 pMW10 carrying the cmeABC promoter from 
NCTC11168 fused to lacZ, KanR 
(18) 
     pMW81-176 pMW10 carrying the cmeABC promoter from 81-176 
fused to lacZ, KanR 
(18) 
     pMWX7199 pMW10 carrying the cmeABC promoter from X7199 
fused to lacZ, KanR 
(18) 
     pMW561 pMW10 carrying the Cj0561c promoter fused to lacZ, 
KanR 
(25) 
     pQE30 Expression vector for N-terminal 6-His tagged proteins, 
AmpR 
Qiagen 
     pQECmeRSS pQE30 carrying CmeR with the C69S and C166S 
substitutions 
(49) 
     pQECj0355c pQE30 carrying Cj0355c This study 
     pQECj0355c652 pQE30 carrying Cj0355c with the T to A mutation at nt 
652 
This study 
     pUC57 Cloning vector, AmpR Genscript 
     pUC57P14D pUC57 with a 14 bp deletion in the cmeABC promoter 
from 81-176 
This study 
   
Campylobacter jejuni strains   
     NCTC 11168  (20) 
     11168ΔcmeR Derivative of NCTC 11168, cmeR::cat (3) 
     11168W7pMW561 Highly motile variant of NCTC 11168 carrying pMW561 (25) 
     X7199 Human clinical isolate (18) 
     81-176 Human clinical isolate (21) 
     81-176pMW10 Derivative of 81-176 carrying pMW10 (18) 
     81-176pMW11168 Derivative of 81-176 carrying pMW11168 (18) 
     81-176pMW81-176 Derivative of 81-176 carrying pMW81-176 (18) 
     81-176pMWX7199 Derivative of 81-176 carrying pMWX7199 (18) 
     81-176pMW561 Derivative of 81-176 carrying pMW561 This Study 
     81-176ΔcmeR  Derivative of 81-176, cmeR::cat (3) 
     81-176ΔcmeR pMW10 Derivative of 81-176, cmeR::cat carrying pMW10 (18) 
     81-176ΔcmeR pMW11168 Derivative of 81-176, cmeR::cat carrying pMW11168 (18) 
     81-176ΔcmeR pMW81-176 Derivative of 81-176, cmeR::cat carrying pMW81-176 (18) 
     81-176ΔcmeR pMWX7199 Derivative of 81-176, cmeR::cat carrying pMWX7199 (18) 
     81-176ΔcmeR pMW561 Derivative of 81-176, cmeR::cat carrying pMW561 This Study 
   
Escherichia coli strains   
     DH5α F-Φ80lacZΔM15 Δ(lacZYA-argF) U169 recA1 endA1 
hsdR17 (tκ-mκ+) phoA supE44λ- thi-1 gyrA96 relA1 
Invitrogen 
     DH5αpRK2013 Helper strain for conjugation (26) 
     JM109 e14-(McrA-) recA1 endA1 gyrA96 thi-1 hsdR17(tκ-mκ+) 
supE44 relA1 Δ(lac-proAB) [F’ traD36 proAB 
lacqZΔM15] 
Agilent 
     JM109pQECj0355c Derivative of JM109 carrying pQECj0355c  This study 
     JM109pQECj0355c652 Derivative of JM109 carrying pQECj0355c652 This study  
     JM109pQECmeRSS Derivative of JM109 carrying pQECmeRSS (49) 
     DH5αpMW561 Derivative of DH5α carrying pMW561 This study 
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TABLE 2:  Oligonucleotide primers used in this study1 
Primer Sequence Source or Reference 
Cj0355c-F1 CGCGGGATCCAGAATTTTAGTTATAGAAGATGAG 
(BamHI) 
This study 
Cj0355c-R1 GCAGGGTACCTGTAAGATTTTTTAGGGAAGCAG 
(KpnI) 
This study 
CosR652-F AGGATACCGTTTCAGCTTCCCTAAAAA This study 
CosR652-R TTTTTAGGGAAGCTGAAACGGTATCCT This study 
GSF CTAAATGGAATCAATAGCTCC (1) 
GSR1 GCACAACACCTAAAGCTAAAA (1) 
AF AACCTCAAGTTAGCGGCGTA (1) 
AR AATCCTTGCTTGCATTTTCG (1) 
1 Restriction sites are indicated by underlined sequences 
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TABLE 3:  Effects of CmeR and CosR on repression of cmeABC during dual regulation1 
Promoter  Effect of CosR in presence of 
CmeR2 
Effect of CmeR in presence of 
CosR3 
11168 1.8a 4.6a 
81-176 2.1a 3.7b 
X7199 1.7a 2.6c 
 
1 One-way ANOVA was performed on log2 transformed transcriptional data to determine 
difference between promoter effects.  Effects with different letters indicate a significant 
difference (p <0.05). 
2 The effect of CosR in presence of CmeR was calculated as the relative fold change in 
transcription levels in the 81-176 wild-type background with and without the anti-CosR 
PNA. 
3 The effect of CmeR in presence of CosR was calculated as the relative fold change in 
transcription between the 81-176ΔcmeR background and the 81-176 wild-type 
background without the anti-CosR-PNA.   
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TABLE 4:  Collective and individual effects of CmeR and CosR on repression of 
cmeABC1  
Promoter  Collective 
Effect2  
Individual 
Effect of 
CosR3 
Individual 
Effect of 
CmeR4 
Sum of 
individual 
effects 
Difference 
between 
collective  and 
sum effects 
11168 6.3a 1.4a 3.5a 4.9 1.4a 
81-176 4.9a 1.4a 2.3b 3.7 1.2a 
X7199 3.5b 1.3a 2.1b 3.4 0.1a 
 
1 One-way ANOVA was performed on log2 transformed transcriptional data to determine 
difference between promoter effects.  Effects with different letters indicate a significant 
difference (p <0.05). 
2 The collective effect was calculated as the relative fold change in transcription levels 
between the 81-176ΔcmeR background with anti-CosR PNA and the 81-176 wild-type 
background without anti-CosR-PNA. 
3 Individual effect of CosR was calculated as the relative fold change in transcription 
levels in the 81-176ΔcmeR background with and without the anti-CosR-PNA. 
4 Individual effect of CmeR was calculated as the relative fold change in transcription 
levels between the 81-176ΔcmeR and the 81-176 wild-type background, in the presence 
of the anti-CosR-PNA. 
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FIGURE 1: Specific binding of CosR to the cmeABC promoter as shown by EMSA. 
rCosRWT (lanes 2 and 4) and rCosRC218S (lanes 3 and 5) were incubated with the DIG- 
labeled 11168 cmeABC promoter (lanes 2 and 3) or the internal cmeA fragment (lanes 4 
and 5).  Lane 1 contains the 11168 cmeABC promoter without added protein (probe-only 
control).  All probes are 0.05 pmol per reaction and the protein (rCosRWT or 
rCosRC218S) concentration is 250 ng per reaction.  
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FIGURE 2: Sensitivity of CosR to oxidation by hydrogen peroxide.   Binding of 250 ng 
of rCosRWT (lanes 2-5) or rCosRC218S (lanes 6-8) to DIG-labeled 11168 cmeABC 
promoter DNA (0.05 pmol).  No protein was added to lane 1 as a probe-only control. The 
promoter probe and protein were incubated for 30 minutes prior to addition of hydrogen 
peroxide.  Hydrogen peroxide was added for final concentrations of 0 nM (lanes 2 and 6), 
5 nM (lanes 3 and 7), 10 nM (lanes 4 and 8), or 20 nM (lanes 5 and 9).  After addition of 
hydrogen peroxide, all reactions were incubated for an additional 30 minutes before 
electrophoresis. 
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FIGURE 3: Dual binding of CosR and CmeR!to!various variants of the cmeABC promoter 
sequence. (A) Alignment of cmeABC promoter sequences from strains NCTC 11168 
(11168), 81-176, X7199, and the artificially designed P14D probe.  The known CosR 
binding site is in bold and the CmeR binding site is in lowercase, underlined italics.  
Mutations in the CmeR binding site are indicated in bold, lowercase, underlined italics.  
(-) indicates a deleted base. (B) EMSA results of the cmeABC promoter probes from 81-
176 (lanes 1-4) and X7199 (lanes 5-8) incubated with 200 ng of rCmeRSS (lanes 2 and 6), 
(A) 
(B) 
Probe  
Probe  
Complex  
Complex  
(C) 
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FIGURE 3 continued: 400 ng of rCosRC218S (lanes 3 and 7), or both (lanes 4 and 8).  
No protein was added to lanes 1 and 5 as probe-only controls. (C) EMSA results of the 
cmeABC promoter probes from 81-176 (lanes 1-4) and P14D (lanes 5-8) incubated with 
200 ng of rCmeRSS (lanes 2 and 6), 400 ng of rCosRC218S (lanes 3 and 7), or both 
(lanes 4 and 8).  No protein was added to lanes 1 and 5 as probe-only controls.   All 
promoter probes were 0.05 pmol per reaction.   !  
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FIGURE 4: Effect of cosR inhibition on expression of CmeB and CmeA. Immunoblotting 
of wild-type 11168 (lanes 1 and 2) and 11168ΔcmeR (lanes 3 and 4) whole cell proteins 
with anti-CmeB, anti-CmeA, and anti-major outer membrane protein (MOMP) antibodies, 
respectively.  The anti-CosR PNA was added to samples loaded in lanes 2 and 4 at 1.5 
µM to inhibit cosR expression.  
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FIGURE 5: Effect of inhibiting CosR by the anti-CosR-PNA on transcription from the 
cmeABC promoter in the presence (A) or absence (B) of CmeR. Transcriptional fusions 
and β-galactosidase assays were used to measure the expression from 11168, 81-176, or 
X7199 cmeABC promoters or the Cj0561c promoter (561). Presence or absence of CmeR 
was determined by using 81-176 wild-type (A) and 81-176ΔcmeR (B) for the 
transcriptional fusions.  Cultures were incubated with (+ CosR PNA; 1.5 µM ) or without 
(A)
_)) 
(B)
_)) 
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FIGURE 5 continued: (-CosR PNA) the PNA.  The Cj0561c promoter was used as a 
control to demonstrate its regulation only by CmeR, not by CosR.  Data are means with 
standard deviation from three independent experiments.   The unpaired Student’s t-test 
with Welch’s correction was used for comparison of the means with significance set at 
0.05.   
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CHAPTER 5: GENERAL CONCLUSIONS 
 
 Using various molecular and biochemical methods, we showed that CmeABC 
was differentially expressed in natural C. jejuni isolates derived from different host 
species with the majority of the isolates exhibiting overexpression of cmeABC compared 
to the reference strain, C. jejuni NCTC 11168.  Overexpression of cmeABC in some 
isolates was linked to mutations in the cmeABC promoter that affected binding of CmeR, 
a transcriptional repressor for CmeABC.  CmeR levels were undetectable in one isolate, 
CT2:2, resulting in increased cmeABC expression.  Interestingly, this isolate also 
harbored a frame shift mutation that caused truncation of the CmeR protein and abolished 
the DNA binding activity in the recombinant CmeR harboring this mutation.  Thus even 
if CmeR was produced, this isolate would continue to overexpress cmeABC. 
Additionally, isolates with mutations (amino acid substitutions) in CmeR that 
overexpressed cmeABC were identified, but the examined mutations did not affect the 
DNA-binding activity of CmeR. Other isolates did not harbor mutations in the known 
cmeABC regulatory regions (CmeR coding sequence or cmeABC promoter) suggesting 
that the increased cmeABC expression in these isolates was due to unidentified regulatory 
mechanisms. This work is the first to evaluate differential CmeABC expression in natural 
isolates and identifies multiple mutations that influence cmeABC expression.   
cmeR is the second of gene of the Cj0369c-cmeR operon and these genes are 
transcribed as a single transcriptional unit (1). No regulatory mechanisms for this operon 
have been described and post-translational investigation into the regulation of CmeR has 
not been evaluated.  Investigation into the mechanisms of cmeR regulation may provide 
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an explanation why CT2:2 did not produce any CmeR.  In addition, if cmeR regulation 
has other mechanisms than transcriptional control, this may also explain the varied cmeR 
transcript levels detected by real time RT-PCR in selected isolates with a phenotype of 
CmeABC overexpression.   
Differential CmeABC overexpression had functional consequences. In the 
cultures treated with ciprofloxacin, cmeABC overexpression promoted the emergence of 
ciprofloxacin-resistant mutants, suggesting that the isolates with this phenotype may be 
better prepared to deal with antibiotic treatment. Thus, the high prevalence of isolates 
with cmeABC overexpression (67%) might have been due to selection by antibiotic 
usage.  
In addition to examining differential CmeABC expression and natural 
mechanisms altering expression, we also evaluated an additional regulator of cmeABC 
named CosR. We determined how CosR interacts with CmeR in binding to the cmeABC 
promoter and how CosR senses oxidative stress. It was found that the two regulators 
provide a dual and possibly synergistic repression of cmeABC. Maximal repression by the 
two regulators requires sufficient spacing between the CosR and CmeR binding sites. 
Shortening of the spacer region causes steric hindrance and reduces dual binding by the 
two regulators, increasing expression of cmeABC.  Additionally, we found that CosR 
utilizes the single cysteine to detect oxidative stress and modulates cmeABC expression. 
These findings indicate that cmeABC is co-repressed by dual regulators that are inducible 
by different signals (bile, oxidative stress, antimicrobials, etc). 
Based on the results from our study we propose the following mechanisms of 
cmeABC regulation (Figure 1). In the absence of environmental stimuli, such as bile or 
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oxidative stress, cmeABC is expressed at a low, basal level (Fig. 1A) (2), but can be 
induced by modifying the functions of CmeR (Fig. 1B), CosR (Fig. 1C), or both (Fig. 
1D).  The presence of bile in the intestinal lumen would induce cmeABC expression 
through CmeR (Fig. 1B) (3, 4), which would undergo a conformational change upon 
binding by bile and disassociate from the cmeABC promoter, increasing the expression of 
the efflux pump (3, 5).  This inducible expression of cmeABC likely contributes to C. 
jejuni adaptation in the intestinal tract. Additionally, association of C. jejuni with the 
epithelial cells triggers the release of hydrogen peroxide (6). Hydrogen peroxide oxidizes 
CosR, resulting in its disassociation from the cmeABC promoter and overexpression of 
the transporter system (Fig. 1D).  Furthermore, CosR-mediated induction of cmeABC 
may occur when C. jejuni encounters phagocytes or after contract with enterocytes, 
where ROS are produced.  The up-regulation of cmeABC under oxidative stress may 
provide a defense mechanism against oxidation, but how CmeABC contributes to this 
defense is unknown and awaits further investigation.    
Given the importance of CmeABC in C. jejuni's adaptation to various 
environments, it is plausible that this efflux machinery can be targeted to control 
Campylobacter.  One possible way is to inhibit expression of cmeABC by using peptide 
nucleic acids, which can be designed for specific inhibition of CmeABC (7). Another 
approach could be use of efflux pump inhibitors, which may block the function of 
CmeABC (8).  Either reduced expression or blocked function of CmeABC would 
sensitize Campylobacter to bile and other antimicrobials. Alternatively, a compound that 
binds to CmeR and make it un-inducible by environmental cues could be developed and 
used to prevent CmeR from disassociating from the cmeABC promoter, thus repressing 
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the expression of CmeABC. Furthermore, CosR cold be targeted for the control of C. 
jejuni. Since CosR is essential for the viability of C. jejuni and is important for oxidative 
defense, a compound that inhibits the expression or function of CosR should produce 
anti-Campylobacter effects. These potential approaches should be examined using both 
in vitro systems and in vivo models in future studies.  
In summary, this work demonstrates the versatile mechanisms and signals that 
modulate the expression of CmeABC. Given that CmeABC is an important player in 
antimicrobial resistance and intestinal colonization, differential expression of this efflux 
system will provide Campylobacter with flexibility in the adaptation to diverse 
environments. The findings from this work further support the notion that CmeABC is a 
potential target for the development of intervention strategies as inhibiting the expression 
or function of CmeABC will sensitize Campylobacter to antibiotics and bile, making the 
organism unable to survive antibiotic treatment or colonize in the intestinal tract. CosR 
also provides an attractive target that would eliminate the concern over CmeABC 
expression levels.  Future efforts are warranted to explore these possibilities. 
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FIGURE 1: Regulatory and induction mechanism of cmeABC expression. A partial promoter sequence for cmeABC is shown. The 
ribosome binding site is underlined and the ATG start codon of cmeA is indicated in bold italics.  The CosR binding site is indicated in
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FIGURE 1 continued: bold lowercase letters and the CmeR binding site is shown in bold uppercase letters. A) Basal level of cmeABC 
transcription in the absence of environmental stimuli with dual repression by CmeR and CosR.  B) Induction of cmeABC by bile 
through CmeR.  Binding of bile to CmeR alters its confirmation, resulting in disassociation of CmeR from the promoter and an 
increase in cmeABC transcription. C) Induction of cmeABC by oxidation through CosR.  ROS oxidize CosR, resulting in its 
disassociation from the cmeABC promoter and increased transcription of cmeABC.  D) Induction of cmeABC by ROS and bile, results 
in disassociation of both CosR and CmeR from the promoter and high levels of cmeABC transcription.  
 
 
 
 
 
 
 
 
 
 
  
 
 
166 
References 
 
 
1. Guo B, Wang Y, Shi F, Barton Y, Plummer P, Reynolds D, Nettleton D, 
Grinnage-Pulley T, Lin J, Zhang Q. 2008. CmeR functions as a pleiotropic 
regulator and is required for optimal colonization of Campylobacter jejuni in vivo. 
J Bacteriol 190:1879-1890. 
2. Lin J, Michel L, Zhang Q. 2002. CmeABC functions as a multidrug efflux 
system in Campylobacter jejuni. Antimicrob Agents Chemother 46:2124-2131. 
3. Lin J, Cagliero C, Guo B, Barton Y, Maurel M, Payot S, Zhang Q. 2005. Bile 
salts modulate expression of the CmeABC multidrug efflux pump in 
Campylobacter jejuni. J Bacteriol 187:7417-7424. 
4. Lin J, Akiba M, Sahin O, Zhang Q. 2005. CmeR functions as a transcriptional 
repressor for the multidrug efflux pump CmeABC in Campylobacter jejuni. 
Antimicrob Agents Chemother 49:1067-1075. 
5. Lei HT, Shen Z, Surana P, Routh MD, Su CC, Zhang Q, Yu EW. 2011. 
Crystal structures of CmeR-bile acid complexes from Campylobacter jejuni. 
Protein Sci 20:712-723. 
6. Corcionivoschi N, Alvarez LA, Sharp TH, Strengert M, Alemka A, Mantell 
J, Verkade P, Knaus UG, Bourke B. 2012. Mucosal reactive oxygen species 
decrease virulence by disrupting Campylobacter jejuni phosphotyrosine signaling. 
Cell Host Microbe 12:47-59. 
7. Jeon B, Zhang Q. 2009. Sensitization of Campylobacter jejuni to 
fluoroquinolone and macrolide antibiotics by antisense inhibition of the CmeABC 
multidrug efflux transporter. J Antimicrob Chemother 63:946-948. 
8. Lin J, Martinez A. 2006. Effect of efflux pump inhibitors on bile resistance and 
in vivo colonization of Campylobacter jejuni. J Antimicrob Chemother 58:966-
972. 
 
 
  
  
 
 
167 
VITA 
 
NAME OF AUTHOR: Tara Leigh Grinnage-Pulley 
  
DATE AND PLACE OF BIRTH:  August 21, 1984, Annapolis, Maryland 
 
DEGREES AWARDED: 
D.V.M., Iowa State University, 2009 
B.S., Animal and Poultry Science, Tuskegee University, 2005 
 
HONORS AND AWARDS: 
Midwest Regional Center for Excellence for Biodefense and Emerging Infectious  
     Diseases Career Development Veterinary Medicine Fellowship, 2010-2013 
Fort Dodge Animal Health Fellowship, 2010 
Pfizer Animal Health Scholarship for a Combined D.V.M.-Ph.D., 2005-2010 
Cum Laude, DVM, Iowa State University, 2009 
Summa Cum Laude, B.S. Animal Science, Tuskegee University, 2005 
USDA 1890 National Scholar, 2002-2005  
 
EXPERIENCE:  
Graduate Research Assistant, Department of Veterinary Microbiology and    
     Preventive Medicine, Iowa State University 2006 – 2013  
Summer Student Trainee, USDA Agricultural Research Service, Environmental     
     Microbial and Food Safety Laboratory, May-August 2005 
Student Trainee, USDA Cooperative State Research, Education, and Extension  
     Service, Animal and Plant Systems, May-August, 2004 
Student Trainee, USDA Animal and Plant Health Inspection Service, Veterinary  
     Services Emergency Management Center June-August 2003  Summer&Student&Trainee,&USDA Cooperative State Research, Education, and  
     Extension Service, Animal and Plant Systems, June/August&2002 
 
PUBLICATIONS: 
  
Guo, B., Y. Wang, F. Shi, Y. Barton, P. Plummer, D. Reynolds, D. Nettleton, T.  
Grinnage-Pulley, J. Lin, and Q. Zhang. 2008. CmeR functions as a pleiotropic regulator 
and is required for optimal colonization of Campylobacter jejuni in vivo. J Bacteriology 
190:1879-90. 
 
  
 
 
168 
ACKNOWLEDGEMENTS 
 
I would like to thank my major professor and committee chair, Dr. Qijing Zhang 
for his guidance and support in completing this dissertation.   My deepest gratitude for his 
patience and encouragement, not only for my graduate studies, but also throughout my 
veterinary program and his assistance with the unique challenges that arose from 
combining these programs.  It has been a wonderful opportunity to have Dr. Zhang as a 
mentor, to share in his knowledge and experiences as I embark on my future career.   
I would also like to thank my committee members, Drs. Ronald Griffith, Susan 
Lamont, Lisa Nolan, and Christine Petersen for their willingness to serve on my 
committee and guide my studies.  A special thanks to Dr. Eileen Thacker for her service 
on my committee and help with navigating the intricacies in balancing my DVM and PhD 
courses.  
Thank you to the members of the Zhang lab, past and present, for your support, 
assistance, and friendship.  A special thanks to Drs. Orhan Sahin, Zhangqi Shen, and Lei 
Dai, for your advice and technical support during experiments.  Thank you to Samantha 
Terhorst for her assistance on the agar dilution experiments.  To our lab managers, thank 
you for ensuring that I had all the necessary reagents and materials for my projects.  
To my professors in both the graduate and veterinary curriculum, mentors, 
classmates and colleagues, thank you for your support, encouragement, and advice.  The 
different perspectives to life and science you have provided are much appreciated.  Thank 
you to Dr. Monica Howard for your advice and willingness to listen through all the 
  
 
 
169 
challenges and triumphs. My thanks to the faculty and staff of the Department of 
Veterinary Microbiology and Preventive Medicine for your support.  
Liz Westberg and Vern Hoyt-without you, I cannot image completing my 
graduate studies.  Your patience and assistance with questions is greatly appreciated. Lisa 
Sebring, thank you for all your help in schedule coordination.   
I thank Pfizer Animal Health (currently Zoetis) for offering the opportunity to 
complete veterinary and graduate programs at Iowa State and providing a network of 
scholars, scientists, and veterinarians for support and advice.  To the members of the 
Midwest Regional Centers for Excellence, thank you for your financial support and 
providing opportunities to travel and visit with many excellent scientists. My thanks to 
Fort Dodge Animal Health for their support of my graduate program.  
And finally to my family and friends, you have provided your love and support 
for many years.  To my dance troupe and dance community thank you for making me 
laugh and reminding me to have fun.  My passion for science and art is equal I channel 
both to fuel my love for learning.  To my best friend Anna, a lot has changed since first 
grade, but you’ve always been there to cheer me on.  Ellie, my fellow veterinarian, you 
started me into the path of veterinary medicine and I look forward all the adventures this 
road will bring me. Mom, Dad, and Godmom, you have always told me to follow my 
dreams and provided the support and encouragement to get me here.  
 
